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Luciano Silvestri - Enteral vancomycin to control severe methicillin-resistant Staphylococcus aureus 
infections in the intensive care unit. 
 
ABSTRACT 
 
Background 
Oropharyngeal chlorhexidine and mupirocin have been used in the intensive care unit 
(ICU) to control lower respiratory tract infection, including methicillin-resistant 
Staphylococcus aureus (MRSA) infection. The use of enteral vancomycin to control 
MRSA carriage of the oropharynx and the gut and to prevent MRSA infection of the 
lower airways and the bloodstream is a promising manoeuvre. 
Aims of the research 
1. To assess the effectiveness of oropharyngeal mupirocin and chlorhexidine to 
control severe ICU infection, including MRSA infection; 
2. To assess the effectiveness of enteral vancomycin to control MRSA infection in 
the ICU, and to assess the safety of the manoeuvre, i.e. emergence of vancomycin-
intermediate Staphylococcus aureus (VISA) and vancomycin-resistant enterococci 
(VRE); 
3. To undertake a cohort study in the ICU in order to evaluate the impact of topical 
oropharyngeal vancomycin on MRSA infection and on the emergence of VISA and 
VRE. 
Design of the research 
Systematic review and meta-analysis of randomised studies for point 1; systematic 
review and meta-analysis of randomised and non-randomised studies for point 2; 
observational retrospective study for point 3. 
Results 
The systematic review and meta-analysis showed that mupirocin and chlorhexidine 
reduced lower respiratory tract infection, but did not demonstrate any impact on 
MRSA infection and mortality in critically ill ICU patients. 
The systematic review and meta-analysis of the effectiveness of enteral vancomycin 
demonstrated a reduction in overall infection rates (Odds Ratio [OR] 0.35, 95% 
confidence interval [CI] 0.24-0.50, p=0.00199), Staphylococcus aureus carriage (OR 
0.03, 95% CI 0.01-0.17, p<0.001) and infection (OR 0.21, 95% CI 0.15-0.32, 
p<0.001). MRSA carriage, MRSA infection, and mortality were reduced by enteral 
vancomycin (OR 0.15, 95% CI 0.09-0.25, p<0.001, OR 0.24, 95% CI 0.12-0.50, p< 
0.001, and 95% CI 0.43-0.79, p<0.001, respectively). VISA and VRE were not a 
clinical problem. 
The 16-year retrospective study showed that, in patients receiving oropharyngeal 
vancomycin, MRSA secondary endogenous infections were significantly reduced 
compared with patients who did not receive enteral vancomycin (OR 0.26 95% CI 
0.1-0.69, p=0.007). VISA and VRE were not demonstrated. 
Conclusions 
Oropharyngeal mupirocin and chlorhexidine did not demonstrate any effect on 
MRSA infection and mortality in systematic review. The use of enteral vancomycin 
may be an effective strategy to reduce MRSA carriage and infection in ICU patient. 
The manoeuvre is safe in terms of emergence of VISA and VRE. 
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ABBREVIATIONS* 
 
AGNB  aerobic Gram-negative bacilli 
BAL  bronchoalveolar lavage 
BSI  bloodstream infection 
CA-MRSA community-acquired methicillin-resistant Staphylococcus aureus 
CFU  colonies forming unit 
Chx  chlorhexidine 
CI  confidence interval 
CLSI  clinical and laboratory standard institute 
CNS  coagulase-negative staphylococci 
COPD  chronic obstructive pulmonary disease 
CDC  centers for disease control and prevention 
CPIS  clinical pulmonary infection score 
DNA  deoxyribonucleic acid 
EPIC  European prevalence of Infection 
EUCAST European committee on antimicrobial susceptibility testing 
H-VISA heteroresistant vancomycin-intermediate Staphylococcus aureus 
ICU  intensive care unit 
IPI  intrinsic pathogenicity index 
IQR  interquartile range 
L  litre 
LRTI  lower respiratory tract infection 
MIC  minimum inhibitory concentration 
ml  millilitre  
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MRSA  methicillin-resistant Staphylococcus aureus 
MSSA  methicillin-sensitive Staphylococcus aureus 
Mup  mupirocin 
NA  not available 
NE  not evaluable 
NNT  number needed to treat 
NOS  Newcastle-Ottawa quality assessment scale 
OR  odds ratio 
PBP  penicillin-binding protein 
PE  primary endogenous 
PRISM preferred reporting items for systematic review and meta-analysis 
PICOS  participants, intervention, comparisons, outcomes, study design 
PICU  paediatric intensive care unit 
PPM  potentially pathogenic microorganism 
PSB  protected specimen brush 
RCT  randomised controlled trial 
RR  relative risk 
SAPS  simplified acute physiology score 
SDD  selective decontamination of the digestive tract 
SE  secondary endogenous 
SOD  selective oropharyngeal decontamination 
SSC  staphylococcal cassette chromosome 
SSI  surgical site infection 
STROBE strengthening the reporting of observational studies in epidemiology 
VISA  vancomycin-intermediate Staphylococcus aureus 
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VRSA  vancomycin-resistant Staphylococcus aureus 
UTI  urinary tract infection 
VAP  ventilator-associated pneumonia 
VRE  vancomycin-resistant enterococci 
 
*Additional abbreviations are included in tables’ and figures’ legends 
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1.1 Staphylococcus aureus and resistance to methicillin 
 
Staphylococci were first described and classified by the Scottish surgeon Sir 
Alexander Ogston in 1882 [1]. He named these bacteria using the Greek words 
“staphylos” (“grape”) and “kokkos” (“berry” or “seed”). The name Staphylococcus 
aureus was coined in 1884 by the German physician Friedrich Rosenbach [2]. He 
distinguished some colonies of staphylococci into “albus” and “aurum”, the Latin 
words indicating “white” and “gold”. The main characteristic of S. aureus as human 
pathogen is its versatility and adaptability to the newer antibiotics. 
An effective therapy for S. aureus infections was available in 1928 when penicillin 
was discovered by Alexander Fleming. Unfortunately, S. aureus quickly developed 
penicillin resistance due to the acquisition of genes producing β-lactamases [3]. 
Within few years S. aureus became able to destroy penicillin by producing a specific 
enzyme called “penicillinase” which was encoded by a plasmid, and which quickly 
spread among S. aureus strains [4]. 
A modified penicillin, methicillin, was introduced in 1959. Methicillin was designed 
to resist the destructive action of the staphylococcal penicillinase. Within two years, 
methicillin-resistant S. aureus (MRSA) strains were reported [5]. Methicillin 
resistance was not due to a hydrolysing enzyme, but to a sophisticated mechanism. 
Methicillin exerts its action by blocking the proteins called penicillin-binding 
proteins (PBPs), which are responsible for the construction and maintenance of the 
bacterial cell wall. S. aureus resistant strains acquired a new protein, called PBP2a, 
which was not blocked by methicillin and could replace the other PBPs, thus 
allowing the survival of S. aureus in the presence of methicillin. PBP2a is encoded 
by the gene mecA. mecA resides in a chromosome as a mobile genetic element called 
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the “staphylococcal cassette chromosome (SCC) mec”. SCCmec is flanked by 
chromosome recombinase genes (ccrA, ccrB or ccrC), which allow intra- and 
interspecies transmission of the SCCmec. The initial reservoir of SCCmec is unclear, 
but may have been a coagulase-negative staphylococcal species. The presence of 
PBP2a means MRSA is resistant not only to methicillin but also to all β-lactam 
antibiotics, including synthetic penicillins, cephalosporins and carbapenems. 
MRSA is worldwide spread in hospitals, with prevalence reaching rates of 25-50% in 
Americas, Australia and Southern Europe [6]. Rates of MRSA among S. aureus in 
Spanish intensive care units (ICUs) from 1994 to 2008 shows similar patterns 
(≈25%) in the first and last years with oscillations ranging from 13% in 1997 to 
42.3% in 2006 [7]. In addition to intra-ICU transmission dynamics of MRSA, 
influenced by colonisation of ICU healthcare workers [8], it should be taken into 
account of MRSA imported cases in the ICU [9], with community-acquired MRSA 
(CA-MRSA) genotypes as emerging cause of carriage among patients admitted in 
adult ICUs [10]. 
MRSA may be multi-drug resistant. The resistance is not only to β-lactam 
antibiotics, but also to other different antibiotic classes, such as tetracyclines, 
fluoroquinolones, macrolides, lincosamides, and aminoglycosides [11]. Intermediate 
resistance to vancomycin (VISA, vancomycin-intermediate S. aureus) or full 
resistance (VRSA, vancomycin-resistant S. aureus) have emerged [12]. The former 
appeared in Japan and subsequently in USA and Europe, and was designated as 
having minimum inhibitory concentrations (MICs) of 8-16 mg/L [13]. Among VISA 
strains, 90% are heterogeneous vancomycin-intermediate (heteroresistant; H-VISA); 
they are methicillin-resistant but contain a low number of VISA, which may increase 
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after vancomycin exposure [14]. A limited number of isolates of VRSA have been 
identified to date. 
In addition to VISA and VRSA, a number of strains have ‘‘decreased susceptibility’’ 
to vancomycin. Some high-inoculum staphylococcal infections as bacteraemia, 
endocarditis and osteomyelitis have been associated with heteroresistance [15]. 
Vancomycin heteroresistance has been linked to strains susceptible to vancomycin 
but with high MIC values within the susceptibility category [16]. These strains are 
still considered susceptible by the sensitivity tests, but high concentration of 
vancomycin, close to the ‘‘intermediate’’ level, are required to inhibit them (MIC 2 
mg/L). Vancomycin MICs of 1.5-2.0 mg/L are considered an independent predictor 
of poor response to vancomycin therapy for MRSA infection, even when 
vancomycin trough levels >15 mg/L are achieved [17]. 
The decreased susceptibility makes serious infections poorly treated by vancomycin. 
This may be especially true for MRSA pneumonia, due to a difficult penetration of 
vancomycin in the alveolar lining fluid [18]. It has been suggested that strains with 
vancomycin MIC of 1-2 mg/L should be considered H-VISA or VISA [19] since 
even the new Clinical and Laboratory Standards Institute (CLSI) susceptibility 
breakpoint for vancomycin (≤2 mg/L) may fail to precisely differentiate potential 
responders to vancomycin therapy. This suggested that the breakpoint value should 
be lowered to 1 or 0.5 mg/L [19]. Additionally, resistance to the newest antibiotics 
licensed to treat MRSA infections, such as linezolid and daptomycin, has emerged 
[20, 21]. Therefore, there are two main problems with MRSA: the therapeutic 
options to treat MRSA infections are limited and, in addition, MRSA has also a 
propensity to acquire resistance to the newest antibiotics. 
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1.2 Epidemiology of MRSA 
 
S. aureus is a human pathogen causing a multitude of infections, not only in the 
hospital, but also in the community [22]. S. aureus infections range from skin 
infections, such as furunculosis and impetigo, to severe infections such as 
bloodstream infections, nosocomial pneumonia, surgical wound infection and 
prosthetic implant infection [23-25]. 
Data from the US National Nosocomial Infections Surveillance System found that, in 
2003, 60% of S. aureus in the ICU were MRSA [26]. In this setting, MRSA causes 
mainly bloodstream infection and lower respiratory tract infection [27]. 
Similarly, the one-day European prevalence of infection (EPIC) study in the ICU 
[28] has shown that S. aureus is the second most common microorganism isolated in 
culture-positive infected patients (16%) after Pseudomonas aeruginosa [29]. Among 
S. aureus, methicillin resistance ranges from 6.2% in countries with low resistance 
(e.g. Denmark, Finland, Netherlands, Norway, and Sweden) to 50.4% in countries 
with high antimicrobial resistance (e.g. Greece, Israel, Italy, Malta, Portugal, Spain, 
and Turkey), accounting for 8% of all isolates. 
However, in the last years, several countries with a high proportion of MRSA, 
including the UK, Italy, France and Spain, reported a significant decrease. In UK the 
percentage of MRSA in bloodstream infection decreased from 31% in 2007 to 19% 
in 2009, perhaps related to national actions such as the mandatory reporting of 
bacteraemia or the use of decolonisation protocols [30, 31]. Nevertheless, the map of 
MRSA prevalence in Europe still shows a remarkable distinction between the rates in 
Southern and Western Europe and those of Northern Europe. 
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The different distribution of MRSA among countries and hospitals may be due to 
several factors [32, 33]: 
- Different national guidelines for prevention of MRSA dissemination and 
infection; 
- Absence of reporting outbreaks at national or regional level; 
- Lack of monitoring of readmission in the hospital of known MRSA carriers; 
- Different hygiene precautions/isolation, recommendations for MRSA 
screening, and barrier precautions to prevent re-colonisation; 
- Different decolonisation strategies and prescriptions; 
- Lack of guidelines on restriction of antibiotic use; 
- Inadequate level of education of personnel; 
- Different guidelines for care or social interactions with MRSA positive 
patients after discharge from the hospital also in relation to decolonisation 
schedules. 
 
1.3 Pathogenesis of ICU infection 
 
1.3.1 Definitions 
Carriage is defined as the patient’s state where the same strain of potentially 
pathogenic microorganism (PPM) is isolated from two consecutive surveillance 
samples of saliva, gastric fluid or faeces, in any concentration, over a period of at 
least one week [34, 35]. 
High-grade carriage or overgrowth is defined as the presence of ≥ 2+ or ≥105 
colonies forming units (CFU) per millilitre of saliva, or per gram of faeces, or per 
millilitre of other digestive tract secretions [34, 35]. 
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Colonisation should be distinguished from carriage. Colonisation is defined as the 
presence of a microorganism in an internal organ that is normally sterile (e.g. lower 
airways, bladder), without inflammatory host response [34, 35]. Samples of lower 
airway secretions, wound fluid, and urine generally yield <105 CFU of PPMs per 
millilitre of diagnostic sample. In general, only a few leukocytes are present in 
colonised internal organs on a semiquantitative scale of + = few, ++ = moderate, and 
+++ = many leukocytes [34, 35]. 
Carriage and colonisation are two different stages of the pathogenesis of endogenous 
infection in ICU patients. The first stage is practically always the oropharyngeal and 
gastrointestinal carrier state followed by overgrowth. Once the PPM is present in 
overgrowth concentrations it migrates into the sterile internal organs in order to 
colonise the lower airways and the bladder [Figure 1.1]. Unfortunately, the term 
colonisation is often used to cover both stages of carriage and colonisation. 
Infection is a microbiologically proven clinical diagnosis of inflammation, local 
and/or generalized. This includes not only clinical signs but also the presence of a 
moderate number of leukocytes, and of ≥105 CFU per millilitre of diagnostic samples 
obtained from an internal organ, or the isolation of the microorganism from blood, 
cerebrospinal fluid, pleural or peritoneal fluid [34, 35]. Criteria for the diagnosis of 
lower respiratory tract infection remain controversial. The association between 
radiological, clinical and laboratory findings are commonly required. The diagnosis 
of microbiologically confirmed lower respiratory tract infection relies on the 
following criteria [36]: 
- presence of new or progressive infiltrate on chest X-ray, and 
- fever ≥ 38.3° C, and 
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- leucocytosis (white blood cells > 12,000/ml) or leucopenia (white blood cells 
< 4,000/ml), and 
- purulent tracheal aspirate, and 
- tracheal aspirate yielding ≥105 CFU/ml, or protected specimen brush (PSB) 
yielding ≥103 CFU/ml, or bronchoalveolar lavage (BAL) yielding ≥104 
CFU/ml. 
In case of the first four criteria are fulfilled, but tracheal aspirate, or PSB, or BAL are 
sterile, the diagnosis is only clinical. Ventilator-associated pneumonia (VAP) is a 
lower respiratory tract infection that develops 48 hours or more after intubation with 
an endotracheal tube or tracheostomy tube, and was not present before intubation 
[37]. The absence of lung infiltrates on chest X-ray defines the diagnosis of 
tracheobronchitis [36, 38]. The diagnosis of urinary tract infection rests on a freshly 
voided catheter urine specimen containing ≥105 bacteria or yeasts per millilitre of 
urine and ≥ 5 white blood cells per high power field [36]. 
Diagnostic samples are samples from internal organs that are normally sterile, such 
as the lower airways, bladder, and blood. They are obtained when clinically indicated 
and allow the diagnosis of colonisation and infection [34, 35]. 
Surveillance samples are samples from body sites where PPMs are carried, such as 
the digestive tract. A set of surveillance samples consists of throat and rectal swabs 
taken on admission of the patient to the ICU and twice weekly, thereafter. The 
purpose of surveillance samples is the determination of the microbiological endpoint 
of the level of carriage of PPMs. They are not useful for diagnosing infection of 
internal organs, as diagnostic samples are required for this purpose [34, 35]. 
Data obtained from surveillance samples and diagnostic samples allow us to 
calculate the intrinsic pathogenicity index (IPI) of microorganisms, including S. 
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aureus (Table 1.1). IPI is defined as the ratio between the number of patients infected 
by a microorganism and the number of carriers of the same microorganism in throat 
and rectum [35, 36]. The range of this index is from 0 to 1. In accordance with IPI 
microorganisms can be divided into three categories: low pathogenic 
microorganisms, potentially pathogenic microorganisms (PPMs), and highly 
pathogenic microorganisms. Low pathogens have an IPI of 0.01 and rarely cause 
infections when carried by an individual. PPMs may cause infection when the 
defence mechanisms are reduced and they have an IPI of about 0.1. MRSA is 
classified as an “abnormal” PPM as its typical feature is an IPI between 0.1 and 0.3 
[40]. The classification is useful in ICU practice because it is best adapted to the ICU 
flora, and integrates several concepts of clinical epidemiology, such as the distinction 
between “normal” and “abnormal” flora rather than the distinction of 
microorganisms into “community” and “hospital”. 
 
Table 1.1 Classification of microorganisms based on their intrinsic pathogenicity 
Microorganisms Intrinsic 
Pathogenicity 
Flora IPI 
1.- Indigenous flora 
Oropharynx: Peptostreptococci, Streptococcus viridans, 
Veilonella spp. 
Gut: Bacteroides spp, Clostridium spp, Enterococci 
Skin: CNS, Propionibacterium acnes 
Vagina: Peptostreptococci, Bacteroides, Lactobacillus spp. 
Low ≤0.01 
2.- Community micro-organisms 
Oropharynx: Streptococcus pneumoniae, Haemophilus 
influenzae, Branhamella catarrhalis, methicillin-sensitive 
Staphylococcus aureus, Candida spp. 
Gut: Escherichia coli, methicillin-sensitive Staphylococcus 
aureus, Candida spp. 
Potential 
Normal 
 
≤0.1 
3.- Hospital micro-organisms 
Klebsiella, Proteus, Morganella, Enterobacter, 
Citrobacter, Serratia, Pseudomonas spp, Acinetobacter 
spp, Stenotropomonas maltophilia, Burkolderia cepacia, 
methicillin-resistant Staphylococcus aureus 
Potential ≤0.1 
4.- Epidemic micro-organisms 
Neisseria meningitidis. Salmonella spp High 
Abnormal 
Around 
1 
IPI, intrinsic pathogenicity index; spp, species; CNS, coagulase-negative staphylococci 
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Figure 1.1 The slippery slope of the pathogenesis of endogenous and exogenous 
infection due to PPMs in the ICU 
 
 
Knowledge of the carrier state allows the distinction between three types of infection 
in the ICU (Table 1.2, Figures 1.1 and 1.2) [35]: 
1. Primary endogenous infections are the most frequent infection in the ICU (50%-
85%) [41, 42]. These infections are caused by normal or abnormal PPMs imported 
into the ICU by the patient’s admission flora. These episodes of infections in general 
occur early, during the first week of ICU stay. Adequate parenteral antibiotics given 
immediately on ICU admission may reduce the incidence of primary endogenous 
infection [43, 44]. 
Acquisition 
Carriage 
Overgrowth 
Colonisation 
Infection 
Surveillance cultures Diagnostic samples 
Oropharynx and gut Internal organs 
Primary endogenous 
infection 
Secondary endogenous 
infection 
Exogenous 
infection 
  
23
 
Table 1.2 Classification of ICU infections according with the criterion of carriage 
Type of infection PPM Timing Frequency
Primary endogenous 
Normal and 
abnormal 
Within 1 week of ICU 
stay 
55% 
Secondary endogenous Abnormal 
After 1 week of ICU 
stay 
30% 
Exogenous Abnormal 
Any time during ICU 
stay 
15% 
PPM, potentially pathogenic microorganism; ICU, intensive care unit. 
 
2. Secondary endogenous infections are caused by abnormal PPMs, including 
aerobic Gram-negative bacteria (AGNB) and MRSA, not carried in throat and/or gut 
at the time of admission to the ICU, but acquired during ICU-treatment prior to the 
infection. The incidence of this infection is about 30% of all ICU infections [35, 41, 
42]. Secondary endogenous infection usually occurs after 1 week of stay on the ICU. 
The PPMs are firstly acquired in the oropharynx and/or gut and subsequently 
carriage and overgrowth may develop. Topical application of antimicrobials has been 
shown to control secondary endogenous infections together with high levels of 
hygiene [44]. 
3. Exogenous infections are approximately 10-15% of all ICU infections and are 
caused by abnormal hospital PPMs introduced into the patient’s internal organ from 
the environment, either animate or inanimate [44]. Bacteria are transferred directly 
into an internal organ, without previous carriage, and surveillance samples are 
negative for PPMs that readily appear in diagnostic samples. This infection may 
occur at any time during ICU stay. High levels of hygiene are required to control 
these infections. 
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According to this criterion of carriage, only secondary endogenous and exogenous 
infections are true ICU-acquired infections, whilst primary endogenous infections are 
considered to be imported infections. 
 
 
 
 
 
Figure 1.2 Flowchart for classifying ICU infections using the carrier state criterion 
PPM, potentially pathogenic microorganism 
Is the PPM 
causing infection 
carried in the 
patient’s 
admission flora? 
Check carriage on 
admission and twice 
weekly using 
surveillance cultures 
Confirm the PPM 
causing infection 
using diagnostic 
samples 
Is the PPM 
causing infection 
carried by the 
patient in throat 
and/or gut? 
Exogenous 
infection 
Primary 
endogenous 
infection
Secondary 
endogenous 
infection
Endogenous 
infection 
Yes No 
Yes
No
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1.3.2 The microbiota of critically ill patients 
In recent years, the use of new laboratory techniques has opened up a new area of 
research, allowing investigation of the complex population of microorganisms (not 
cultivable under conventional methods) present in the gut of the critically ill: the 
microbiota and the microbiome. The microbiota is an ecological community of 
commensal, symbiotic and pathogenic microorganisms, including bacteria, archaea, 
protists, fungi and viruses. The microbiome describes their collective genome [45]. 
In literature, the distinction in terminology is sometimes ambiguous as microbiome is 
used interchangeably with microbiota. 
The intestinal microbiota in healthy adults is dominated by four phyla: Firmicutes 
(64%), Bacteroidetes (23%), Proteobacteria (8%) and Actinobacteria (3%) [46]. 
Firmicutes are Gram-positive aerobic and anaerobic bacteria, including 
Staphylococci, Streptococci, Enterococci, Bacilli, and Clostridia. Bacteroidetes are 
Gram-negative bacteria including Bacteroides species. Proteobacteria are the major 
phylum of Gram-negative bacteria, including aerobic and anaerobic Gram-negative 
bacteria: potentially pathogenic aerobic Gram-negative bacilli belong to this phylum. 
In general, the Firmicutes to Bacteroidetes ratio is important in human microbiota 
composition. It evolves during different stages of age being 0.4 in infants, 10.9 in 
adults, and 0.6 in elderly individuals [47]. Within the microbiota exists a hierarchy of 
dominant anaerobic bacteria of the genera Bacteroides, Aubacterium, 
Bifidobacterium, Peptostreptococcus, Ruminococcus, Clostridium and 
Propionibacterium, and a subdominant bacteria of Enterobacteriaceae family, in 
particular E. coli, and the genera Streptococcus, Enterococcus, Lactobacillus, 
Fusobacterium, and Methanobrevibacter [48]. 
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Dysbiosis of the gut microbiota, i.e. a condition in which normal composition of 
microbiota is disrupted and is detrimental to the host, has been associated with 
different diseases such as diabetes, obesity, inflammatory bowel disease, and 
rheumatoid arthritis [49]. In healthy subjects intestinal microbiota protects against 
the invasion of low pathogenic microorganisms (e.g. Enterococci), potentially 
pathogenic microorganisms (e.g. AGNB), and C. difficile. 
In critically ill patients the severity of the underlying disease, nutrients deprivation, 
the use of vasoactive agents, opioids, stress ulcer prophylaxis, and other drugs 
including antibiotics, have been shown to impact the gut microbiota [50]. However, 
it is not yet clear which of these factors are more important in contributing to 
dysbiosis [50]. Antibiotic treatment may cause a disruption of normal microbiota 
allowing for the carriage and overgrowth of antibiotic-resistant PPMs and 
opportunistic microorganisms [51]. In general, the microbiota of the critically ill 
shows a loss of microbial diversity and richness, and demonstrates a tendency for a 
single taxon, usually PPMs, to dominate a given microbiota, and a loss of site 
specificity, i.e. carriage with the same microorganism at multiple sites [52]. 
Therefore, restoring the microbiota may have a potential to reduce infection, but, at 
the present time, information on the dynamics of the microbiota in the critically ill is 
limited. Section 1.4 will provide current evidence of the impact of selective 
decontamination of the digestive tract on gut microbiota. 
 
1.3.2.1 Carriage, overgrowth and infection due to PPMs. 
 
Microorganisms carried by healthy individuals usually belong to the normal flora 
(Table 1.1). They are mainly anaerobes and aerobes of the indigenous flora, together 
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with PPMs, such as Streptococcus pneumoniae, methicillin-sensitive S. aureus 
(MSSA), Haemophilus influenzae, Branhamella catarrhalis, Escherichia coli and 
Candida albicans. E. coli is considered normal flora in the intestinal tract, but its 
presence in the oropharyngeal cavity is abnormal. S. aureus is part of the flora of the 
oropharynx, anterior nares, and the intestinal tract in 20-40% of healthy individuals 
and is considered normal flora [34]. Abnormal flora is uncommon in healthy people, 
and may be only transiently carried, and includes AGNB, such as Klebsiella, 
Proteus, Morganella, Enterobacter, Citrobacter, Serratia, Acinetobacter, and 
Pseudomonas species, and MRSA [34, 53]. About 30% of patients with an 
underlying chronic disease, such as diabetes, chronic obstructive pulmonary disease 
(COPD), end-stage renal failure receiving haemodialysis, may demonstrate abnormal 
flora in their oropharynx and gut [34]. Moreover, previously healthy patients 
admitted to the ICU and requiring long-term ventilatory support due to an acute 
insult, such as (surgical) trauma, pancreatitis, or acute liver failure, may become 
carriers of abnormal flora in their digestive tract. Therefore the critical illness is the 
most important factor in the conversion of normal to abnormal carrier state and from 
low- to high-grade carriage [34, 44]. 
The anterior nares are the main ecological niche for S. aureus, including MRSA. 
About 20% of individuals are nasal carriers of S. aureus, and 30% are transiently 
carriers [54]. However, S. aureus may be carried in other different sites such as 
axillae, groin, oropharynx and gastrointestinal tract, also in overgrowth 
concentration. Oropharyngeal carriage in overgrowth concentration is a reservoir 
from which S. aureus may migrate through aspiration into the tracheobronchial tree 
causing colonisation and infection of the lower airways. Similarly, gut carriage and 
overgrowth favour migration into the urinary tract and translocation into the 
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bloodstream, causing urinary tract and bloodstream infection, respectively (Figure 
1.3). Subjects with S. aureus carriage generally develop infection with their 
colonising strain [55]. In a study on bacteraemia, blood isolates of S. aureus were 
related to nasal isolates in 82% of patients [56]. 
During mechanical ventilation, micro aspiration of the oropharyngeal content, and 
subsequent endogenous colonisation of the lower airways is the main mechanism of 
lower respiratory tract infection, and, in particular, of ventilator associated 
pneumonia (Figure 1.1, Figure 1.3). Additionally, MRSA may be introduced directly 
into the lower airways from an external source, either animate or inanimate (i.e. 
exogenous colonisation). The host’s mechanical, cellular and humoral defences are 
available in the oropharynx and the lower airways to prevent pneumonia. 
Risk factors for MRSA carriage and infection on admission to the hospital or the 
ICU are previous MRSA infection and/or carriage, previous nursing home 
admission, prior hospital or ICU admission, prior antibiotics, presence of skin lesions 
or pressure ulcers, comorbidities such as heart failure, COPD, renal failure and 
diabetes [57]. 
The basis for S. aureus carriage is complex and not clearly understood, but appears 
to involve the host's contact with S. aureus, and the ability of S. aureus of adhering 
to host cells and to escape the immune response [54]. S. aureus has an extensive 
body of virulence factors, which are involved in infection. Numerous surface 
proteins bind to collagen, fibronectin and fibrinogen, and may explain the ability of 
S. aureus to cause vascular, bone and joint, and prosthetic-device infections. Once S. 
aureus adheres to tissue or devices, it is able to grow and live forming biofilms, or to 
survive into the endothelial cells in order to escape host defences and antibiotics 
[58]. Additionally, S. aureus generates an anti-phagocytic microcapsule, is able to 
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bind the Fc portion of immunoglobulins, secretes a protein which inhibits the 
chemotaxis, and produces leukocidines which destroy leukocytes [54]. S. aureus 
produces numerous enzymes, proteases, lipases, elastases, that allow it to invade and 
destroy host tissues. S. aureus is able to determine septic shock by interacting with 
the immune system and the coagulation pathway [59]. Some strain produces 
exfoliative toxins capable of causing scalded skin syndrome or bullous impetigo. In 
summary, S. aureus has many mechanisms to produce disease and to escape host 
defences. Strains of S. aureus, including MRSA, are different to each other due to a 
different distribution and presence of virulence factors. 
Although there is a level of uncertainty about whether MRSA is more virulent than 
MSSA, invasive MRSA infections are associated with higher cost and limited 
treatment options. A meta-analysis and epidemiological studies demonstrated an 
increased morbidity and mortality from nosocomial MRSA infections, such as 
pneumonia, bloodstream infections, and surgical-site infections, compared with those 
from MSSA [60-65]. Other studies did not demonstrate this correlation [66-68]. A 
recent systematic review evaluated the impact of methicillin resistance on mortality 
in S. aureus VAP [69]. The crude in-hospital and ICU-mortality was higher in 
patients with VAP due to MRSA as opposed to MSSA (OR 1.79, 05% CI 1.21-2.65 
and OR 2.49, 95% CO 1.54-4.06, respectively). 
 
1.4 Prevention of ICU infections 
 
This section briefly illustrates the evidence of the literature behind the manoeuvres 
used to prevent ICU infection with a particular attention to the use of enteral 
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antimicrobials to control carriage, overgrowth and infection due to PPMs. Figure 1.3 
shows the pathogenesis of ICU infections and the preventative manoeuvres. 
 
 
 
 
 
 
Figure 1.3 Summary of the pathogenesis of ICU infections due to potentially 
pathogenic microorganisms and their preventative measures. 
PPMs, potentially pathogenic microorganisms; SDD, selective decontamination of the digestive tract; 
SOD, selective oropharyngeal decontamination. Black arrows indicate endogenous infections. Orange 
arrows indicate exogenous infections. 
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1.4.1 Hygiene measures 
 
Handwashing is a fundamental manoeuvre for the prevention of infection in the ICU. 
It is a well recognized, simple, and low-cost prevention strategy that reduces the risk 
of healthcare workers transmitting PPMs from one patient to another and, thus, 
reducing ICU-acquired infection. Therefore, handwashing and other hygiene 
manoeuvres can prevent secondary endogenous and exogenous infection. 
Handwashing does not affect primary endogenous infections caused by PPMs 
already present in throat and gut of the patient on ICU admission [37, 70]. 
 
1.4.2 Probiotics 
 
Probiotics are “living microorganisms that (when ingested) have a beneficial effect in 
the prevention and treatment of specific pathologic conditions” [71]. They may 
prevent ICU infections by reducing carriage and overgrowth of PPMs in the 
oropharynx and gut. Additionally, probiotics exert their beneficial effect by 
enhancing gut barrier function, maintaining a normal intestinal microbiota, 
synthesizing antibacterial substances, and stimulating local immunity [72]. Two 
recent meta-analyses showed that probiotics reduced the incidence of lower 
respiratory tract infection in mechanically ventilated patients, although an impact on 
mortality was not demonstrated [73, 74]. However, these results are not robust do to 
several limitations of meta-analyses. Large sample size and high-quality RCTs are 
required to assess the effect of probiotics in preventing lower respiratory tract 
infection, and in reducing mortality in ventilated ICU patients. 
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1.4.3 Semirecumbent position 
 
The guidelines of the American Thoracic Society, the Infectious Diseases Society of 
America, and the Centers for Disease Control and Prevention (CDC), have 
recommended semi-recumbent positioning for the prevention of VAP in 
mechanically ventilated patients (i.e. head of bed elevation to 30°-45°) [75, 76]. 
Supine positioning, gastric tubes and stomach contents lead to the reflux of gastric 
contents and aspiration, causing VAP. Semi-recumbent position may avoid these 
events and may reduce VAP. Using radioactively labelled enteral feeding, the risk of 
gastro-oesophageal reflux and aspiration was lower among patients in a semi-
recumbent position than those in a supine position [77, 78]. 
A recent systematic review showed that semirecumbent position of 30° to 60° 
significantly reduced the risk of clinically suspected VAP compared to supine 
position (8 trials, 759 participants, relative risk [RR] 0.36, 95% CI 0.25-0.50) [79]. 
However, semirecumbent position did not impact microbiologically confirmed VAP, 
mortality, length of ICU stay, duration of mechanical ventilation, and antibiotic use. 
Adequately powered RCTs are needed to assess whether the semi-recumbent 
position is superior to the supine position regarding patient-important outcomes, and 
which degree of head-of bed elevation is optimal to balance the benefits with the 
potential risks, e.g. thromboembolism, pressure sores or haemodynamic instability. 
 
1.4.4 Subglottic secretion drainage 
 
Current guidelines recommend the use of endotracheal tubes with subglottic 
secretion drainage to prevent ventilator-associated pneumonia. In a recent meta-
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analysis including 17 trials and 3,369 patients, subglottic secretion drainage was 
associated with lower ventilator-associated pneumonia rates (RR, 0.58; 95% CI, 
0.51-0.67), but there were no significant differences between groups in duration of 
mechanical ventilation, ICU length of stay, ventilator-associated events, and 
mortality (RR, 0.93; 95% CI, 0.84-1.03) [80]. Further studies are required to 
demonstrate the benefits of subglottic secretion drainage on mortality. 
 
1.4.5 Oral care 
 
Oral care with chlorhexidine to prevent lower respiratory tract infection in ICU 
patients has been reported by scientific societies. However, the evidence that 
chlorhexidine is effective and safe seems less robust than previously supposed. Many 
meta-analyses of RCTs have reported lower VAP rates, but in blinded studies the 
impact was absent [81]. Additionally, chlorhexidine has never been shown to reduce 
mortality, and, even, some meta-analyses have demonstrated an increased mortality 
[83]. The first part of this thesis will focus on the efficacy of oral chlorhexidine 
(chapter 5) and topical mupirocin (chapter 4) to control infection in ICU patients. 
 
1.4.6 Selective decontamination of the digestive tract 
 
To control carriage and overgrowth of PPMs in the oropharynx and gut of critically 
ill ICU patients a regimen of antimicrobial prophylaxis using parenteral and enteral 
antimicrobials was designed in the early eighties of the previous century. The aim of 
the manoeuvre was to eradicate carriage of normal and abnormal flora, and to 
prevent endogenous and exogenous infections due these microorganims. This 
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regimen was termed selective decontamination of the digestive tract or SDD. Its full 
protocol is based on four pillars [44, 84]: 
1. parenteral antibiotics given immediately on admission for 4 days to control 
primary endogenous infections due to PPMs already present in the patient’s 
admission flora. Healthy patients with normal flora can be treated with 
cefotaxime 80-100 mg/kg/day. Patients with a chronic underlying disease or 
patients transferred from other ICUs or general wards may carry both normal and 
abnormal flora in throat and gut, and may require an antipseudomonal 
cephalosporin or a glycopeptide if P. aeruginosa or MRSA carriage are expected, 
respectively. 
2. enteral non-absorbable antimicrobials, i.e. polymyxin E, tobramycin and 
amphotericin B (PTA) to control secondary carriage/overgrowth and subsequent 
secondary endogenous infections due to PPMs acquired during ICU stay. Half a 
gram of gel or paste containing 2% PTA is applied to the oropharyngeal mucosa 
four times a day. Additionally, 10 ml of a suspension containing 100 mg of 
polymyxin E, 80 mg of tobramycin and 500 mg of amphotericin B is 
administered into the gut through the nasogastric tube four times a day. In case of 
MRSA endemicity in the ICU or MRSA carriage, half a gram of a 4% 
vancomycin gel/paste in the oropharynx and/or 500 mg of vancomycin solution 
in the intestine can be added four times a day to the classical PTA regimen to 
eradicate MRSA carriage and to prevent MRSA infections. 
3. high standards of hygiene are required to control secondary endogenous and 
exogenous infections due to transmission of ICU-associated microorganisms. 
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4. surveillance cultures of throat and rectum on admission and, afterwards, twice 
weekly are needed to monitor the efficacy of SDD, and to detect the emergence 
of resistance at early stage. 
The combination of polymyxin and tobramycin was chosen because it covers the 
majority of abnormal AGNB, including Pseudomonas species, and it is synergic in 
vitro. The use of a polyene, such as amphotericin B or nystatin, eradicates fungal 
overgrowth [44]. The use of the parenteral antibiotic cefotaxime was chosen because 
its spectrum included both normal and most abnormal PPMs, and its 
pharmacokinetic properties included a high excretion in saliva and bile, associated 
with eradication of overgrowth [44]. 
A modified regimen of SDD, called oropharyngeal selective decontamination (SOD), 
was introduced. SOD includes the oropharyngeal component without intestinal and 
parenteral antimicrobials. 
There have been 71 RCTs of SDD and more than 15 meta-analyses of RCTs over a 
research period of more than 30 years. The most robust meta-analyses showed that 
SDD significantly reduced lower airway infection by 72% (odds ratio [OR] 0.28, 
95% CI, 0.20-0.38), bloodstream infection by 27% (OR 0.73, 95% CI, 0.59-0.90), 
and mortality by 18% (OR, 0.82, 95% CI, 0.72-0.93) to 29% (OR, 0.71, 95% CI, 
0.61-0.82) [44, 83, 85-87]. A recent meta-analysis demonstrated that SDD was 
superior to SOD in reducing mortality [88]. This difference in effectiveness may be 
related to the intestinal and parenteral components which are not part of the SOD 
regimen [88]. Emergence of resistance was not demonstrated in meta-analyses and 
large RCTs of SDD/SOD [89, 90]. 
Recent studies analysed the impact of SDD on gut microbiota. These studies showed 
that, compared with healthy subjects, the microbiota of ICU patients receiving SDD 
  
36
was characterized by lower microbial diversity, lower levels of E. coli and anaerobic 
Gram-positive butyrate-producing bacteria (e.g. Faecalibacterium prausnitzii), and 
increased abundance of Bacteroidetes and enterococci [91-93]. 
A common effect of SDD is a relative increase of enterococci in the gut [90]. This 
can be explained by the intrinsic resistance of enterococci to the SDD antimicrobials. 
Enterococci have been considered low pathogenic microorganisms as usually, in case 
of infection, lead to a relative low inflammatory state. However, these 
microorganisms may be a concern in ICU due to emerging antibiotic resistance (e.g. 
VRE) and increasing virulence. Previous studies have shown that SDD therapy can 
select for intestinal colonisation by enterococci [91, 94]. A recent meta-analysis of 
van der Bij et al [95], determined the antibiotic resistance rate of Gram-positive cocci 
in blood and respiratory specimens in 42 Dutch ICUs in the period from 2008 to 
2013, indicating that SDD was not associated with an increase of antibiotic resistance 
in Gram-positive cocci, including enterococci. Additionally, a meta-analysis of the 
microbiology of SDD did not demonstrate any increase in Gram-positive infections 
[96]. 
There are scarce data regarding the re-colonisation of the gut and infection rates upon 
ICU discharge and cessation of SDD. After discontinuation of SDD/SOD patients 
may acquire carriage with typical hospital pathogens or suppressed carriage of these 
bacteria may emerge. Although incidences of hospital acquired infections tend to be 
higher in patients that had received SDD or SOD during ICU-stay, it seems unlikely 
that these infections have an effect on hospital mortality [97]. 
As the traditional SDD regimen does not target MRSA, adjustment of the SDD 
antimicrobials by adding vancomycin have been used to control MRSA carriage and 
overgrowth in ICUs with MRSA endemicity. The enteral administration of 2 gr/day 
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of vancomycin obtains faecal vancomycin levels between 3,000 and 24,000 μg per 
gram of faeces, whilst after 2 gr/day of parenteral vancomycin faecal vancomycin 
levels are between 6 and 11 μg per gram of faeces [98, 99]. High levels of faecal 
vancomycin may explain why VRE is absent when using enteral vancomycin. On the 
contrary, non-lethal, low concentrations of vancomycin in the gut after parenteral 
administration may promote the selection of VRE. 
Although data on the impact of enteral vancomycin on gut microbiota in ICU 
patients are very limited, changes of the gut microbiota in these patients should be 
acknowledged. In non-ICU patients, oral vancomycin treatment decreases the 
richness and diversity of human microbiota, reduces the level of Bacteroidetes 
phylum, whilst Proteobacteria and Fusobacteria phyla increase. Additionally, 
among Proteobacteria, abnormal AGNB increase [100]. Additionally, a 
disadvantage of this approach might be the increased selective pressure for VRE and 
VISA in the ICU. 
The main issue of this thesis is the effectiveness of enteral vancomycin to control 
MRSA infection in ICU patients. The effect of enteral vancomycin on the emergence 
of resistant strains, i.e. VISA and VRE, will be assessed, and the potential impact on 
gut microbiota will be discussed. 
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2 AIMS OF THE THESIS 
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2.1 Background 
 
Traditionally, the control of MRSA infection has been focused on the prevention of 
transmission between patients via the hands of healthcare workers, such as 
handwashing, patient’s isolation or cohorting, use of sterile equipments, hygiene, and 
cleanliness of the environment [101, 102]. However, it has been repeatedly shown 
that a large proportion of MRSA infections in the ICU originate from the patient’s 
own flora (i.e. endogenous infections) [103, 104], as critical illness promotes 
abnormal carriage in throat and gut of abnormal potential pathogens, including 
MRSA [105]. Moreover, MRSA carriage in the oropharynx and gut has been shown 
to be an independent risk factor for overgrowth and subsequent endogenous MRSA 
infection of the lower respiratory tract and the bloodstream. 
Both oropharyngeal chlorhexidine and nasal mupirocin have been used to control 
oropharyngeal overgrowth of MRSA [104, 106, 107]. However, these manoeuvres 
are expected to impact only lower respiratory tract infection. The use of enteral 
vancomycin, including oropharyngeal and intestinal administration, to control 
MRSA carriage of the oropharynx and gut, and to prevent severe MRSA infection of 
the lower airways and the bloodstream is uncommon [108]. 
 
2.2 Aims of the thesis 
 
The aims of the thesis are: 
- To assess the effectiveness of oropharyngeal mupirocin and chlorhexidine to 
control severe ICU infections, including MRSA infection; 
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- To assess the effectiveness of enteral vancomycin to control MRSA infections in 
ICU patients and to evaluate the safety of the manoeuvre in terms of VISA and VRE 
emergence; 
- To evaluate the impact of oropharyngeal vancomycin on MRSA infection in 
mechanically ventilated ICU patients. 
  
41
 
 
 
 
 
 
 
 
 
3 MATERIALS AND METHODS 
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3.1 Structure of the research 
 
The research project is divided into two research sections: 
1. The first part focuses on the effectiveness of some manoeuvres applied to the oral 
cavity to control severe ICU infections, including MRSA infections. 
2. The second part explores: 
- The effectiveness of enteral vancomycin to control severe ICU infection, 
including MRSA infection; 
- The safety of enteral vancomycin; 
- The impact of enteral vancomycin on MRSA infections in a cohort of 
mechanically ventilated ICU patients. 
 
3.2 Details of the research 
 
The main details of the research project are depicted in Figure 3.1, and are reported 
in the following summary. The research is divided into four chapters: 
1. Chapter 4: systematic review and meta-analysis of RCTs to assess the 
effectiveness of topical mupirocin to control severe ICU infections, including 
infections due to both MSSA and MRSA, and to evaluate the impact on 
mortality. 
2. Chapter 5: systematic review and meta-analysis to assess the effectiveness of 
oropharyngeal chlorhexidine to control severe infection in critically ill 
patients, including MRSA infection, and to evaluate the impact on mortality. 
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Figure 3.1 Diagram flow of the research project 
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3. Chapter 6: systematic review and meta-analysis to assess the effectiveness of 
enteral vancomycin to control MRSA carriage and infection. The emergence 
of VISA and VRE is evaluated. 
4. Chapter 7: retrospective, 16-year, cohort study in ICU patients receiving 
enteral vancomycin. The endpoint is the incidence of MRSA severe infection. 
 
For each chapter a separate section named “materials and methods” or “patients and 
methods” will be provided. Additionally, for each chapter a separate section entitled 
“discussion” will comment the results in the context of the evidence and the 
literature. 
The main structure of the four chapters is described in the following points 3.3 and 
3.4. 
 
3.3 Systematic review and meta-analysis 
 
In accordance with the PRISMA (Preferred Reporting Items for Systematic Review 
and Meta-analysis) guidelines [109], chapters 4, 5, and 6 include specific sections 
labelled introduction, materials and methods, results, discussion, and conclusion. 
Each section will be differently expanded according to the endpoints of the 
systematic review. In general: 
- The introduction describes the rationale of the review and what is already 
known, and delineates all questions being addressed with reference to 
participants, interventions, comparisons, outcomes and study design (PICOS) 
[109]. 
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- The materials and methods section specifies the eligibility criteria for each 
included study, the sources of information (e.g. databases), the search 
strategy, the study selection, the inclusion and exclusion criteria, the data 
collection process, the assessment of the quality of study using the Jadad 
score [110] or the risk of bias tool of the Cochrane collaboration [111] for 
RCTs, and the Newcastle-Ottawa scale for non-randomised studies [112], the 
summary measures (i.e. odds ratio with 95% confidence interval using the 
random effects model), and the synthesis of the results, including the 
evaluation of the heterogeneity (Cochran Q statistics and I2) [113]. A funnel 
plot is created (if appropriate) for the main outcome to explore the presence 
of a publication bias. Computations are performed using the EasyMA 
software (M. Cucherat, Lyon, France) [114]. 
- The result section gives details on the number of studies screened, assessed 
for eligibility, and included in the review, with reasons for exclusions at each 
stage. A flow diagram of the research is provided. Results of different 
outcomes are presented in detail, including confidence intervals, measures of 
heterogeneity, and if necessary, the forest plot of meta-analysis. Results of 
additional analyses, e.g. subgroup analyses, are included. 
- The discussion section examines the main findings in the context of the 
evidence and the literature, presents details on the study limitations, and, if 
applicable, suggests implications for a future research. 
- The conclusion section provides a summary of the results. 
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3.4 Observational study 
Chapter 7 includes a retrospective, cohort study in intensive care unit patients 
receiving long-term mechanical ventilation and enteral vancomycin with the 
endpoint of MRSA infections. 
The study adheres to the STROBE (Strengthening the Reporting of Observational 
studies in Epidemiology) statement [115]. The study includes the following sections: 
introduction, patients and methods, results, discussion, and conclusions. Details for 
each section are included in chapter 7. In general: 
- The introduction section explains the rationale, the background, and the 
objectives of the study. 
- The patients and methods section presents the key elements of the study 
design, describes the setting, the period of recruitment, the method of data 
collection, the participants (including the eligibility criteria), the 
microbiological methods, and the statistics. 
- The results section gives details on participants, descriptive data 
(demographic and clinical data), and outcome data. 
- The discussion summarises the key results, discusses limitations of the study, 
and gives the interpretation of the results. 
- The conclusion provides a summary of the results. 
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4 EFFECTIVENESS OF MUPIROCIN TO CONTROL INFECTION IN 
ICU PATIENTS. 
 A SYSTEMATIC REVIEW AND META-ANALYSIS 
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4.1 Introduction 
 
Digestive tract carriage and subsequent colonisation of internal organs are important 
steps in the pathogenesis of S. aureus infection, including MRSA infection. 
Approximately 30% of the population carries S. aureus in the oropharyngeal cavity, 
nares and the digestive tract. A large proportion of S. aureus infections originate 
from the patient’s own flora [56, 116]. Carriage of S. aureus in overgrowth 
concentration has been considered a risk factor for endogenous infection, both 
primary and secondary, in patients undergoing surgery, in patients on dialysis, in 
those with liver cirrhosis, and in ICU patients [22, 57]. 
Mupirocin is a pseudomonic acid naturally produced by Pseudomonas fluorescens. It 
inhibits bacterial protein synthesis by reversibly binding to bacterial isoleucyl-tRNA-
synthetase. It has excellent in vitro activity against staphylococci and the majority of 
streptococci, but has less activity against other Gram-positive and most Gram-
negative bacteria. Used as topical ointment, mupirocin is effective against both 
MSSA and MRSA. The first trial in volunteers was undertaken in 1986. It 
demonstrated the ability of mupirocin applied into the anterior nares to eliminate 
staphylococcal nasal carriage [117]. Subsequently, several studies conducted in 
different populations showed that mupirocin was effective in the short term in 
eradicating nasal carriage of S. aureus when compared with placebo [118]. 
Mupirocin ointment has been used to eradicate staphylococcal carriage and to 
prevent infections, to control infections in surgical, cardiac and orthopaedic patients, 
in non-surgical patients and in haemodialysis patients [107, 119-123]. However, its 
efficacy on MRSA infection in critically ill ICU patients has not yet been assessed in 
a systematic review. 
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We undertook a systematic review and meta-analysis to assess the efficacy of topical 
mupirocin to control infection, including lower respiratory tract infection due to both 
MSSA and MRSA, and to evaluate the impact on mortality in critically ill ICU 
patients. 
 
4.2 Materials and methods 
 
4.2.1  Search strategy 
The systematic review was performed in accordance with PRISMA guidelines [109]. 
PubMed, Embase and the Cochrane Register of Controlled Trials for RCTs were 
searched with no language restriction. Search terms were mupirocin, 
decontamination, decolonisation, nasal, intensive care unit. Previous published meta-
analyses were searched and references were crosschecked. Two investigators 
independently performed the search and screened titles and abstracts for relevant 
clinical trials published from 1983 to April 2016. Finally, RCTs were analyzed based 
on the full text using a standardized data extraction form. 
 
4.2.2 Selection criteria 
Inclusion and exclusion criteria were decided before reviewing abstracts and articles. 
All RCTs including usable information on MSSA and/or MRSA infection were 
included. RCTs were in critically ill ICU patients receiving topical mupirocin in the 
test group; the control group received placebo or different oral care products. RCTs 
in neutropenic and bone marrow transplant patients were excluded. 
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4.2.3 Data extraction 
Two investigators independently retrieved and compared the sets of data from each 
clinical trial. Any disagreement was resolved by discussion. The following data were 
sought: first author, publication year, population included, description of test and 
control arms, randomization and allocation procedures, blinding, handling of 
dropouts and withdrawals, number of patients included, number of patients with 
infection, number of patients with lower respiratory tract infection due to MSSA and 
MRSA, and overall mortality. 
 
4.2.4 Quality assessment 
The quality of RCTs was assessed using the Jadad score [110]. The studies were 
considered of low quality if the score was ≤ 2 and of high quality if the score was ≥ 
3. 
 
4.2.5 Endpoints and statistical analysis 
The primary endpoints were infection and lower respiratory tract infection due to 
MSSA and MRSA. The secondary endpoint was mortality. A subgroup analysis was 
performed in high quality vs. low quality studies, and in blinded vs. non-blinded 
studies. 
Results were presented as odds ratio (OR) with 95% confidence interval (CI) using 
the random effects model. The Cochran Q statistic for heterogeneity was used both 
for the outcome measures and throughout subgroup analyses; heterogeneity was 
significant if the p value was <0.10. Additionally, I2 was evaluated using the formula 
100% x (Q-df)/Q, where Q is Cochran’s Q statistics and df is the degree of freedom 
(number of studies- 1). Negative values of I2 are equal to 0%; an I2 of 0% indicates 
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no observed heterogeneity, whilst < 30% indicates mild heterogeneity, 30-50% 
moderate, and > 50% severe. Significant heterogeneity was predefined as an I2 
greater than 50% [113]. We explored the funnel plot to estimate potential publication 
bias. Computations were performed using the EasyMA software (M. Cucherat, Lyon, 
France) [114]. 
 
4.3 Results 
 
4.3.1 Search findings and description of studies 
The search strategy yielded 240 publications. After the exclusion of duplicates and 
irrelevant publications, we considered 23 RCTs for more detailed evaluation. The 
subsequent screening yielded six randomised controlled trials undertaken in the 
intensive care unit, and assessed for eligibility. Two RCTs were not included: one, 
including 74.256 patients, because data on infection were reported as number of 
infection per 1000 attributable days [124], the second due to unclear data on 
infection [125]. A final sample of 4 RCTs, including 1024 patients (521 mupirocin, 
503 control), was the basis for the systematic review and meta-analysis [126-129] 
(Figure 4.1). 
Tables 4.1 and 4.2 describe the main characteristics and data on outcomes extracted 
from the 4 RCTs published from 1999 to 2011. Two studies were Italian [126, 127] 
and two were French [128, 129]. One RCT was published in Italian [126]. All RCTs 
were performed in medical or surgical ICUs. One study used 2 millilitres of 
mupirocin ointment three times a day compared with placebo [126]. In the other 
Italian study [127] the test group received 0.2 millilitres of a 2% mupirocin ointment 
four times a day into the nostrils; the placebo group received 0.2 millilitres of a 
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placebo ointment which was indistinguishable from mupirocin ointment. In a 
multicenter French study [128] including three test arms, only the arm using 2% 
mupirocin was compared with the control group which received a placebo. In the 
second French study [129] only MRSA carriers were treated with nasal mupirocin 
and were compared with the control group receiving standard care. In three studies 
mupirocin was administered three times a day [126, 128, 129], and in one study four 
times a day [127]. The site of administration was the anterior nares in all studies, and 
in one [127] was combined with the oropharynx. In one study [127] both test and 
control patients received also oropharyngeal and intestinal SDD, containing 
polymyxin E, tobramycin and amphotericin B. Three studies were performed in 
mechanically ventilated subjects [126-128], and one study in ICU patients admitted 
for more than 48 hours [129]. 
 
 
Figure 4.1 Diagram flow of the research strategy
Potentially relevant 
publications identified and 
screened for retrieval 
(n=240)
Studies retrieved for more 
detailed evaluation 
(n=41)
Review, inappropriate design, non-
randomised trials, letter, commentary 
(n=199) 
Potentially appropriate 
RCTs for inclusion 
(n=23)
Duplicate publication (n=18) 
Not intensive care patients (n=17) 
No data available on infection (n=2) 
RCTs included in the 
systematic review 
(n= 4) 
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Table 4.1 Characteristics of RCTs on mupirocin 
Patients Intervention  First Author Year 
Mup C Mup C 
Population Randomization Allocation Blinding Jadad 
score 
Di Filippo 
[126] 
1999 24 24 2 ml mupirocin ointment  
into the nostrils 3 times a 
day for 3 days 
Placebo same 
frequency 
Medical and 
surgical ICU 
List of random 
numbers 
Unclear Only 
personnel 
was 
blinded 
0 
Nardi [127] 2000 119 104 0.2 ml of a 2% 
mupirocin ointment into 
the nostrils 4 times a day, 
plus SDD containing 2% 
mupirocin in the 
oropharyngeal paste 
0.2 ml of a 
placebo ointment 
into the nostrils 
same frequency, 
plus SDD without 
mupirocin 
Medical, 
surgical and 
trauma ICU 
Computer 
generated list 
Unclear Double 
bind 
2 
Camus [128] 2005 130 126 2% mupirocin into the 
anterior nares 3 times a 
day 
Placebo same 
frequency 
Medical ICU 
of 3 hospitals 
Computer 
generated list 
Not stated Double-
blind 
3 
Camus [129] 2011 248 249 2% mupirocin into the 
anterior nares 3 times a 
day for 5 days 
Standard care Medical ICU 
of 2 university 
hospitals 
Computer 
generated list 
Unclear Not blinded 0 
Mup, mupirocin; C, control; SDD, selective digestive tract decontamination (polymyxin E, tobramycin, amphotericin B); ICU, intensive care unit; ml, millilitres. 
 
Table 4.2 Summary of data retrieved from RCTs on mupirocin 
Patients enrolled LRTI Bloodstream 
infection 
Urinary tract 
infection 
Mortality MSSA 
LRTI 
MRSA LRTI First Author 
Mup C Mup C Mup C Mup C Mup C Mup C Mup C 
Di Filippo [126] 24 24 3 5       0 3 1 1 
Nardi [127] 119 104 9 20     25 26 0 2 1 7 
Camus [128] 130 126 14 20 8 14 27 24 36 41     
Camus [129] 248 249       49 52     
Total 521 503 26 45 8 14 27 24 110 119 0 5 2 8 
RCTs, randomised controlled trials; Mup, mupirocin; C, control; LRTI, lower respiratory tract infection; MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-
resistant S. aureus
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Data on the type of microorganism causing bloodstream infection were reported by 
three studies [126-128]. Data on infections due to S. aureus were obtainable from 
three studies [126, 127, 129]. A French study [128] reported details on episodes of 
infection only, and details on S. aureus infection were not given. Mortality data were 
available from three studies [127-129]. 
The quality assessment for all trials using the Jadad score showed a median of 2; 
only one RCT was classified as high-quality study [128]. Two studies were double 
blinded [127, 128], in one study [126] only the personnel was blinded, and one study 
was not blinded [129]. The randomization procedure was adequate in all studies, but 
the allocation procedure was at high risk of bias in all studies. We did not explore the 
funnel plot asymmetry for publication bias due to the small number of included 
studies. 
 
4.3.2 Infection 
Three studies [126-128], including 527 patients (273 mupirocin, 254 control), were 
the basis for the meta-analysis of overall lower respiratory tract infection (LRTI) 
(Figure 4.2). There were 26 patients (9.5%) with lower respiratory tract infection in 
the mupirocin group, and 45 (17.7%) in the control group demonstrating a significant 
reduction of lower respiratory tract infection (OR 0.49, 95% CI 0.29-0.83, p=0.008). 
The test for heterogeneity was not significant (χ2=1.2161, p=0.54, I2=0%). 
One trial [128] reported data on urinary tract infection and bloodstream infection. 
Mupirocin did not impact any of these infections (OR 1.11, 95% CI 0.60-2.06, and 
OR 0.53, 95% CI 0.21-1.30, respectively). 
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Results from two RCTs including 271 patients (143 test, 128 control) were available 
for the analysis of MRSA lower respiratory tract infection [126, 127]. There were 
two (1.4%) and 8 (6.2%) patients with MRSA lower respiratory tract infection, 
indicating a lack of effect of mupirocin (OR 0.28, 95% CI 0.04-2.16, p=0.22). The 
test for heterogeneity was not significant (χ2=1, p=0.32, I2= 0%) (Figure 4.3). The 
incidence of methicillin-sensitive S. aureus lower respiratory tract infection was 
reported by 2 RCTs [126, 127], and no impact of mupirocin was found (OR 0.08, 
95% CI 0.00-1.48, p=0.09). 
 
 
 
Figure 4.2 Forrest plot of the impact of mupirocin on LRTI 
OR, odds ratio; CI, 95% confidence interval. OR < 1 favours treatment; OR > 1 favours controls. 
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Figure 4.3 Forrest plot of the impact of mupirocin on MRSA LRTI 
OR, odds ratio; CI, 95% confidence interval. OR < 1 favours treatment; OR > 1 favours controls. 
 
 
 
Figure 4.4 Forrest plot of the impact of mupirocin on mortality 
OR, odds ratio; CI, 95% confidence interval; OR < 1 favours treatment; OR > 1 favours controls. 
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4.3.3 Mortality 
The analysis of mortality was based on 3 RCTs and 976 patients (497 test, 479 
control) [127-129]. There were 110 (22.1%) and 119 (24.8%) deaths in test and 
control group, respectively. Mupirocin did not significantly reduce mortality (OR 
0.86, 95% CI 0.64-1.15, p=0.31). The test for heterogeneity was negative (χ2=0.2729, 
p=0.87, I2=0%) (Figure 4.4) 
 
4.3.4 Subgroup analysis 
The subgroup analysis for lower respiratory tract infection is reported in Table 4.3. In 
double-blinded [127, 128] and in low-quality RCTs (126, 128) mupirocin reduced 
overall lower respiratory tract infection (OR 0.49, 95% CI 0.27-0.89, p=0.02 and OR 
0.49 95% CI 0.29-0.83, p=0.007, respectively). No effect on other variables has been 
shown. 
The study by Nardi et al [127] was the only positive study for overall and MRSA 
lower respiratory tract infection: Additionally, in this study both test and control 
arms received the antibiotic policy of SDD. A post-hoc analysis of RCTs after the 
exclusion of this study, did not demonstrate any significant impact of mupirocin on 
LRTI (OR 0.62, 95% CI 0.32-1.21, p= 0.16) and other outcome measures. 
 
Table 4.3 Subgroup analysis of the endpoint of lower respiratory tract infection 
N° Patients N° events Subgroups N° 
RCTs Mup C Mup C 
OR (95% CI) p 
Blinding 
- double-blinded 
- not blinded 
Quality 
- low quality 
- high quality 
 
2 
1 
 
3 
- 
 
249 
24 
 
273 
- 
 
230 
25 
 
254 
- 
 
23 
3 
 
26 
- 
 
40 
5 
 
45 
- 
 
0.49 (0.27-0.89) 
0.54 (0.11-2.58) 
 
0.49 (0.29-0.83) 
- 
 
0.02 
0.5 
 
0.007 
- 
RCTs, randomised controlled trials; Mup, mupirocin; C, control; OR, odds ratio; CI, confidence 
interval. NE, not evaluable The I2 test for heterogeneity was not significant in all comparisons. 
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4.4 Discussion 
 
Two main findings emerge from this systematic review of only RCTs: 
1. Mupirocin reduces lower respiratory tract infection, but not mortality; 
2. There was not any evidence of the effect of mupirocin on MSSA and MRSA lower 
respiratory tract infection. 
This is the first analysis of the effectiveness of topical mupirocin to prevent lower 
respiratory tract infection and MRSA infections in ICU patients. A subgroup analysis 
showed that the effect on lower respiratory tract infection has been found in only 
low-quality studies. Additionally, the analysis after the exclusion of the only positive 
study on overall and MRSA lower respiratory tract infection, did not demonstrate 
any significant effect of mupirocin [127]. 
Our findings that mupirocin reduced overall lower respiratory tract infection in 
critically ill patients is consistent with previous observations and meta-analyses in 
non-ICU patients. In a meta-analysis of 4 studies in surgical patients, van Rijen et al. 
[120] showed that among 686 mupirocin-treated surgical patients with S. aureus 
nasal carriage, there were 25 S. aureus infections (3.6%), compared with 46 (6.7%) 
in the controls (relative risk [RR] 0.55, 95% CI 0.34–0.89; p=0.02). They concluded 
that prophylactic intranasal mupirocin significantly reduced the rate of post-operative 
S. aureus infections among surgical patients who were S. aureus carriers. In surgical 
patients who were not carrying S. aureus, there was no effect of treatment, with a 
slightly higher infection rate noted in the treated group (RR 1.09, 95% CI 0.52–2.28). 
Nine RCTs, involving 3396 participants, were included in a meta-analysis of the 
same group on the prevention of S. aureus infections in nasal carriers [106]. Patient 
populations varied and several types of nosocomial S. aureus infection were 
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described including bacteraemia, exit-site infections, peritonitis, respiratory tract 
infections, skin infections, surgical site infections, and urinary tract infections. After 
pooling eight studies that compared mupirocin with placebo or no treatment, there 
was a statistically significant reduction in the rate of S. aureus infection associated 
with intranasal mupirocin (RR 0.55, 95% CI 0.43 to 0.70). The infection rate caused 
by microorganisms other than S. aureus was significantly higher in patients treated 
with mupirocin compared with control patients (RR 1.38, 95% CI 1.12-1.72). The 
surgical sub-group of patients showed a significant reduction in nosocomial S. 
aureus infection with mupirocin (RR 0.56, 95% CI 0.34-0.91), but failed to extend to 
surgical site infection (RR 0.63, 95% CI 0.38-1.04). 
Another systematic review analysed the different manoeuvres to control healthcare-
associated MRSA infection [130]. Among them, 11 RCTs, 23 comparative studies 
and one prospective cohort study evaluated the effectiveness of mupirocin-based 
nasal decontamination regimens for the prevention of S. aureus infections. Six out of 
7 studies included in the review were carried on in ICU setting and demonstrated a 
successful effect of mupirocin treatment. However, all these studies were not 
randomised trials and included observational, historical, and before-after studies. 
A recent meta-analysis assessing the relationship between nasal carriage of S. aureus 
and the development of osteo-articular infection showed increased risk of surgical 
site infection in case of nasal carriage of S. aureus (OR 5.92, 95% CI 1.15-30.39, p = 
0.033) [122]. The review confirmed that nasal carriage of S. aureus is a major risk 
factor for surgical site infection. The efficacy of eradication could not be 
demonstrated for orthopaedic surgery as samples were too small. Very large numbers 
of patients would be needed to confirm intranasal mupirocin efficacy in reducing 
surgical site infection with statistical significance. It is estimated that about 14.000 
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patients with a baseline surgical site infection rate of 5% would be needed to 
demonstrate a 20% reduction in the SSI rate [131]. 
This meta-analysis showed that mupirocin did not reduce MSSA and MRSA lower 
respiratory tract infections. However, only two studies, including 271 patients, 
reported data on these infections. The sample size and the number of patients with 
MRSA or MSSA infection were too small to draw robust conclusions. 
Although not included in this systematic review and meta-analysis, a large cluster-
randomised multicenter trial in 74 adults ICUs, including 74,256 patients, was 
carried on to explore the effectiveness nasal mupirocin and daily bathing with 
chlorhexidine to all patients known to have MRSA carriage or infection (targeted 
decolonisation) compared with universal decolonisation in all patients and no 
decolonisation (only screening and isolation) to prevent ICU infection [128]. 
Unfortunately, the unit of randomization was the hospital, not the patient. The 
authors concluded that universal decolonisation in all patients was more effective 
than targeted decolonisation or no decolonisation in reducing MRSA isolates and 
bloodstream infection from any pathogen, but not MRSA bloodstream infection. 
In this meta-analysis mupirocin has been shown to control lower respiratory tract 
infection in ICU patients, but this effect was not associated with a mortality 
reduction. First, the small sample size of 976 patients may explain the lack of any 
effect on mortality. Second, mupirocin does not affect the intestinal overgrowth of S. 
aureus, and, therefore, does not prevent bloodstream infection [57] which is 
associated with an increased mortality [60]. MRSA LRTI is also associated with an 
increase in mortality [68]. The lack on any significant effect on MRSA LRTI and 
bacteraemia may explain why mortality is not affected by mupirocin. Finally, an 
inherent limitation of mupirocin is the control of exogenous infections. The source of 
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PPMs causing this infection is external to the patient (e.g. tracheostomy care, 
devices). 
Development of resistance is an important issue during mupirocin use. Mupirocin 
resistance occurs in two phenotypes: low-level mupirocin resistance (MIC between 8 
and 64 mg/L) and high-level mupirocin resistance (MIC ≥512 mg/L). High-level 
resistance is mediated by plasmids carrying the mupA gene, while low-level 
resistance occurs through point mutations in the isoleucyl-tRNA synthetase gene. An 
increase in mupirocin resistance in response to increasing use has been reported in 
practice [132-135]. A recent simulation of the transmissibility of the mupirocin-
resistant and mupirocin-sensitive MRSA strain demonstrated that, although the 
transmission probability of a mupirocin-sensitive MRSA is higher than a mupirocin-
resistant strain, in the long term the prevalence of a mupirocin-resistant strain will 
increase with the universal use of mupirocin [136]. 
This systematic review has some limitations. First, after the exclusion of the only 
positive study on overall lower respiratory tract infection [127], the impact of 
mupirocin on this outcome was not significant. Therefore, results on overall lower 
respiratory tract infection should be interpreted with an appropriate degree of 
caution. Second, a clinical heterogeneity was present due to different sites of 
administration of mupirocin, different definitions of lower respiratory tract infection, 
different treatment of the control patients (placebo, standard care), the use of SDD 
antimicrobials in both test and control patients in one study [127], different types of 
patients (medical, surgical, and trauma patients), and the use of mupirocin only in 
MRSA carriers in one study [129]. Third, the quality of studies included in the 
review was low. Low quality studies and non-blinded studies are prone to possible 
increased risk of bias. A subgroup analysis has been performed on these variables. 
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Fourth, this review includes a small number of studies. Small meta-analyses (i.e. less 
than 200 outcome events) may be mainly useful for generating hypotheses for further 
research [137]. Therefore, the results of this systematic review and meta-analysis 
should be cautiously interpreted. 
 
4.5 Conclusion 
 
This systematic review showed that mupirocin, although reduces lower respiratory 
tract infection, does not reduce mortality and does not impact MSSA and MRSA 
LRTI. The results should be interpreted with caution due to several important 
limitations. Future RCTs of topical mupirocin to prevent lower respiratory tract 
infection in ICU patients are warranted. 
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5 EFFECTIVENESS OF ORAL CHLORHEXIDINE ON INFECTION, 
MICROORGANISMS AND MORTALITY IN ICU PATIENTS. 
A SYSTEMATIC REVIEW AND META-ANALYSIS 
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5.1 Introduction 
 
Lower respiratory tract infection and bloodstream infection are the most common 
serious infections developing in critically ill patients requiring treatment on the ICU 
[75, 138]. Hospital-acquired lower respiratory tract infection accounts for up to 25% 
of all ICU infections; VAP occurs in 9-27% of all intubated patients [75]. Lower 
respiratory tract infection prolongs the length of ICU treatment and hospital stay 
[75], increases costs [139] and mortality [140].The incidence of BSI is between 5 and 
19 per 1,000 patient days, and is associated with increased mortality and costs [24, 
138]. Therefore, the prevention of these infections is a high priority for infection 
control in the ICU. 
Oropharyngeal carriage of potential pathogens in overgrowth concentrations is the 
first essential step in the pathogenesis of lower respiratory tract infection in critically 
ill patients [44]. There is a qualitative and quantitative relationship between 
surveillance cultures of the throat and the diagnostic samples of lower airway 
secretions. As soon as the potential pathogen reaches overgrowth concentration in 
the oropharynx the lower airway secretions become positive for the same potential 
pathogen. This leads to colonisation and subsequent infection of the lower 
respiratory tract [141, 142]. 
The main sources of BSI are internal organs (i.e. lung and bladder) and the gut [87, 
143], apart from catheter-related BSI. Microorganisms causing infection of the lower 
airways or the bladder may be responsible for blood invasion [143-145]. Moreover, 
gut overgrowth promotes translocation of bacteria into the systemic circulation [56, 
146]. Finally, a substantial number of catheter-related BSI may be due to skin 
microorganisms [143]. 
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There are approximately 14 potential pathogens causing severe infection in ICU 
patient [44]. Five “normal” bacteria are the causative agents in healthy individuals 
and include S. pneumoniae, MSSA, H. influenzae, M. catarrhalis, and E. coli. There 
are nine “abnormal” bacteria causing pneumonia. They include eight AGNB, such as 
Klebsiella, Proteus, Morganella, Enterobacter, Citrobacter, Serratia, Acinetobacter, 
and Pseudomonas species, and MRSA. Abnormal flora is uncommon in healthy 
people, whilst disease promotes oropharyngeal and gastrointestinal carriage of these 
microorganisms. 
Control of oropharyngeal overgrowth of potential pathogens using antimicrobials and 
antifungal agents applied into the oropharynx is termed oropharyngeal 
decontamination, and has been shown to prevent lower respiratory tract infection and 
bloodstream infection [44, 84, 87]. Chlorhexidine is an antiseptic agent active against 
Gram-positive and Gram-negative, “normal” and “abnormal” bacteria [147]. The 
efficacy of oral chlorhexidine in preventing lower respiratory tract infection has been 
assessed in several RCTs and meta-analyses [82, 148-157]. A recent Belgian meta-
analysis, including 12 RCTs, showed a significant 28% reduction in the relative risk 
for VAP [156]. However, none of those meta-analyses had bloodstream infection as 
morbidity endpoint, or the causative micro-organism as bacteriological endpoint. 
The aim of this systematic review is to explore the effectiveness of oral 
chlorhexidine in the prevention of lower respiratory tract infection and bloodstream 
infection, to assess which microorganism causing LRTI and BSI is impacted by 
chlorhexidine, and to evaluate the effect on mortality in critically ill patients. 
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5.2 Materials and methods 
 
5.2.1 Search strategy 
The systematic review and meta-analysis has been performed in accordance with the 
PRISMA guidelines [109]. We searched PubMed, Embase and the Cochrane 
Register of Controlled Trials for RCTs with no language restriction. Search terms 
were chlorhexidine, oral care, oral hygiene, oral health, oral rinse, oral 
decontamination, mouthwashes, bloodstream infection, bacteraemia, lower airway 
(respiratory tract) infection, nosocomial pneumonia, ventilator-associated 
pneumonia, hospital-acquired pneumonia, dental plaque, with the search limits of 
“clinical trial” and “humans”. Additionally, we searched abstracts from scientific 
meetings, crosschecked the references of papers and published meta-analyses, and 
searched unpublished studies in the register of clinical trials. Four investigators 
independently cooperated in performing the search and in screening titles and 
abstracts for relevant clinical trials published until June 2014. RCTs were analyzed 
based on the full text using a standardized data extraction form. 
 
5.2.2 Selection criteria 
We established inclusion and exclusion criteria before reviewing abstracts and 
articles. Only RCTs in critically ill patients receiving oral care with chlorhexidine 
were included. The control intervention could include placebo, standard therapy, or 
another product for oral care. We excluded RCTs in which topical oropharyngeal 
antibiotics or probiotics were used. We also excluded RCTs in which both arms 
received chlorhexidine and RCTs in cancer patients, neutropenic, stem cell and bone 
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marrow transplant patients. RCTs with usable information by outcome were finally 
included in the meta-analysis. 
 
5.2.3 Data extraction 
Three investigators independently retrieved the published findings from each clinical 
trial and compared the sets of data. Any disagreement was resolved by discussion. 
The following data were sought for each study: author, publication year, population 
included, description of the intervention/control arm, randomization, allocation 
concealment, blinding, and handling of dropouts/withdrawals, definition of lower 
respiratory tract infection, number of patients included, number of patients with 
lower respiratory tract infection, number of patients with the microorganism causing 
lower respiratory tract infection, number of patients with BSI, number of patients 
with the microorganism causing BSI (individual microorganism, Gram-positive, 
Gram-negative, “normal” flora, “abnormal” flora) and total mortality. We used the 
term ‘lower respiratory tract infection’ throughout the review; this comprised 
nosocomial pneumonia, hospital-acquired pneumonia, and VAP. 
Microorganims causing infection have been classified with two methods: the Gram 
staining technique which distinguishes Gram-positive from Gram-negative 
microorganisms, and the method using the distinction between “normal” and 
“abnormal” flora. “Normal” flora included S. pneumoniae, H. influenzae, methicillin-
sensitive S. aureus, M. catarrhalis, and E. coli [158]. Nine microorganisms belonged 
to the “abnormal” flora: eight AGNB including Klebsiella, Proteus, Morganella, 
Enterobacter, Citrobacter, Serratia, Acinetobacter, and Pseudomonas species, and 
MRSA [158]. Coagulase-negative staphylococci, enterococci and yeasts were not 
included in lower respiratory tract infection as they generally do not cause this 
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infection in immune-competent host, unless the authors stated that there was a 
histological evidence of lung infection due to these microorganisms [75, 159]. 
 
5.2.4 Quality assessment 
The quality of the included RCTs was assessed by two investigators using the Jadad 
score [110]. The studies are considered of low quality if the score was ≤ 2 and high 
quality if the score was ≥ 3. 
 
5.2.5 Endpoints and statistical analysis 
The primary endpoint was the number of patients developing lower respiratory tract 
infection and bloodstream infection, and mortality. The secondary endpoint was the 
microorganism involved. We planned a priori the following subgroup analyses of the 
endpoints of lower respiratory tract infection, bloodstream infection and mortality: a) 
randomization/allocation procedures concealment (adequate or inadequate) (smaller 
treatment effect in concealed vs. unconcealed allocation); b) blinding of patients and 
caregivers to allocated treatment (blinded or unblinded) (smaller treatment effect in 
blinded compared with unblinded studies); c) quality of the studies (low or high 
quality) (smaller treatment effect in high quality studies); d) concentration of 
chlorhexidine (0.12%-0.2% or 1%-2%) (smaller treatment effect in lower 
concentrations); e) type of population (surgical, medical or mixed) (smaller treatment 
effect in medical/mixed population); f) age (adults, children) (smaller treatment 
effect in children). 
Results were presented as odds ratio (OR) with 95% confidence interval (CI) using 
the random effects model. The random effects model provides a more conservative 
estimate of the 95% CI, taking heterogeneity into account. The Cochran Q statistic 
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for heterogeneity was used both for the outcome measures and through subgroup 
analyses; we considered heterogeneity to be significant if the p value was <0.10. I2 
was also evaluated with the formula 100% x (Q-df)/Q, where Q is Cochran’s Q 
statistics and df is the degree of freedom (number of studies- 1). Negative values of I2 
are put equal to 0%; zero percent indicates no observed heterogeneity, whilst an I2 of 
< 30% indicates mild heterogeneity, 30-50% moderate, and > 50% severe; we 
predefined significant heterogeneity as an I2 measure greater than 50% [113]. A 
funnel plot was constructed to estimate potential publication bias. Computations 
were performed using the EasyMA software [114]. 
 
5.3 Results 
 
5.3.1  Search findings and description of studies 
The initial search resulted in 60 potentially relevant clinical trials (Figure 5.1). Of 
these, 28 were excluded: 18 clinical trials were not randomised, two RCTs were 
double publications, six RCTs received chlorhexidine in both study arms, and in two 
RCTs chlorhexidine was used in the control arm. Of the remaining 32 potentially 
appropriate RCTs, 10 were excluded: three because lower respiratory tract infection 
was not the endpoint and 7 because details on the number of patients with lower 
respiratory tract infection were absent, insufficient or unclearly reported. A final 
sample of 22 RCTs, totalling 4,277 patients (2,119 chlorhexidine, 2,158 controls), 
was the basis for the systematic review and meta-analysis [160-181]. 
Tables 5.1, 5.2 and 5.3 describe the main characteristics and data on outcomes 
extracted from the 22 RCTs. Studies were published during the time period from 
1996 to 2012. Two studies were available only in abstract form [165, 174]. The 
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randomization procedure, including allocation concealment, was adequate in 8 
studies [160, 164, 165, 170, 176-178, 181]. Eleven studies were double-blinded [160, 
164-168, 170, 171, 173, 177-179, 181], one was single-blinded [160], nine were not 
blinded [161, 166-168, 171, 173-175, 179], and in one study the blinding method 
was not reported [163]. Nineteen RCTs included adults [160-176, 178, 180], and 
three paediatric patients [177, 179, 181]. Twelve studies were performed in 
mixed/trauma ICU population, four in cardiac surgery patients [160, 162, 165, 177], 
two in surgical patients [173, 180] and four in medical patients [161, 169, 178, 181]. 
Fifty-one percent of patients of this review (i.e. 2,168) were included in the six 
surgical studies. Half of the studies [160, 162, 165, 167, 170-172, 174, 175, 177, 
179] used 0.12% chlorhexidine, seven studies employed 0.2% chlorhexidine [161, 
163, 164, 169, 173, 176, 178], one study used 1% chlorhexidine [181], two studies 
used 2% chlorhexidine [166, 168], and in one study the chlorhexidine concentration 
was not clearly stated [180]. Chlorhexidine was applied one [175, 180], two [160, 
162, 163, 167, 169, 170, 1727 178, 179], three [161, 164, 171, 173, 181] or four 
[165, 166, 168, 178] times a day. Different protocols of administration, or a 
combination of them, were described in the RCTs (e.g. mouth rinse, mouth 
cleansing, toothbrushing, gingival brushing, use of a gloved finger or swab, etc), as 
well as different chlorhexidine formulations (i.e. saline solution, alcoholic 
preparation, gel). Nosocomial lower respiratory tract infection was the endpoint of all 
included studies. 
Studies were performed on mechanically ventilated subjects. In three studies only a 
portion of patients were ventilated, i.e. 39% and 34% [169], 65% and 72% [171], 
57% and 77% [173], in chlorhexidine and control group, respectively. However, in 
two studies [169, 171], nearly all patients with lower respiratory tract infections 
  
71 
belonged to the mechanically ventilated group. Data on the type of microorganism 
causing lower respiratory tract infection were present in nine [160, 161, 164-166, 
168, 169, 173, 181] and seven [161, 164-166, 169, 173, 181] RCTs which included 
data on the Gram stain and on “normal” and “abnormal” bacteria classifications, 
respectively. Mortality data were available from 16 studies [160-166, 168-171, 173, 
177-179, 181]. 
All, but one [178], studies reported a definition of lower respiratory tract infection. 
Five studies [165, 170, 174, 177, 179] used the clinical pulmonary infection score, 
five studies [162, 165, 171, 177, 181] simply referred to the Centers for Disease 
Control and Prevention definition [182], and one [172] to the American Thoracic 
Society/Infectious Disease Society of America statement [183]. One study [167] did 
not provide a clear description of lower respiratory tract infection. The remaining 
nine studies [160, 161, 164, 166, 168, 171, 173, 176, 180] clearly defined lower 
respiratory tract infection. 
The methodological quality assessment for all trials showed a median of 3.5 (quartile 
range 0-5). Accordingly, 14 RCTs were high-quality studies (160, 164-166, 169-171, 
173, 175-179, 181). 
The inspection of the funnel plot for lower respiratory tract infection suggested no 
evidence of publication bias. The funnel plot for bloodstream infection was not 
created due to the low number of studies. 
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Figure 5.1 The flow diagram of the search strategy 
 
 
2233 citations identified through 
databases searching  
60 studies screened for more 
detailed evaluation 
2199 identical and irrelevant publications 
removed 
Excluded: 
18 were non-randomised or with inappropriate 
design 
2 were duplicates in different language of the 
main publication 
3 did not have lower respiratory tract infection or 
bloodstream infection as outcomes 
37 randomised controlled 
trials assessed for eligibility 
and screened 
22 randomised controlled 
trials included in the 
systematic review 
26 citations identified through 
manual searching 
Excluded: 
6 received chlorhexidine in both arms 
2 used chlorhexidine in the control arm, not in the 
test arm 
7 had incomplete or not clear data on bloodstream 
infection 
RCTs with usable information by 
outcome: 
- LRTI (n=22) 
- BSI (n= 5) 
- Gram positive/negative (n=9) 
- Nornal/abnormal flora (n=7) 
- Mortality (n=16) 
RCTs withdrawn for specific outcome 
only when data not available 
  
 
73 
 
 
Table 5.1 Summary of RCTs on oropharyngeal chlorhexidine for the prevention of infection 
First Author Year Test Control Population Allocation 
concealment  
Randomization Blinding Jadad 
score 
DeRiso [160] 1996 0.12% chx gluconate oral rinse 
preoperatively + two times a day 
until ICU discharge 
Placebo, same colour, 
taste and smell 
Cardiac 
surgery ICU 
Central 
randomization 
(pharmacy) 
Computer 
generated 
random 
numbers 
Double blind 4 
Fourrier [161] 2000 0.2% chx gel three times a day 
until ICU discharge 
Standard oral care 
(mouth rinsing with 
bicarbonate isotonic 
serum) 
Medical ICU NR Computer 
generated 
balanced 
randomization 
table 
Single blind 2 
Houston [162] 2002 15 ml of 0.12% chx gluconate 
oral rinse preoperatively + two 
times a day for 10 days or until 
extubation, tracheostomy, death, 
or diagnosis of lower respiratory 
tract infection 
Solution of a phenolic 
mixture 
Cardiac 
surgery ICU 
NR Patients’ 
medical record 
numbers 
No 0 
Macnaughton [163] 2004 0.2% chx mouthwash two times a 
day 
Placebo of identical 
appearance and smell 
Medical/ 
surgical- 
ICU 
NR NR NR 0 
Fourrier [164] 2005 0.2% chx gel three times a day for 
max 28 days 
Placebo, same colour, 
taste, odour and smell 
Medical/ 
surgical ICU 
Central 
randomization 
(pharmacy) 
Block 
randomization 
Double-
blind 
5 
Segers [165] 2006 0.12% chx gluconate oral rinse 
and nasal gel four times a day 
until extubation 
Placebo, same colour, 
taste and smell 
Cardiac 
surgery ICU 
Central 
randomization 
(pharmacy) 
Computer 
generated table 
Double-
blind 
5 
Koeman [166] 2006 0.5 gr of 2% chx ointment four 
times a day 
0.5 gr of 2% chx with 2% colistin 
ointment four times a day 
Placebo, same taste, 
smell, and consistency 
Mixed and 
surgical 
ICUs 
NR Computer 
generated 
schedule 
Double-
blind 
5 
Bopp [167] 2006 0.12% chx gluconate oral 
brushing two times a day 
Standard care 6 times a 
day 
Medical/ 
surgical ICU 
NR Coin flipped 
(heads, chx; 
tails, control) 
No 0 
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Tantipong [168] 2008 15 ml of 2% chx solution four 
times a day 
Oral care with normal 
saline 
Medical and 
surgical 
ICUs and 
medical 
ward 
NR Randomization 
according to sex 
and hospital 
location of the 
patient 
No 0 
Panchabhai [169] 2009 10 ml of 0.2% chx gluconate 
solution oral cleansing two times 
a day 
0.01% potassium 
permanganate solution 
two time a day 
Medical 
neurology 
ICU 
NR Concealed 
simple 
randomization 
No 3 
Scannapieco [170] 2009 0.12% chx oral rinse two times a 
day 
0.12% chx oral rinse once a day + 
placebo once a day 
 
Placebo same colour, 
taste and smell two 
times a day 
Trauma ICU Central 
randomization 
(pharmacy) 
Web-based 
enrolment 
system 
generating a set 
of SID that 
identified 
individual 
treatment 
assignments 
Double-
blind 
5 
Bellissimo-
Rodrigues [171] 
2009 0.12% chx solution three times a 
day 
Placebo same colour, 
consistency, taste and 
smell 
Medical/ 
surgical ICU 
Central 
randomization 
(pharmacy) 
A code number 
was selected 
from a box 
corresponding 
to a bottle 
containing 
placebo or test 
Double-
blind 
4 
Rujipong [172] 2009 0.12% chx toothbrushing and 
mouth wash two times a day 
Routine oral care two 
times a day 
Medical/ 
surgical ICU 
NR Lottery method No 0 
Cabov [173] 2010 0.2% chx gel three time/day Placebo gel same taste, 
colour, and odour 
Surgical 
ICU 
NR Computer 
generated 
balanced 
randomization 
Double blind 4 
Zouka [174] 2010 0.12% chx solution in saline (3:1) Hexetidine 0.1% 
solution 
Medical/ 
surgical ICU 
NR NR No 0 
Grap [175] 2011 5 mL of 0.12% chx solution once 
a day 
Standard oral care 
without chx 
Trauma ICU NR Block 
randomization 
scheme 
No 3 
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Berry [176] 2011 0.2% chx solution oral rinse two 
times a day + sterile water oral 
rinse two hourly 
Sodium bicarbonate mouth wash 
rinsed two hourly 
Sterile water oral rinse 
two hourly 
Medical/ 
surgical ICU 
Allocation of 
identical study 
packs 
remained 
blinded until 
the study pack 
was opened by 
the attending 
nurse 
Computer 
generated table 
No 3 
Jacomo [177] 2011 0.12% chx gluconate  alcoholic 
solution preoperatively and two 
times a day postoperatively 
Placebo solution same 
texture, colour, flavour 
preoperatively and 
postoperatively 
Paediatric 
cardiac 
surgery 
Central 
randomization 
(pharmacy) 
Computer 
generated table 
Double-
blind 
5 
Ozcaka [178] 2012 0.2% chx solution four times a 
day 
Saline four times a day Respiratory 
ICU 
The head 
nurse assigned 
the treatment 
once received 
the SID 
Set of SID that 
identified 
individual 
treatment 
assignments 
Double-
blind 
5 
Kusahara [179] 2012 0.12% chx gel two times a day Placebo gel same 
colour, and odour 
Medical/ 
surgical 
PICU 
NR Computer 
generated 
balanced 
randomization 
table 
Double blind 5 
Zaiton [180] 2012 15 ml chx diluted in 50 ml of 
water once a day 
Oral care with normal 
saline 0.9% once a day 
Surgical 
ICU 
NR NR No 0 
Sebastian [181] 2012 0.5 gr of 1% chx gel three times a 
day 
Placebo gel same 
appearance, 
consistency, taste and 
smell 
Medical 
PICU 
Personnel not 
involved in the 
study and the 
allocation 
sequence 
remained 
concealed 
throughout the 
study 
Computer 
generated 
random 
sequence 
Double blind 5 
Chx, chlorhexidine; ICU, Intensive Care Unit; PICU, Paediatric Intensive Care Unit; NR, not reported; SID, subject identification number. 
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Table 5.2 Summary of RCTs on oral chlorhexidine and the impact on lower respiratory tract infection, mortality and the type of 
microorganism causing lower respiratory tract infection 
N° patients 
enrolled 
N° patients 
with 
infection 
Mortality N° patients 
with infection 
due to Gram 
positive 
pathogens 
N° patients 
with infection 
due to Gram 
negative 
pathogens 
N° patients 
with infection 
due to normal 
flora 
N° patients 
with infection 
due to 
abnormal flora 
First Author 
Chx C Chx C Chx C Chx C Chx C Chx C Chx C 
DeRiso [160] 173 180 3 9 2 10 1 2 3 8     
Fourrier [161] 30 30 5 15 3 7 0 3 5 11  0 3 5 11 
Houston [162] 270 291 4 9 6 3         
Macnaughton [163] 91 88 34 27 36  33         
Fourrier [164] 114 114 13 12 31 24 1 2 11 8 2 3 10 7 
Segers [165] 485 469 45 74 8 6 2 10 41 52 24 49 19 13 
Koeman [166] 127 130 13 23 49 39 2 7 9 15 4 11 7 12 
Bopp [167] 2 3 0 1           
Tantipong [168] 102 105 5 12 36 37 0 0 5 12     
Panchabhai [169] 224 247 16 19 78 70 2 3 11 13 3  3 10 13 
Scannapieco [170] 50 49 7 12 8 8         
Bellissimo-Rodrigues [171] 98 96 19  20  35 33         
Rujipong [172] 12 12 0 2           
Cabov [173] 30 30 1 6 1 3 0 0 1 6 0 0 1 6 
Zouka [174] 14 13 2 2           
Grap [175] 21 18 7 10           
Berry [176] 33 43 4 1           
Jacomo [177] 87 73 16 11 5 5         
Ozcaka [178] 29 32 12 22 17 19         
Kusahara [179] 46 50 15 16 8 12         
Zaiton [180] 40 40 13 24           
Sebastian [181] 41 45 12 14 16 21 1 0 10 14 2 1 9 13 
Total 2119 2158 246 341 339 330 8 28 96 139 35 70 61 75 
Chx, chlorhexidine, C, control. 
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Table 5.3 Summary of randomised controlled trials of oral chlorhexidine and the impact on bloodstream infection, and the 
type of microorganism causing bloodstream infection 
N° patients enrolled N° patients with 
BSI 
N° patients 
with BSI due 
to Gram 
positive 
pathogens 
N° patients 
with BSI due 
to Gram 
negative 
pathogens 
N° patients 
with BSI due 
to normal 
pathogens 
N° patients 
with BSI due 
to abnormal 
pathogens 
First Author 
Chx C Chx C Chx C Chx C Chx C Chx C 
DeRiso [160] 173 180 1 4         
Fourrier [161] 30 30 4 4 2 2 2 2 2 3 2 1 
Fourrier [164] 114 114 7 3 3 4 0 3 3 4 0 3 
Segers [165] 485 469 9 17         
Cabov [173] 30 30 1 2 0 2 1 0 0 2 1 0 
Total number of patients 832 823 22 30 5 8 3 5 5 9 3 4 
N°, number; Chx, chlorhexidine, C, control; BSI, bloodstream infection 
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5.3.2 Lower respiratory tract infection and VAP 
Twenty-two trials included information on lower respiratory tract infection [160-
181]. A total of 4,277 patients (2,119 chlorhexidine, 2,158 controls) were available 
for the analysis. There were 246 patients (11.61%) with lower respiratory tract 
infection in the chlorhexidine group and 341 (18.8%) in controls. Chlorhexidine 
significantly reduced the number of patients who developed lower respiratory tract 
infection (OR 0.66, 95% CI 0.51-0.85, p<0.001) (Figure 5.2). The test for 
heterogeneity yielded a non significant result (χ2=21.66, p=0.42, I2=3%). Twenty-one 
studies were used for the analysis of VAP [160-168, 170-181]. There were 240 
patients with VAP in 2089 patients of the test group (11.5%), and 328 over 2128 
patients in the control group (15.4%) (OR 0.68, 95% CI 0.53-0.87, p<0.001). 
Heterogeneity was not demonstrated (χ2=20.37, p=0.44, I2=1.8%). 
 
 
Figure 5.2 Impact of oral chlorhexidine on lower respiratory tract infection 
OR, odds ratio; CI, 95% confidence interval. OR < 1 favours treatment; OR > 1 favours controls. 
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5.3.3 Bloodstream infection 
Five studies [160, 161, 164, 165, 173] including 1,655 patients (832 chlorhexidine, 
823 controls) were the basis for the meta-analysis of BSI. There were 22 patients 
(2.6%) with BSI in the chlorhexidine group, and 30 (3.6%) in the control group 
giving a non significant reduction of BSI (OR 0.74, 95% CI 0.37-1.50, p=0.40; I2 
=0%) (Figure 5.3). 
 
Figure 5.3 Forrest plot of the effect of oral chlorhexidine on bloodstream infection. 
OR, odds ratio; CI, 95% confidence interval. OR < 1 favours treatment; OR > 1 favours controls. 
 
5.3.4 Mortality 
The overall mortality analysis was based on 16 trials [160-166, 168-171, 173, 177-
179, 181] yielding a total of 4,026 patients (1,997 chlorhexidine, 2.029 control). 
There were 339 deaths in the chlorhexidine group (16.97%) and 330 among controls 
(16.26%). The analysis demonstrated a slight, not significant, increase in the ORs for 
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mortality in the chlorhexidine group (OR 1.11, 95% CI 0.92-1.33, p=0.28) (Figure 
5.4). The test for heterogeneity was not significant (χ2=24.20, p=0.51, I2=0%). 
 
Figure 5.4 Impact of oral chlorhexidine on mortality 
OR, odds ratio; CI, 95% confidence interval. OR < 1 favours treatment; OR > 1 favours controls. 
 
5.3.5 Microorganisms causing lower respiratory tract infection 
There were nine and 27 patients with lower respiratory tract infection due to Gram-
positive bacteria in test and control group, respectively, indicating a protective effect 
of oral chlorhexidine (OR 0.41, 95% CI 0.19-0.85, p = 0.017) (Figure 5.5). The test 
for heterogeneity for the overall comparisons was not significant (χ2=3.98, p=0.86, 
I2=0%). 
Gram-negative bacteria were the causative agents of lower respiratory tract infection 
in 96 patients of the chlorhexidine group and in 139 patients of the control group 
demonstrating a significant 32% reduction of Gram-negative lower respiratory tract 
infection with chlorhexidine use (OR 0.68, 95% CI 0.51-0.90, p=0.0073) (Figure 
5.6). Heterogeneity was not significant (χ2=8.0, p=0.43, I2=0%). 
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Figure 5.5 Impact of oral chlorhexidine on lower respiratory tract infection due to 
Gram-positive bacteria. 
OR, odds ratio; CI, 95% confidence interval. OR < 1 favours treatment; OR > 1 favours controls. 
 
Figure 5.6 Impact of oral chlorhexidine on lower respiratory tract infection due to 
Gram-negative bacteria. 
OR, odds ratio; CI, 95% confidence interval. OR < 1 favours treatment; OR > 1 favours controls. 
 
Seven RCTs [161, 164-166, 169, 173, 181] enrolling 2,116 patients (1,051 
chlorhexidine, 1,065 control) reported information on “normal” and “abnormal” 
bacteria. Thirty-five and 70 patients suffered from lower respiratory tract infection 
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due to “normal” flora in test and control group, respectively. Chlorhexidine 
significantly reduced lower respiratory tract infection due to these microorganisms 
(OR 0.50, 95% CI 0.33-0.75, p<0.001) (Figure 5.7). Heterogeneity was absent 
(χ2=4.07, p=0.67, I2=0%). 
 
Figure 5.7 Impact of oral chlorhexidine on LRTI due to normal flora. 
OR, odds ratio; CI, 95% confidence interval. OR < 1 favours treatment; OR > 1 favours controls. 
 
Figure 5.8 Impact of oral chlorhexidine on LRTI due to abnormal flora. 
OR, odds ratio; CI, 95% confidence interval. OR < 1 favours treatment; OR > 1 favours controls. 
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“Abnormal” flora caused lower respiratory tract infection in 61 patients of 
chlorhexidine group and 75 patients of the control group. Chlorhexidine reduced, 
albeit not significantly, the odds of lower respiratory tract infection by these 
microorganims (OR 0.79, 95% CI 0.50-1.25, p=0.32) (Figure 5.8). Heterogeneity 
was not demonstrated (χ2=6.36, p=0.38, I2=5.6%). 
 
5.3.6 Microorganisms causing bloodstream infection 
Results from 3 trials including 348 patients (174 chlorhexidine, 174 controls) were 
available for the analysis of BSI classified according to both the Gram stain and 
normal and abnormal flora [161, 164, 173]. There were five (2.9%) and eight (4.6%) 
patients with BSI due to Gram-positive bacteria in test and control group, 
respectively, indicating a lack of effect of oral chlorhexidine (OR 0.72, 95% CI 0.23-
2.22, p=0.57; I2 = 0%). Gram-negative bacteria were the causative agents of BSI in 3 
(1.7%) patients of the chlorhexidine group and in 5 (2.9%) patients of the control 
group demonstrating a non significant reduction of BSI (OR 0.83, 95% CI 0.16-4.41, 
p = 0.83; I2 = 0.9%). 
Five (2.9%) and 9 (5.2%) patients suffered from BSI due to “normal” flora in test 
and control group, respectively. Chlorhexidine did not significantly reduce BSI due 
to these microorganisms (OR 0.63, 95% CI 0.21-1.88, p = 0.49; I2=0%). “Abnormal” 
flora caused BSI in 3 (1.7%) patients of chlorhexidine group and 4 (2.3%) patients of 
the control group (OR 1.12, 95% CI 0.14-8.66, p = 0.91; I2=3%). No heterogeneity 
was demonstrated. 
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5.3.7 Type of microorganism causing LRTI and BSI 
A separate analysis was performed for each individual microorganism (Tables 5.4 
and 5.5). Table 5.4 shows the impact of chlorhexidine on the individual 
microorganism causing lower respiratory tract infection. Although most 
microorganisms were impacted by chlorhexidine, this effect was not significant for 
all comparisons. Additionally, the efficacy of oral chlorhexidine on MRSA lower 
respiratory tract infection was not significant in the only RCTs reporting these data. 
There were not lower respiratory tract infections due to MRSA in the chlorhexidine 
group compared with one patient with nosocomial lower respiratory tract infection 
due to MRSA in the control group (OR 0.20, 95% CI 0.01-14.64). 
 
Table 5.4 Meta-analysis of the impact of chlorhexidine on the individual microorganism 
causing lower respiratory tract infection 
N° patients 
randomised 
N° patients 
with LRTI 
Microorganisms 
Chx C Chx C 
OR (95% CI) p 
MSSA 1021 1035 7 18 0.48 (0.20-1.16) 0.10 
MRSA 114 114 0 1 0.20 (0.01-14.65) NE 
Streptococcus pneumoniae 612 599 1 6 0.24 (0.39-1.43) 0.12 
Haemophilus influenzae 612 599 20 28 0.69 (0.38-1.23) 0.21 
Moraxella spp. 485 469 4 9 0.42 (0.13-1.39) NE 
Escherichia coli 864 875 3 9 0.63 (0.15-2.74) 0.54 
Pseudomonas spp. 1051 1065 19 30 0.80 (0.44-1.48) 0.48 
Acinetobacter spp. 536 566 12 12 1.08 (0.47-2.48) 0.85 
Citrobacter spp. 30 30 1 0 5.17 (0.07-390.74) NE 
Serratia spp. 515 499 4 2 1.67 (0.34-8.15) 0.53 
Proteus spp. 30 30 0 1 0.19 (0.01-14.61) NE 
Enterobacter spp. 629 613 5 7 0.81 (0.25-2.60) 0.73 
Klebsiella spp 780 791 13 12 1.05 (0.34-3.22) 0.93 
S. maltophilia 30 30 0 2 0.10 (0.01-6.68) NE 
Enterobacteriaceae 127 130 7 8 0.89 (0.31-2.53) NE 
N°, number; Chx, chlorhexidine; C, control; MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, 
methicillin-resistant Staphylococcus aureus; spp, species; LRTI, lower respiratory tract infection; OR, 
odds ratio; CI, confidence interval; NE, not evaluable. 
 
Table 5.5 shows the impact of chlorhexidine on microorganisms causing bloodstream 
infection. Data on microorganisms were available only from three RCTs [161, 164, 
173]. Although the majority of microorganisms were reduced by chlorhexidine (8 
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episodes in chlorhexidine group, 13 episodes in control group), this effect was not 
significant for all comparisons. Five episodes in both test and control group were 
caused by coagulase-negative staphylococci, anaerobes and enterococci. No MRSA 
bloodstream infections were found. 
 
Table 5.5 Meta-analysis of the impact of chlorhexidine on individual microorganisms 
causing bloodstream infection 
N° patients 
randomised 
N° patients 
with BSI 
Microorganisms 
Chx C Chx C 
OR (95% CI) P  
MSSA 174 174 0 4 0.14 (0.01-2.03) 0.14 
Pseudomonas aeruginosa 114 114 0 1 0.33 (0.01-8.19) 0.50 
Acinetobacter baumannii 30 30 1 0 3.10 (0.12-79.23) 0.50 
Serratia marcescens 30 30 1 0 3.10 (0.12-79.23) 0.50 
Proteus mirabilis 114 114 0 1 0.33 (0.01-8.19) 0.50 
Enterobacter aerogenes 30 30 0 1 0.32 (0.01-8.24) 0.49 
Klebsiella pneumoniae 114 114 1 1 1 (0.06-16.19) 1 
Coagulase-negative staphylococci 144 144 3 4 0.74 (0.16-3.40) 0.70 
Anaerobes 30 30 1 1 1 (0.06-16.76) 1 
Enterococcus faecalis 114 114 1 0 3.03 (0.12-75.08) 0.50 
N°, number; Chx, chlorhexidine; C, control; MSSA, methicillin-sensitive Staphylococcus aureus; BSI, 
bloodstream infection; OR, odds ratio; CI, confidence interval. 
 
5.3.8 Subgroup analysis 
Table 5.6 shows the result of the subgroup analysis of lower respiratory tract 
infection. The impact of chlorhexidine on the reduction of lower respiratory tract 
infection was significant in studies with inadequate randomization procedures (OR 
0.62, 95% CI 0.44-0.87, p=0.005), and both in blinded (OR 0.51, 95% CI 0.51-0.89, 
p = 0.005) and unblinded studies (OR 0.60, 95% CI 0.37-0.99, p=0.047), although in 
unblinded studies the significance was borderline. Chlorhexidine reduced lower 
respiratory tract infection both in low and in high quality studies, although the 
confidence interval in low quality studies was wider than in high quality studies. 
Chlorhexidine concentrations of 0.12%-0.2% and 1%-2% were associated with a 
significant lower respiratory tract infection reduction, although the latter showed a 
wide confidence interval with a borderline significance. 
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Table 5.6 Subgroup analysis of the endpoint of lower respiratory tract infection 
N° Patients N° events Subgroups N° 
RCTs Chx C Chx C 
OR (95% CI) p 
Randomization/allocation 
- adequate 
- not adequate 
Blinding 
- double-blinded 
- not blinded 
Quality 
- low quality 
- high quality 
Chlorhexidine concentration 
- 0.12% - 0.2% 
- 1% - 2% 
Population type 
- surgical 
- medical 
- mixed 
- adult population 
- paediatric population 
 
8 
14 
 
11 
11 
 
8 
14 
 
18 
3 
 
6 
4 
12 
19 
3 
 
1012 
1107 
 
1280 
839 
 
561 
1558 
 
1809 
270 
 
1085 
324 
710 
1945 
174 
 
1005 
1153 
 
1268 
890 
 
582 
1576 
 
1838 
280 
 
1083 
354 
721 
1990 
168 
 
112 
134 
 
156 
90 
 
63 
183 
 
203 
30 
 
82 
45 
119 
203 
43 
 
155 
186 
 
219 
122 
 
92 
249 
 
268 
49 
 
133 
70 
138 
300 
41 
 
0.71 (0.46-1.07) 
0.62 (0.44-0.87) 
 
0.68 (0.51-0.89) 
0.60 (0.37-0.99) 
 
0.49 (0.26-0.92) 
0.70 (0.54-0.92) 
 
0.70 (0.52-0.94) 
0.59 (0.35-0.97) 
 
0.52 (0.33-0.82) 
0.53 (0.26-1.09) 
0.82 (0.60-1.12) 
0.59 (0.45-0.79) 
1.07 (0.65-1.77) 
 
=0.1 
=0.005 
 
=0.005 
=0.047 
 
=0.026 
=0.011 
 
=0.018 
=0.04 
 
=0.005 
=0.083 
=0.22 
<0.001 
=0.79 
RCTs, randomised controlled trials; Chx, chlorhexidine; C, control; OR, odds ratio; CI, confidence 
interval. The I2 test for heterogeneity was not significant in all comparisons. 
 
Six studies including 2,168 patients, i.e. half the population of this review, were 
performed in surgical patients; 4 of them were undertaken in heart surgery. The 
reduction in lower respiratory tract infection was significant (OR 0.52, 95% CI 0.33-
0.82, p=0.005). 
In four RCTs carried on medical population and in 12 studies in mixed ICU 
populations the lower respiratory tract infection reduction was not significant (OR 
0.53, 95% CI 0.26-1.09, p=0.083, and 0.82, 95% CI 0.60-1.12, p=0.22, respectively). 
Rates of lower respiratory tract infection in the controls were 12.2%, 19.8%, and 
19.1% in surgical, medical and mixed population, respectively. 
Finally, chlorhexidine did not impact lower respiratory tract infection in three studies 
including a small subset of 342 paediatric patients. 
The reduction of BSI was significant (OR 0.47, 95% CI 0.22-0.97, p=0.04) in three 
studies including 1,367 patients, i.e. more than 80% of the study population, and 
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performed in surgical patients; 2 of them including 1,307 patients, were undertaken 
in cardiac surgery (Table 5.7). Both in medical and in mixed population the impact 
of chlorhexidine on BSI was not significant (OR 1, 95% CI 0.23-4.43, and OR 2.4, 
95% CI 0.61-9.61, respectively). 
 
Table 5.7 Subgroup analysis of the endpoint of bloodstream infection 
N° patients N° events Subgroups N° 
RCTs Chx C Chx C 
OR (95% CI) p 
Randomization/allocation 
- adequate 
- inadequate 
Blinding 
- Blinded 
- Not blinded 
Quality 
- High quality 
- Low quality 
Chlorhexidine concentration 
- Chx 0.12% 
- Chx 0.2% 
Population type 
- Surgical population 
- Medical population 
- Mixed population 
 
3 
2 
 
4 
1 
 
4 
1 
 
2 
3 
 
3 
1 
1 
 
772 
60 
 
802 
30 
 
802 
30 
 
685 
174 
 
686 
30 
114 
 
763 
60 
 
793 
30 
 
793 
30 
 
649 
174 
 
679 
30 
114 
 
14 
5 
 
18 
4 
 
18 
4 
 
10 
12 
 
11 
4 
7 
 
24 
6 
 
26 
4 
 
26 
4 
 
21 
9 
 
23 
4 
3 
 
0.74 (0.23-2.45) 
0.82 (0.23-2.94) 
 
0.70 (0.28-1.79) 
1 (0.23-4.43) 
 
0.70 (0.28-1.79) 
1 (0.23-4.43) 
 
0.46 (0.22-0.99) 
1.35 (0.53-3.45) 
 
0.47 (0.22-0.97) 
1 (0.23-4.43) 
2.4 (0.61-9.61) 
 
0.63 
0.76 
 
0.46 
1 
 
0.46 
1 
 
0.049 
0.53 
 
0.04 
1 
0.21 
RCTs, randomised controlled trials; Chx, chlorhexidine; C, control; OR, odds ratio; CI, confidence 
interval. The I2 test for heterogeneity was not significant in all comparisons 
 
 
The results of the subgroup analysis for the endpoint of mortality confirmed the 
previous pooled data. In particular, the analysis of subgroups of RCTs including 
adequate randomization, surgical and medical patients, and paediatric population 
demonstrated a not significant reduction in mortality, whilst in the other subgroups 
there was an increase, albeit not significant, in mortality. Interestingly, the baseline 
mortality rate in surgical patients, which represent 52% of the entire study 
population, was very low (2.6%) compared with medical (33%) or mixed population 
(29.4%) (Table 5.8). 
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Table 5.8 Subgroup analysis of the endpoint of mortality 
N° Patients N° events Subgroups N° 
RCTs Chx C Chx C 
OR (95% CI) p 
Randomization/allocation 
- adequate 
- not adequate 
Blinding 
- double-blinded 
- not blinded 
Quality 
- low quality 
- high quality 
Chlorhexidine concentration 
- 0.12% - 0.2% 
- 1% - 2% 
Population type 
- surgical 
- medical 
- mixed 
- adult population 
- paediatric population 
 
7 
9 
 
11 
5 
 
4 
12 
 
13 
3 
 
5 
4 
7 
13 
3 
 
979 
1018 
 
1280 
717 
 
493 
1504 
 
1727 
270 
 
1045 
324 
628 
1823 
174 
 
962 
1067 
 
1268 
761 
 
514 
1515 
 
1749 
280 
 
1043 
354 
632 
1861 
168 
 
87 
252 
 
180 
159 
 
81 
258 
 
238 
101 
 
22 
114 
203 
310 
29 
 
15935 
237 
 
180 
150 
 
80 
250 
 
233 
97 
 
27 
117 
186 
292 
38 
 
0.97 (0.67-1.41) 
1.16 (0.93-0.44) 
 
1.05 (0.82-1.36) 
1.17 (0.89-1.55) 
 
1.03 (0.69-1.52) 
1.13 (0.92-1.40) 
 
1.10 (0.88-1.37) 
1.13 (0.78-1.62) 
 
0.80 (0.35-1.81) 
0.99 (0.62-1.58) 
1.15 (0.90-1.46) 
1.16 (0.96-1.41) 
0.73 (0.41-1.30) 
 
=0.88 
=0.18 
 
=0.68 
=0.26 
 
=0.90 
=0.24 
 
=0.41 
=0.52 
 
=0.59 
=0.98 
=0.27 
=0.13 
=0.28 
RCTs, randomised controlled trials; Chx, chlorhexidine; C, control; OR, odds ratio; CI, confidence 
interval. The I2 test for heterogeneity was not significant for all comparisons 
 
 
5.4 Discussion 
 
Three main findings emerge from this systematic review and meta-analysis of 22 
RCTs and including 4,277 patients: 
1. Chlorhexidine significantly reduces lower respiratory tract infection, but not 
bloodstream infection; the subgroup analysis demonstrates that there is a 
significant reduction of lower respiratory tract infection and bloodstream 
infection only in the subgroup of surgical, mainly cardiac, patients. 
2. Chlorhexidine shows a protective effect against lower respiratory tract infections 
caused by potential pathogens when these bacteria are classified using the Gram 
staining technique; remarkably, when the causative bacteria are classified into 
“normal” and “abnormal” bacteria, chlorhexidine reveals a significant reduction 
in lower respiratory tract infection due to “normal” flora only. The analysis for 
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each individual microorganism causing infections does not demonstrate any 
impact on MSSA and MRSA lower respiratory tract infection and bloodstream 
infection. 
3. Mortality is not impacted by oral chlorhexidine. 
Our observation that chlorhexidine is effective in reducing lower respiratory tract 
infections is in line with previous systematic reviews [149-157]. However, this result 
should be interpreted with caution. Half the population included in the analysis of 
lower respiratory tract infection, i.e. 2,168 of 4,277 patients, comes from only 6 
RCTs performed on surgical, mainly cardiac (2,038 patients), individuals. The 
analysis revealed that chlorhexidine significantly reduced lower respiratory tract 
infection in this subgroup of patients, whereas in medical and in mixed ICU 
population it did not. These observations are in line with those of previous meta-
analyses [148, 155, 156]. There are several reasons explaining the greater treatment 
effect in surgical population. Firstly, the severity of the underlying disease and the 
duration of mechanical ventilation are less in patients undergoing elective surgery 
than in medical or mixed population. Most surgical patients received 4 to 8 hours 
[162], 12 hours [165] or 24 hours [177] of mechanical ventilation after surgery, 
whereas non-surgical patients are ventilated for more than one week. Secondly, 
surgical patients are intubated in the operating theatre under optimal and controlled 
conditions rather than in emergency circumstances. Moreover, all cardiac surgery 
patients usually receive an adequate preoperative oral care. Finally, the sample size 
of medical and mixed population could be too small to detect an effect of 
chlorhexidine on lower respiratory tract infection. However, subgroup analyses are 
observational by nature and are not based on randomised comparisons. The results of 
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this subgroup analysis should be taken with caution and should be best viewed as 
hypothesis generating. 
Recently, Helman et al. found that oral chlorhexidine reduced lower respiratory tract 
infection due to Gram-positive but not Gram-negative bacteria [184]. Conversely, an 
intriguing finding of this review is that oral chlorhexidine was beneficial in 
preventing lower respiratory tract infections due to both Gram-positive and Gram-
negative potential pathogens, whereas, if the causative pathogens were classified into 
“normal” and “abnormal” flora, chlorhexidine covered only “normal” pathogens. The 
Gram staining technique is intrinsically unable to differentiate “normal” from 
“abnormal” flora: for example, Gram-negative bacteria comprise both “normal” (i.e. 
E. coli, H. influenzae, and M. catarrhalis) and “abnormal” pathogens (i.e. Klebsiella, 
Proteus, Morganella, Enterobacter, Citrobacter, Serratia, Acinetobacter, and 
Pseudomonas species). The “normal” Gram-positive and -negative bacteria usually 
cause primary endogenous lower respiratory tract infection in previously healthy 
individuals, such as trauma or surgical patients; in these patients lower respiratory 
tract infection develops “early” during the first week of ICU treatment [44]. On the 
contrary, the “abnormal” Gram-positive and negative microorganims are, in general, 
the causative agents of secondary endogenous lower respiratory tract infection which 
develops “late”, after one week of ICU treatment [44]. The failure of oral 
chlorhexidine to protect against oropharyngeal carriage of “abnormal” bacteria may 
be due to the chlorhexidine inactivation by saliva resulting in non-bactericidal levels 
for these bacteria in the oropharynx [185]. Additionally, our finding that oral 
chlorhexidine is beneficial in surgical patients fits well with the result that 
chlorhexidine impacts only “normal” flora, and confirms the hypothesis of a previous 
systematic review [156] that oral chlorhexidine could have an effect on “early onset” 
  
91 
lower respiratory tract infection only. Additionally, this review investigated the 
impact of each individual microorganism causing LRTI and BSI. There were 
insufficient data from this review on MRSA infection, while there was no impact of 
chlorhexidine on MSSA LRTI and BSI. Additionally, this review was not design to 
detect the type of microorganims causing infection in the subsets of ICU patients, i.e. 
surgical or medical population. 
Three reasons may explain the lack of the efficacy of oral chlorhexidine on BSI. 
First, owing to the pathogenesis of lower respiratory tract infection in the critically ill 
ICU patient, the application of antiseptics or antimicrobials into the oropharynx is 
expected to control only lower respiratory tract infection rather than BSI. Previous 
experiences with the use of oropharyngeal topical antibiotics in ICU patients confirm 
this hypothesis [186, 187]. A recent Dutch RCT demonstrated that ICU-acquired 
bacteraemia occurred in 4.6% of patients receiving the combination of oropharyngeal 
and gut antimicrobials (selective digestive decontamination, SDD) compared with 
5.9% of patients receiving only oropharyngeal antimicrobials (selective 
oropharyngeal decontamination, SOD) (OR 0.77 95%, CI 0.65-0.91) [141]. AGNB 
bacteraemia has also been shown to be higher in patients receiving SOD than in 
those receiving SDD [187]. Second, the finding of our systematic review reinforces 
the critical role of gut decontamination in the control of BSI, despite the availability 
of reports showing that the oropharynx may be the source of S. aureus [146, 188] and 
AGNB bacteraemia [189]. Chlorhexidine applied into the oropharynx does not affect 
the gut flora and, therefore, overgrowth of potentially pathogenic microorganisms is 
the unavoidable consequence. Gut decontamination is important as it eradicates gut 
overgrowth, a phenomenon known to cause translocation [190], inflammation [191] 
and absorption of endotoxin [192]. Third, as oral chlorhexidine has been shown to 
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reduce lower respiratory tract infection, and lower respiratory tract infection may 
cause BSI [193-195], we would assume that BSI is also reduced. However, the link 
between lower respiratory tract infection and BSI is not robust. The sensitivity of 
blood cultures to diagnose lower respiratory tract infection is less than 25%, and, 
when positive, the microorganism may originate from an extra-pulmonary source, 
such as the urinary tract and vascular devices [75, 196, 197]. This information is 
supported by our analysis which found that 62% and 35% of microorganims causing 
BSI in test and control group, respectively, do not generally cause lower respiratory 
tract infection (e.g. coagulase-negative staphylococci, enterococci and anaerobes). 
Similarly to the results of the subgroup analysis of lower respiratory tract infection, 
the subgroup analysis of BSI showed a significant reduction of bloodstream infection 
in surgical patients (OR 0.47; 95% CI 0.22-0.97; p=0.04). The majority of them, i.e. 
1,300 patients (95%), underwent cardiac surgery. 
Mortality was unaffected by oral chlorhexidine in previous meta-analyses, the main 
explanations being both the small sample size [148, 149] and the presence of 
heterogeneity [150, 155, 156]. Two meta-analyses showed an increase in mortality 
[82, 83]. Our mortality analysis included a large sample size of 4,026 patients, and 
did not show any significant heterogeneity using the random effects model, but was 
still unable to demonstrate a survival benefit and showed a non significant increase in 
mortality. There are some explanations for this finding. Firstly, none of the trials 
were powered to detect mortality differences, and, despite combining the RCTs, a 
final sample size with a baseline mortality rate of 16% could yet be inadequate to 
detect a survival benefit [198]. This hypothesis may be consistent with the very low 
baseline 2.6% mortality rate in surgical patients which are 52% (2,088 of 4,026) of 
subjects included in the analysis of mortality. The administration of parenteral 
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antibiotic prophylaxis may explain the low mortality rate in surgical, mainly cardiac, 
patients [199]. In the remaining population, the sample sizes of 678 medical and 
1260 mixed patients with a mortality rate of 33% and 29%, respectively, may be not 
large enough to detect a survival benefit. Secondly, the infection-mortality relation 
may be difficult to demonstrate with the chlorhexidine manoeuvre which only 
impacts the oropharyngeal “normal” flora without affecting gut carriage of 
“abnormal” microorganisms, and thus, without reducing other severe infections, e.g. 
bloodstream infections. In the literature, an example of this issue is the survival 
benefit of SDD compared with SOD [44]. SDD reduced mortality by 29% (OR 0.71, 
95% CI 0.61-0.82), reaching a 42% reduction (OR 0.58, 95% CI 0.45-0.77) when the 
gut was successfully decontaminated [85]. This may be due to the prevention of 
infections of the lower airways [86] and the bloodstream [87, 200] following the use 
of enteral antimicrobials which controls gut overgrowth [44]. On the contrary, SOD, 
in controlling only oropharyngeal carriage, failed to demonstrate any significant 
impact on survival in a meta-analysis [201], and, in a recent and large meta-analysis 
SOD was inferior to SDD in reducing mortality [88]. 
The strengths of this analysis are the comprehensive search for relevant RCTs, the 
assessment of methodological quality, the use of pre-specified subgroup analyses, 
and the use of the random effects model which takes heterogeneity into account. 
However, we acknowledge some important limitations. Firstly, we did not use an 
intention-to-treat analysis as some studies did not report whether the number of 
patients analysed reflected the total amount of patients randomised, and how 
withdrawals and dropouts were treated. Secondly, clinical heterogeneity was present 
because of: a) different types of patients included; b) different chlorhexidine 
concentrations, application forms, dosages, and duration of treatment; c) different 
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definitions of lower respiratory tract infection; d) the use of parenteral antibiotic 
prophylaxis. Moreover, there were only 14 high quality and 11 double-blinded 
RCTs. These variables might have impacted the results. However, we decided a 
priori to use the more conservative random effects model, which fits the distribution 
of the effects sizes, and takes into account the relevant source(s) of error [202]. 
Additionally, we addressed some of the aforementioned limitations by performing a 
pre-specified subgroup analysis of those variables, and we provided the clinical 
reason why a particular group of participants or studies needed to be looked at 
separately. Finally, although our search strategy was comprehensive, we could have 
missed some relevant trials. 
 
 
5.5 Conclusion 
 
This review demonstrates that oral care with chlorhexidine reduces overall lower 
respiratory tract infection, and lower respiratory tract infection due to Gram-positive 
and Gram-negative “normal” flora. Bloodstream infection is not impacted by 
chlorhexidine. Mortality is not affected. There are insufficient data to assess the 
efficacy of oral chlorhexidine on lower respiratory tract infection and bloodstream 
infection due to MRSA. Half the population of this review is surgical, and, therefore, 
the results can not be generalizable to the entire ICU population. This should warrant 
further large RCTs to test the effectiveness of oral chlorhexidine in preventing lower 
respiratory tract infection and in reducing mortality in medical and mixed critically 
ill patients. These RCTs should be adequately powered to detect the effect of 
chlorhexidine on the control of MRSA infection. 
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6 EFFECTIVENESS OF ENTERAL VANCOMYCIN TO CONTROL 
MRSA CARRIAGE AND INFECTION IN ICU PATIENTS. 
A SYSTEMATIC REVIEW AND META-ANALYSIS 
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6.1 Introduction 
 
Control of MRSA carriage and infection is an important issue in the ICU. In an 
international study on the prevalence and outcomes of infection in ICUs the most 
common Gram-positive microorganism was S. aureus (20.5% of all isolates); MRSA 
accounted for 10% of all isolates [28]. The traditional approach to control MRSA 
spread in high-risk areas such as ICU includes several measures which have often 
failed because of the impracticalities in implementing them [21, 203-206]. They are: 
a) screening of MRSA carrier state in the nose, oropharynx or rectum in selected 
patients population such as cardiosurgical patients, orthopaedic patients, dialysis 
patients and intensive care unit patients in case of MRSA endemicity; b) high levels 
of hygiene and isolation to prevent transmission; c) topical mupirocin in the nose and 
throat to eradicate oropharyngeal and nasal carrier state; d) oropharyngeal 
chlorhexidine to clear the carrier state; e) chlorhexidine bathing to reduce skin 
carriage; f) parenteral vancomycin in case of infection. 
Parenteral vancomycin is the first choice therapy of MRSA infection. However, 
vancomycin may be harmful in ICU patients particularly in those with impairment of 
the renal function and in subjects with septic shock. Moreover, penetration of 
vancomycin in some tissues, such as the lung, is limited. Additionally, there are 
concerns about the emergence of microorganisms resistant to vancomycin, such as 
VRE and VISA [205]. 
There is a large body of evidence from the literature that oropharyngeal and intestinal 
carriage and overgrowth of AGNB and yeasts can be controlled using SDD [44]. 
SDD includes a combination of polymyxin E, tobramycin and amphotericin B 
administered in the oropharynx and gut together with a short course of parenteral 
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antibiotic (e.g. cefotaxime). SDD has been shown to reduce AGNB and fungal 
carriage, lower respiratory tract infections, bloodstream infections, multiple organ 
failure and mortality, without the emergence of resistance [84, 89]. SOD, is a 
modified SDD regimen including only the oropharyngeal component. SOD 
demonstrated a reduction of lower respiratory tract infection and mortality, although 
bacteraemia was not controlled [44]. 
Using the same philosophy, the administration of vancomycin into the intestinal tract 
has been reported to eradicate Clostridium difficile from the gut [207]. Additionally, 
enteral vancomycin has been added to the classical SDD antimicrobials to control 
MRSA overgrowth or MRSA endemicity in the ICU [208, 209]. 
A systematic review and meta-analysis has been undertaken to assess the efficacy of 
enteral vancomycin to control MRSA carriage and infection in ICU patients. The 
secondary endpoint was to evaluate the emergence of resistance to vancomycin, in 
particular VRE and VISA. 
 
6.2 Materials and methods 
 
6.2.1 Search strategy 
A systematic review and meta-analysis was performed using the PRISMA guidelines 
[109]. PubMed and the Cochrane Register of Controlled Trials were screened for 
randomised and non-randomised studies published until June 2016 with no language 
restriction. Search terms were selective decontamination of the digestive tract, 
selective bowel decontamination, selective gut decontamination, methicillin-resistant 
Staphylococcus aureus, vancomycin, topical vancomycin, vancomycin oropharynx, 
gut vancomycin, intestinal vancomycin, and oral vancomycin. The search limits were 
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“humans”. A hand search of references from papers and published meta-analyses 
was done. Studies were analyzed using a standardized data extraction form. The 
search, the screening of the titles and abstracts, and the analysis of studies were made 
independently by two investigators. 
 
6.2.2 Selection criteria 
Inclusion and exclusion criteria were established before starting the review process. 
All studies in critically ill patients receiving enteral vancomycin (topical application 
to the oropharynx, intestine or both) in the test group and no vancomycin or placebo 
in the control group were included. Studies using vancomycin together with other 
antimicrobials to decontaminate the oropharynx and the gut were also included. 
Studies or interventions in neutropenic and bone marrow transplant patients were not 
included. 
 
6.2.3 Data extraction 
Two investigators independently retrieved and compared the sets of data from each 
trial. Any disagreement was resolved by discussion. The following data were sought: 
author, publication year, population included, description of the intervention in the 
test arm and in the control arm, randomization and allocation concealment, blinding, 
handling of dropouts and withdrawals, number of patients included, number of 
patients with infection, number of patients with Staphylococcus aureus infection and 
carriage, number of patients with MRSA infection and carriage, mortality, and 
antimicrobial resistance (e.g. presence of VRE and VISA). 
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6.2.4 Quality assessment 
Two investigators assessed the quality of RCTs using the Cochrane Collaboration 
risk of bias tool [111].  The Newcastle-Ottawa quality assessment scale (NOS) was 
used to appraise the quality of non-randomised studies [112]. The Newcastle-Ottawa 
scale assigns a maximum of 4 points for selection of patients, two points for 
comparability of test and control groups, and 3 point for outcome assessment. A 
priori, we decided that randomised studies with a high or unclear risk of bias in less 
than two domains or observational studies with an NOS score greater than 7 would 
be considered to be high quality. 
 
6.2.5 Endpoints and statistical analysis 
The primary endpoints were the number of patients with infection, the number of 
patients with Staphylococcus aureus carriage and infection, the number of patients 
with MRSA carriage and infection, and mortality; the secondary endpoint was the 
occurrence of resistant microorganisms (i.e. VRE and VISA). For the primary 
outcomes we decided a priori to separately analyse data from randomised and non-
randomised studies, and from studies using vancomycin combined with other enteral 
antimicrobials. We did not assess statistical differences between these strata. 
Results were presented as odds ratio (OR) with 95% confidence interval (CI) using 
the random effects model and p value. The Cochran Q statistic for heterogeneity has 
been used; heterogeneity is considered to be significant if the p was <0.10. 
Additionally, I2 has been evaluated with the formula 100% x (Q-df)/Q, where Q is 
Cochran’s Q statistics and df is the degree of freedom (number of studies- 1). 
Negative values of I2 are equal to 0%; an I2 of 0% indicates no observed 
heterogeneity, whilst < 30% indicates mild heterogeneity, 30-50% moderate, and > 
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50% severe (significant heterogeneity I2 greater than 50%) [113]. The funnel plot to 
estimate potential publication bias has been explored. Computations were performed 
using the EasyMA software [114]. 
 
6.3 Results 
 
6.3.1 Search findings and description of studies 
After the exclusion of duplicates and irrelevant publications we considered 15 studies 
for more detailed evaluation. The subsequent screening yielded a final sample of 12 
studies, 9 RCTs, including 1473 patients (711 vancomycin group, 762 controls) and 
3 non-randomised studies including 1240 patients (654 vancomycin group, 586 
controls). This set of studies was the basis for the systematic review and meta-
analysis [210-221]. Figure 6.1 depicts the search strategy and the reason for 
exclusion of studies. 
Tables 6.1, 6.2 and 6.3 describe the main characteristics and data extracted from 
RCTs and non-RCTs included in the systematic review. 
All 9 RCTs included in the systematic review were European: three from France 
[211, 212, 214], two from Germany [213, 217], one from The Netherlands [210], 
one from Switzerland [215], one from Spain [216], and one from Italy [218]. 
Studies were published from 1990 to 2004. One study was published as abstract of a 
scientific meeting [216]. One study was performed in neonatal ICU [214], three 
studies were performed in surgical/trauma patients [213, 215, 217], one in 
neurosurgical ICU [212], four in mixed medical-surgical ICU [210, 211, 216, 218]. 
The oropharynx was decontaminated with vancomycin in 5 RCTs [210, 212, 214, 
215, 218], the gut was decontaminated in 2 RCTs [211, 217], and in 2 RCTs 
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vancomycin was administered both in the oropharynx and in the gut [213, 216]. In 
general, vancomycin was administered four times a day, apart from one study in 
which it was given six times a day [215]. Different concentrations of vancomycin 
were used: one study used 2% [210], three studies used 4% [212, 217, 218], and the 
remaining studies employed different dosages of vancomycin solution in the 
oropharynx or in the gut. 
In six RCTs vancomycin was combined with other enteral antimicrobials, such as 
polymyxin E or B, different aminoglycosides (gentamicin, tobramycin) and 
polyenes [210-213, 215, 217]. In two RCTs vancomycin was used alone [214, 216], 
and in one RCT both test and control group received the classical SDD protocol of 
polymyxin E, tobramycin and amphotericin B, but only the test group received 
vancomycin [218]. In only two RCTs [216, 218] the primary endpoint was the 
control of MRSA carriage and/or infection. In the remaining RCTs [214], which 
used a combination of different antimicrobials, vancomycin was included to control 
S. aureus carriage and/or infections, but no details were given about the inclusion of 
MRSA under S. aureus isolates. 
Tables 6.2 and 6.3 (second part) show the main characteristics and data extracted 
from three non-randomised studies [219-221]. Two studies were from Spain [219, 
220], and one study was Italian [221]. Studies were published between 2002 and 
2007. One study was in burn ICU patients [219], and two studies were in medical-
surgical ICUs [220, 221]. In two studies vancomycin was administered in both 
oropharynx and gut [219, 220], and one study in the intestinal tract only [221]. In 
two studies [219, 220] a 4% vancomycin paste was administered in the oropharynx 
together with vancomycin solution in the gut; one study employed only a 
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vancomycin solution in the gut [221]. In one study the test group received 
vancomycin together with SDD [219]. 
 
Figure 6.1 Diagram flow of study selection 
 
971 citations identified through 
databases searching  
Studies screened for more 
detailed evaluation (n=15) 
963 identical, duplicate and irrelevant 
publications, publication regarding C. difficile 
treatment removed 
Studies excluded: 
- comparing different vancomycin 
concentrations (2% vs 4%) (n=1) 
- comparing two different policies of 
vancomycin administration (n=1) 
-not including a control group (n=1) 
Studied included in the systematic 
review (n=12): 
randomised controlled trials (n=9) 
non-randomised studies (n=3) 
7 citations identified through manual 
searching, reference list, expert consultation 
Trials withdrawn from specific outcomes only 
when data not available from publication 
Studies with usable information by outcome: 
Primary outcome: overall infection (n=9) 
Primary outcome: S. aureus carriage (n=2) 
Primary outcome: S. aureus infection (n=6) 
Primary outcome: MRSA carriage (n=4) 
Primary outcome: MRSA infection (n=5) 
Primary outcome: mortality (n=9) 
Secondary outcome: resistance (n=7)
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Table 6.1 Characteristics of randomised controlled trials of enteral vancomycin 
Patients Intervention First 
Author 
Year 
Test C Test C 
Population Randomization Allocation Blinding 
Bergmans 
[210] 
2001 87 139 2% gentamicin + Pb + 2% van 
four times a day oropharynx. 
No parenteral antibiotics 
Placebo Medical, surgical, trauma 
and neurological patients 
Yes, but not specified Not specified Double blind 
Gaussorgues 
[211] 
1991 59 59 Gentamicin 20 mg, colistin 36 
mg, van 50 mg, amphotericin B 
500 mg gut four times a day 
Not 
reported 
ICU ventilated patients Yes, but not specified Not specified No 
Korinek 
[212] 
1993 63 60 PTA + 4% van oropharynx + 
PTA gut four times a day. No 
parenteral antibiotic 
Placebo Neurosurgery Yes, but not specified The pharmacist 
delivered the 
drugs 
Double blind 
Krueger 
[213] 
2002 265 262 Gentamicin 80 mg, Pb 50 mg, 
van 125 mg four times a day 
nostrils, oropharynx and 
stomach 
Sodium 
chloride 
0.9% 
Surgical population Yes. A computer 
generated randomization 
scheme 
The pharmacist 
assigned to 
treatment or 
placebo 
Double blind 
Marchand 
[214] 
1990 20 20 Pharyngeal instillation of 4 
drops of a 5% van solution 4 
times a day 
No local 
treatment 
Neonate intensive care 
unit 
Yes, but not specified Not specified No 
Pugin [215] 1991 25 27 150 mg Pb+ 1 gr Neo+ 1 gr 
van solution 6 times a day 
oropharynx 
Placebo Surgical, trauma 
population 
Yes, but not specified Not specified Double blind 
Sanchez 
[216] 
1997 48 50 4% oropharyngeal van paste + 
250 mg van in the intestine 
four times a day 
Placebo Mechanically ventilated 
patients in general ICU 
Yes, but not specified Not specified Double blind 
Shardey 
[217] 
1997 102 103 Pb 100 mg, tobramycin 80 mg, 
van 125 mg, AmB 500 mg four 
time a day gut 
Placebo Surgical population (total 
gastrectomy) 
Yes, but not specified Not specified Double blind 
Silvestri 
[218] 
2004 42 42 0.5 gr of 4% van gel + PTA 
four times a day oropharynx 
Only PTA Mixed Yes; computer generated 
random number table  
Yes, statistician  No 
C, control; ICU, intensive care unit; van, vancomycin; Pb, polymyxin B; Neo, neomycin; PTA, polymyxin E 100 mg + tobramycin 80 mg 
+amphotericin B 100 mg, AmB, amphotericin B. 
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Table 6.2 Characteristics of non-randomised studies of enteral vancomycin 
Patients Intervention First 
Author 
Year 
Test C Test C 
Population and 
setting 
Design Endpoint(s) 
Cerdà [219] 2007 375 402 4% van into the nose, 4% van in 
the oropharynx and 500 mg van in 
the gut, four times a day. All 
patients received PTA 
Standard infection 
control policy 
All patients 
admitted to the burn 
ICU 
Prospective, 
sequential, cohort, 
9-year period 
To evaluate the 
effectiveness and safety of 
protocols to control 
endemicity of MRSA 
de la Cal 
[220]  
2004 258 140 Only patients with a MRSA carrier 
state received 4% van in the 
oropharynx and 500 mg van in the 
gut, four times a day 
Standard infection 
control policy 
Patients requiring 
mechanical 
ventilation. 
Medical-surgical 
ICU 
Prospective, 
cohort, sequential, 
four-year period 
To evaluate the 
effectiveness and safety of 
protocols to control 
endemicity of MRSA 
Silvestri 
[221] 
2002 21 44 500 mg van in the gut four times a 
day. All patients received PTA 
plus standard infection control 
policy 
Standard infection 
control policy + PTA 
Patients requiring 
mechanical 
ventilation. 
Medical-surgical 
ICU 
Prospective, 
cohort, sequential, 
8-month period 
during outbreak 
Enteral van was evaluated 
as a measure to control an 
outbreak of MRSA 
infection 
C, control group; van, vancomycin; MRSA, methicillin resistant Staphylococcus aureus; ICU, intensive care unit; PICU, paediatric intensive care 
unit; PTA, polymyxin E 100 mg + tobramycin 80 mg +amphotericin B 100 mg. 
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Table 6.3 Results of randomised (first part of the table) and non-randomised studies (second part of the table) of enteral vancomycin 
N° patients 
enrolled 
N° patients with 
infection 
Mortality N° patients with 
S. aureus 
carriage 
N° patients with 
S. aureus 
infection 
N° patients 
with MRSA 
carriage 
N° patients 
with MRSA 
infection 
First Author 
Test C Test C Test C Test C Test C Test C Test C 
Bergmans [210] 87 139 31 66 25 53 0 9 3 11     
Gaussorgues [211] 59 59 5 15 29 59   1 2     
Korinek [212] 63 60 29 49 3 7         
Krueger [213] 265 262 91 149 52 75   15 63     
Marchand [214] 20 20 1 5   2 16 0 4     
Pugin [215] 25 27 4 21 10 11         
Sanchez [216] 48 50 0 3       0 9 0 3 
Shardey [217] 102 103 21 36 5 11   9 40     
Silvestri [218] 42 42 16 24 12 15   9 21 8 20 8 12 
Total  711 762 198 368 136 231 2 16 37 141 8 29 8 15 
 
Cerdà [219] 375 402         14 102 10 76 
de la Cal [220] 258 140           37 44 
Silvestri [221] 21 44   7 17     13 39 2 22 
Total 654 586   7 17     27 141 49 142 
MRSA, methicillin-resistant Staphylococcus aureus; N°, number 
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In the Italian study both test and control group received SDD but only the test group 
received vancomycin [221]. The endpoint of all three studies was the efficacy of 
enteral vancomycin to control endemicity or outbreak due to MRSA. Therefore, the 
only available data were MRSA carriage and infection and only one study [221] 
reported the mortality rate. 
 
6.3.2. Quality assessment 
Nine studies were randomised, but in only two RCTs the randomization method was 
detailed [213, 218]. The allocation was adequate in three RCTs [212, 213, 218]; in 
the remaining the procedure was not specified. Six out of nine RCTs were double 
blinded [210, 212, 213, 215-217], one study was single blinded [218], and the 
remaining two studies were not blinded. The quality of RCTs assessed with the 
Cochrane collaboration risk of bias tool showed that the majority of information for 
the primary outcomes was from studies at high or unclear risk of bias. The quality 
of the three non-randomised studies was evaluated using NOS; all studies achieved 
7 points, indicating a low quality. 
 
6.3.3 Infection and carriage 
Data on overall infection was available from 9 RCTs [210-218] including 1473 
patients (711 test, 762 controls). There were 198 (27.8%) patients with infection in 
test group and 368 (48.3%) in controls, indicating a significant reduction of the odds 
of infection (OR 0.35, 95% CI 0.24-0.50, p=0.00199). Heterogeneity was mild (χ2 
9.5541, p=0.30, I2=16%) (Figure 6.2). 
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Figure 6.2 Forrest plot of the effect of enteral vancomycin on infection. 
An odds ratio < 1 favours test; an odds ratio > 1 favours controls. 
 
S. aureus carriage was described in two RCTs [210, 214] including 107 patients in 
test group and 159 in control group. Carriage developed in 2 (1.9%) and 25 (15.7%) 
patients in test and control group, respectively (OR 0.03, 95% CI 0.01-0.17, 
p<0.001). Heterogeneity was absent (χ2 0.0102, p=0.92, I2=0%). 
S. aureus infection was described in 6 studies [210, 211, 213, 214, 217, 218], 
including 1280 patients (575 test, 626 control), and affected 27 patients (2 test, 25 
control), showing a significant reduction of infection (OR 0.21, 95% CI 0.15-0.32, 
p<0.001). There was not heterogeneity (χ2 3.5143, p=0.62, I2=0%). 
Four studies [216, 218, 219, 221] comprising a total of 1024 patients (486 test, 538 
controls) provided data on MRSA carriage. There were 35 (7.2%) and 170 (31.6%) 
MRSA carriers in test and control group, respectively, demonstrating a significant 
impact of vancomycin (OR 0.15, 95% CI 0.09-0.25, p<0.001) with no heterogeneity 
(χ2 2.9271, p=0.40, I2=0% (Figure 6.3). 
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Figure 6.3 Forrest plot of the effect of enteral vancomycin on MRSA carriage. 
An odds ratio < 1 favours test; an odds ratio > 1 favours controls. 
 
 
In 5 studies [216, 218-221] reporting data on MRSA infection and including 1422 
patients (744 test, 678 controls) there were 57 (7.66%) patients with MRSA 
infection in the vancomycin group and 157 (23.16%) in the control group, 
indicating a significant impact of vancomycin on MRSA infection (OR 024, 95% CI 
0.12-0.50, p< 0.001). No heterogeneity was demonstrated (χ2 3.5025, p=0.48, 
I2=0%) (Figure 6.4) 
 
6.3.4 Mortality 
Mortality data were available from 9 studies in 2177 patients [210-213, 215, 217-
219, 221], 1039 test and 1138 controls. Mortality was significantly reduced (184 
test, 321 control) with an OR of 0.59 (95% CI 0.43-0.79, p<0.001). A mild 
heterogeneity was demonstrated (χ2 10.3372, p=0.24, I2=22.6%) (Figure 6.5). 
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Figure 6.4 Forrest plot of the effect of enteral vancomycin on MRSA infection. 
An odds ratio < 1 favours test; an odds ratio > 1 favours controls. 
 
 
 
Figure 6.5 Forrest plot of the effect of enteral vancomycin on mortality. 
An odds ratio < 1 favours test; an odds ratio > 1 favours controls 
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6.3.5 Resistance 
Results on resistance were available from 7 studies (Table 6.4). In five studies VRE 
was not isolated [210, 212, 214, 218, 221]. In one study VRE carriage was reduced 
in vancomycin group compared with placebo [216]. In one study there were 4 VRE 
carriers only in the control group [219]. Finally, in another study VRE was imported 
and caused an outbreak of VRE infection in 13 patients which was brought under 
control [220]. Four studies gave details on VISA which has never been isolated 
[214, 218, 219, 221]. 
 
Table 6.4 Summary of resistance data from randomised and non-randomised studies 
of enteral vancomycin 
First Author Comments on resistance 
Bergmans [210] No VRE were isolated 
No cases of acquired resistance to the antibiotics used in the oropharyngeal paste 
Gaussorgues [211] No reported data  
Korinek [212] No VRE were isolated 
No evidence of increased incidence if resistant strain to the antibiotic used 
Krueger [213] No data  
Marchand [214] No VRE, VISA and VRSA 
Pugin [215] No reported data 
Sanchez [216] VRE was acquired in the oropharynx in 5 test and 9 placebo patients. 
The administration of vancomycin does not increase the incidence of VRE carriage 
Shardey [217] No data 
Silvestri [218] No VRE, VISA and VRSA 
Cerdà [219] There were 4 cases of VRE in control group. VISA was not detected. 
de la Cal [220] A VRE outbreak affecting 13 patients after two patients imported VRE into the unit. 
The outbreak resolved. 
Silvestri [221] A total of 895 microbiological samples were processed: neither VISA nor VRE were 
isolated. 
 
 
6.3.6 Subgroup analysis 
We did the analysis of the primary outcomes using data obtained from RCTs and 
non-randomised studies (Table 6.5). In RCTs overall infection, S. aureus carriage 
and S. aureus infection were significantly reduced; MRSA carriage and infection 
were reduced but not significantly (OR 0.17, 95% CI 0.03-1.06, p=0.057), and OR 
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0.53, 95% CI 0.20-1.41, p=0.20, respectively). Mortality was significantly reduced 
(OR 0.56, 95% CI 0.36-0.87, p=0.0011). Non-randomised trials did not report any 
data on overall infection, S. aureus carriage and S. aureus infection. Both MRSA 
carriage and infection were significantly reduced (OR 0.13, 95% CI 0.08-0.21, p< 
0.001, χ2 0.7048; OR 0.19, 95% CI 0.07-0.46, p<0.001, respectively). Mortality was 
significantly reduced (OR 0.58, 95% CI 0.39-0.85, p=0.005). 
 
Table 6.5 Subgroup analysis of randomised and non-randomised studies 
N° patients N° events Outcomes N° RCTs Test C Test C OR (95% CI) P I
2 
Randomised trials 
Overall infection 
S. aureus carriage 
S. aureus infection 
MRSA carriage 
MRSA infection 
Mortality 
 
9 
2 
6 
2 
2 
7 
 
711 
107 
575 
90 
90 
643 
 
762 
159 
625 
92 
92 
692 
 
198 
2 
37 
8 
8 
136 
 
368 
25 
141 
29 
15 
231 
 
0.35 (0.24-0.50) 
0.03 (0.01-0.17) 
0.21 (0.15-0.32) 
0.17 (0.03-1.06) 
0.53 (0.20-1.41) 
0.56 (0.36-0.87) 
 
<0.001 
<0.001 
<0.001 
= 0.057 
= 0.20 
= 0.011 
 
16% 
0% 
0% 
0% 
0% 
36% 
Non-randomised studies 
MRSA carriage 
MRSA infection 
Mortality 
 
2 
3 
2 
 
396 
654 
396 
 
446 
586 
446 
 
27 
49 
48 
 
141 
142 
90 
 
0.13 (0.08-0.21) 
0.19 (0.07-0.46) 
0.58 (0.39-0.85) 
 
<0.001 
<0.001 
= 0.005 
 
0% 
0% 
0% 
C, control group; MRSA, methicillin-resistant S. aureus. Non-randomised studies did not provide data 
for overall infection, S. aureus carriage and infection 
 
Table 6.6 shows the analysis of studies using vancomycin combined with the SDD 
regimen in the test group and studies using only vancomycin in the test group. Five 
studies were included in the group receiving vancomycin [214, 216, 218, 220, 221]. 
Two of them were included in this group although they used SDD in both test and 
controls, as the effect of SDD is equally distributed in both study groups [218, 221]. 
In these five studies there was a significant reduction of all outcome measures, apart 
from mortality. In studies in which the test group received vancomycin combined 
with antimicrobials of the SDD regimen all outcome measures were significantly 
reduced [210-213, 215, 217, 219]. A moderate heterogeneity was found for overall 
infection and mortality. 
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Table 6.6 Subgroup analysis of RCTs using enteral vancomycin combined with 
other enteral antimicrobials 
N° patients N° events Outcomes N° RCTs Test C Test C OR (95% CI) P I
2 
Vancomycin combined with 
other topical antimicrobials 
Overall infection 
S. aureus carriage 
S. aureus infection 
MRSA carriage 
MRSA infection 
Mortality 
 
 
6 
1 
4 
1 
1 
7 
 
 
601 
87 
513 
375 
375 
976 
 
 
650 
139 
563 
402 
402 
1052 
 
 
181 
0 
28 
14 
10 
165 
 
 
336 
9 
116 
102 
76 
289 
 
 
0.33 (0.21-0.53) 
0.08 (0.01-1.37) 
0.20 (0.13-0.31) 
0.11 (0.06-0.20) 
0.15 (0.08-0.30) 
0.58 (0.38-0.80) 
 
 
<0.001 
= 0.08 
<0.001 
<0.001 
<0.001 
= 0.0017
 
 
33% 
- 
0% 
- 
- 
38% 
Vancomycin 
Overall infection 
S. aureus carriage 
S. aureus infection 
MRSA carriage 
MRSA infection 
Mortality 
 
3 
1 
2 
3 
4 
2 
 
110 
20 
62 
111 
369 
63 
 
112 
20 
61 
136 
276 
86 
 
17 
2 
9 
21 
47 
19 
 
32 
16 
25 
68 
81 
51 
 
0.38 (0.17-0.84) 
0.03 (0.01-0.17) 
0.25 (0.10-0.64) 
0.22 (0.11-0.48) 
0.35 (0.20-0.61) 
0.75 (0.37-1.52) 
 
<0.016 
<0.001 
= 0.0035
<0.001 
<0.001 
= 0.42 
 
0% 
- 
0% 
0% 
6% 
0% 
C, control group; MRSA, methicillin-resistant S. aureus; I2 was not considered when the outcome 
included only one study.  
 
6.3.7 Publication bias 
We did not inspect the funnel plot for publication bias for the primary outcomes due 
to the low number of studies [222]. 
 
6.4 Discussion 
 
Four main findings emerge form this systematic review and meta-analysis of 9 
randomised and 3 non-randomised trials in patients receiving enteral vancomycin: 
1. Overall infections, S. aureus carriage and infection are reduced; 
2. MRSA carriage and infection are reduced; 
3. Mortality is reduced; 
4. There is no emergence of VRE and VISA. 
This is the first systematic review and meta-analysis evaluating the impact of enteral 
vancomycin on S. aureus and MRSA carriage and infection. Carriage or carrier state 
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is defined as the patient's state where S. aureus or MRSA are isolated from at least 
two consecutive surveillance samples (i.e. throat and/or rectal swabs taken on 
admission and two times a week, thereafter), in any concentration, over a period of 
at least one week. Transient presence or acquisition was defined if the 
microorganism is isolated only once. Overgrowth is defined as ≥105 CFU/ml of 
oropharyngeal secretion or gram of faeces. 
 
6.4.1 Overall infection 
This systematic review demonstrated a significant reduction in overall infection. 
This result needs a careful appraisal. Although this endpoint was available from all 
9 RCTs included in the systematic review, 6 of them [210-213, 215, 217] used 
vancomycin combined with the classical SDD regimen, including different 
antimicrobials such as polymyxins, aminoglycosides and polyenes. Therefore, the 
effect of vancomycin on overall infection could not be distinguished from that of 
the classical SDD protocol. However, we performed a subgroup analysis of studies 
in which the test group received vancomycin combined with other enteral antibiotic 
and of studies assessing the effect of only vancomycin. The results were not 
substantially different from those obtained from all pooled studies, although a 
moderate heterogeneity has been found in studies using vancomycin as a part of the 
SDD regimen (Table 6.6). 
 
6.4.2 MRSA carriage and infection 
The aim of the administration of enter vancomycin is the control of oropharyngeal 
and/or intestinal MRSA carriage and overgrowth. This meta-analysis demonstrated 
that MRSA carriage was reduced by 85% (OR 0.15, 95% CI 0.09-0.25) in patients 
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receiving topical vancomycin compared with those who did not. MRSA gut 
overgrowth is an independent risk factor for secondary endogenous MRSA 
infection. MRSA in overgrowth concentration in the oropharynx may migrate into 
the lower respiratory tract causing colonisation and subsequent infection of the 
lower respiratory tract (i.e. secondary endogenous infection). MRSA overgrowth is 
also a risk factor for transmission via hands of carers, promoting secondary 
endogenous carriage, colonisation and infection, and maintaining MRSA 
endemicity in the ICU. This meta-analysis demonstrated that vancomycin reduced 
MRSA infection by 76% (OR 024, 95% CI 0.12-0.50). Several studies included in 
this systematic review used vancomycin together with the SDD regimen. However, 
no changes are expected by the administration of antimicrobials directed against 
aerobic Gram-negative bacilli and fungi as they are not active against MRSA. The 
decrease in MRSA carriage and infection is only explained by the addition of 
vancomycin. The subgroup analysis of studies in which vancomycin was part of the 
SDD regimen confirmed this hypothesis (Table 6.6). 
These findings are confirmed by the results of 3 non-randomised studies not 
included in this systematic review due to their study design, which, however, 
deserve some comments (Table 6.7). An Italian study [209] was undertaken in 
mechanically ventilated patients in an ICU where MRSA was endemic (i.e. one new 
case per month with a diagnostic sample positive for MRSA throughout a six-month 
period). The study was based on the hypothesis that the prevention of MRSA 
carriage using 4% vancomycin gel applied in the oropharynx was more effective in 
reducing carriage and lower respiratory tract infection than the treatment of 
established MRSA carriage. In period one, from July 2002 to December 2003, 98 
patients received oropharyngeal vancomycin when they were MRSA carriers, i.e. 
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two consecutive surveillance samples positive for MRSA. In period two, from 
January 2004 to June 2005, 93 patients received vancomycin immediately on 
admission to the ICU. In period one there were 40 MRSA carriers while in period 
two there were no MRSA carriers (p<0.001). Patients with MRSA lower respiratory 
tract infection were less in period two (10 patients) compared with period one (30 
patients), p<0001 due to the reduction of secondary endogenous MRSA infections 
(p=0.01). A total of 2321 microbiological samples were processed. Neither VRE nor 
VISA were isolated. MICs of vancomycin were always ≤ 1 μ/ml for MRSA and ≤ 4 
μ/ml for enterococci. Viviani et al. [208] compared MRSA carriage and infections 
in two groups of patients receiving different concentrations of oropharyngeal 
vancomycin gel. One group received 4 ml of 2% gel and the other received 4 ml 4% 
gel divided into four doses. The vancomycin protocol was started as soon as 
surveillance cultures of the oropharynx were positive for MRSA. The 4% 
vancomycin protocol significantly reduced MRSA carriage and infection compared 
with the 2% vancomycin protocol. Neither VRE nor VISA were detected. A 4-year 
observational study [223] from the paediatric ICU of the Alder Hey Children 
Hospital, Liverpool, UK, assessed the effect of throat and gut surveillance combined 
with enteral vancomycin on gut overgrowth, transmission of MRSA, infection and 
mortality. Children identified as MRSA carriers received enteral vancomycin (0.5 gr 
of 2% oropharyngeal paste four times a day in the oropharynx, and 40 mg/kg/day 
oral vancomycin suspension in the gut). Enteral vancomycin reduced MRSA 
overgrowth, preventing secondary endogenous MRSA infections. Neither VRE nor 
VISA was isolated from any surveillance and diagnostic sample. 
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Table 6.7 Non-randomised studies of enteral vancomycin not included in the analysis due to study design 
Patients Intervention First 
Author 
Year 
Test C Test C 
Population 
and setting 
Design Endpoint(s) 
Silvestri 
[209] 
2010 98 93 Only patients with a MRSA 
carrier state received 1 gr of 4% 
vancomycin gel in the oropharynx 
four times a day until carriage 
was abolished. 
All patients received SDD as 
infection control policy 
All patients enrolled 
received 1 gr of 4% 
vancomycin gel in the 
oropharynx four times a 
day immediately on 
admission, irrespective of 
their MRSA carrier state. 
All patients received SDD 
as infection control policy 
Patients 
requiring 
mechanical 
ventilation for 
more than 72 
hours. 
Medical-
surgical ICU 
Prospective, 
cohort, 
sequential, 3-
year study 
To evaluate the effectiveness 
of two different policies of 
topical vancomycin on 
oropharyngeal carriage and 
lower respiratory tract 
infection due to MRSA 
Thornburn 
[223] 
2006 1241 Patients who were carriers, 
colonised or infected by MRSA 
received 0.5 gr of 2% 
vancomycin paste or gel, or 5 mg 
vancomycin lozenge four times a 
day, plus 40 mg/kg/day of oral 
vancomycin suspension. 
Patients who were carrier, 
colonised or infected by Gram-
negative bacilli received also 
enteral polymyxin/tobramycin 
There was no control group 
as the study was 
observational 
Paediatric 
patients 
requiring 
mechanical 
ventilation for 
more than 
four days. 
Medical-
surgical PICU 
Prospective, 
observational, 
4-year study 
To assess the efficacy of 
enteral vancomycin on MRSA 
gut overgrowth, transmission, 
infections and mortality 
Viviani 
[208] 
2005 123 142 MRSA carriers received 1 ml of 
2% vancomycin gel in the 
oropharynx four times a day. 
All patients received SDD as 
infection control policy 
MRSA carriers received 1 
ml of 4% vancomycin gel 
in the oropharynx four 
times a day. 
All patients received SDD 
as infection control policy 
Patients 
requiring 
mechanical 
ventilation for 
more than 72 
hours. 
Medical-
surgical ICU 
Prospective, 
cohort, 
sequential, 2-
year study 
To assess the efficacy of 
oropharyngeal 
decontamination with 2% 
vancomycin gel compared 
with 4% vancomycin on 
carriage and infection due to 
MRSA 
MRSA, methicillin-resistant Staphylococcus aureus; C, control group; ICU, intensive care unit; SDD, selective decontamination of the digestive tract
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6.4.3 Mortality 
This systematic review showed a significant mortality reduction in 2177 patients 
(0.59, 95% CI 0.43-0.79). However, these results may be influenced by the 
concomitant use of SDD in 7 studies including 2028 patients. Selective digestive 
decontamination has been shown to reduce mortality by 27% (OR 0.73, 95% CI 
0.64-0.84) to 29% (OR 0.71, 95% CI 0.61-0.82) [83, 85]. A subgroup analysis 
confirmed that in studies using vancomycin as part of the SDD protocol there was a 
mortality reduction (OR 0.58, 95% CI 0.38-0.80), albeit with a moderate level of 
heterogeneity. In contrast, in studies assessing the efficacy of only vancomycin the 
mortality reduction was not significant (OR 0.75, 95% CI 0.37-1.52). However, the 
sample size was too small (two studies, 149 patients) to detect any effect on 
mortality. 
 
6.4.4 Resistance 
This systematic review showed that the emergence of VISA and VRE was not a 
clinical problem, supporting the safety of enteral vancomycin. VRE was not isolated 
in 7 studies and in one study VRE was reduced in patients receiving enteral 
vancomycin. About twenty years ago the American recommendations on the spread 
of vancomycin resistance discouraged the enteral decontamination with vancomycin 
[224, 225]. These recommendations were based on the hypothesis that oral and 
intestinal administration of vancomycin may select for VISA and VRE. The updated 
strategies on the prevention of transmission and infection of MRSA in acute care 
setting do not include the use of vancomycin among decolonisation strategies [226]. 
However, enteral vancomycin is largely used to control Clostridium difficile colitis 
[227]; VRE has never been isolated in a large C. difficile outbreak despite the 
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administration of oral vancomycin [227], and has rarely been found in a recent trial 
of vancomycin versus fidaxomicin for the treatment of C. difficile infections [228]. 
On the contrary, two studies in which volunteers received low doses (i.e. 0.5 gr/day) 
of oral vancomycin suggested a selection of enterococci with reduced sensitivity to 
vancomycin [229, 230]. Another study demonstrated that the administration of 
parenteral vancomycin is a risk factor for the acquisition of VRE gut carriage [231]. 
It is important to appreciate that after 2 gr/day of parenteral vancomycin faecal 
vancomycin levels are between 6 and 11 μg per gram of faeces; in contrast, after 2 
gr/day of oral vancomycin the intestinal concentration may vary between 3,000 and 
24,000 μg per gram of faeces [98, 99]. High levels of faecal vancomycin may 
explain the absence of VRE when using enteral vancomycin, while non-lethal, low 
concentrations of vancomycin in the gut may promote the selection of VRE. This 
observation is in line with some studies showing that parenteral broad spectrum 
antibiotics that disregard the gut ecology, rather than high doses of enteral 
vancomycin, promote VRE [232-234]. 
This concept can be also applied for the selection of VISA. Repeated vancomycin 
exposure and suboptimal vancomycin concentrations are risk factor for VISA and 
heteroresistant-VISA [235]. Vancomycin creates a selection pressure that favours 
overgrowth of vancomycin-resistant clones leading to heteroresistant-VISA and 
VISA. Additionally, it should be recognized that enteral vancomycin may have an 
impact on the remaining gut microbiota. This issue will be considered in chapter 8. 
 
6.4.5 Limitations 
Some limitations of this systematic review and meta-analysis should be 
acknowledged. First, due to study design, both randomised and non-randomised 
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studies were included. This may reduce the robustness of findings. However, a 
subgroup analysis was performed on randomised and non-randomised studies. 
Second, although a significant statistical heterogeneity has not been demonstrated in 
this review, a possible clinical heterogeneity might be present due to different 
patients’ population (e.g. paediatric, burns, medical, surgical, neurosurgical), 
different definitions of infection, different sites of vancomycin decontamination 
(oropharynx, intestine, or both), different vancomycin concentrations (2%, and 4%), 
and the use in both test and control groups of other antibiotics, such as SDD. Third, 
the test group of 9 out of 12 studies of this review received vancomycin together 
with polymyxins, aminoglycosides, and polyenes. Although this may have 
influenced the results of overall infection rate, polymyxins and aminoglycosides did 
not affect the results of MRSA carriage and infection, as they do not cover this 
microorganism. Nevertheless, a subgroup analysis on this issue was planned a 
priori. Fourth, the CLSI (Clinical and Laboratory Standards Institute) revised the 
criteria for susceptibility to vancomycin in 2006 [236]. The minimum inhibitory 
concentration (MIC) breakpoint for MRSA susceptible to vancomycin was lowered 
from 4 mg/L to ≤ 2 mg/L, and VISA from 8-16 mg/L to 4-8 mg/L. These values are 
maintained by EUCAST (European Committee on Antimicrobial Susceptibility 
Testing) [237]. The MIC breakpoint for enterococci sensitive to vancomycin has 
been held to 4 mg/L [237]. Therefore, the findings of the absence of VISA may be 
interpreted with caution, as all studies were carried out before the introduction of 
the new MIC breakpoints. Interestingly, in two Italian studies [218, 221] MICs of 
vancomycin were always ≤ 1 mg/L for MRSA and ≤ 4 mg/L for enterococci 
(personal communication). Finally, although the majority of studies included in this 
review are randomised controlled trials, and 6 of them are blinded, the quality 
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assessment revealed the presence of an unclear or high risk of bias for most 
outcome measures and a low quality of the non-randomised studies. Therefore, a 
possible bias may affect the interpretation of the results. 
 
6.5 Conclusion 
 
This systematic review and meta-analysis of randomised and non-randomised trials 
in critically ill patients showed that in studies using enteral vancomycin overall 
infection rates, S. aureus and MRSA carriage and infection, and mortality are 
significantly reduced. Enteral vancomycin is safe in terms of emergence of VISA 
and VRE. The results of this review should be interpreted with caution due to some 
limitations. Future large, high quality, randomised trials are warranted to confirm 
these findings. 
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7 ENTERAL VANCOMYCIN TO CONTROL MRSA INFECTION IN 
THE ICU. 
A 16-YEAR OBSERVATIONAL STUDY IN MECHANICALLY 
VENTILATED PATIENTS 
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7.1 Introduction 
 
During the last decades methicillin-resistant Staphylococcus aureus (MRSA) has 
become one of the most frequent pathogen causing infection and increasing 
morbidity, mortality and healthcare costs in the hospital setting: in the ICU the 
burden related to MRSA is even higher [28]. In the study of the prevalence and 
outcomes of infection in the ICU, MRSA was one of the most frequent 
microorganisms causing infection [28]. An Italian survey performed in 125 ICUs 
showed that MRSA was the main causative pathogen of ICU-acquired infections, 
including ventilator-associated pneumonia [238]. 
To contrast MRSA problem in the ICU, education programs for the healthcare 
personnel, hand hygiene, disinfection of the environment, isolation or cohorting of 
infected patients or carriers, use of protective equipment, have been recommended 
and implemented worldwide. However, these measures have often failed to control 
MRSA carriage, infection, and endemicity. A systematic review of the measures for 
the eradication of MRSA carriage, including both randomised and non-randomised 
studies, in non-ICU patients showed that mupirocin was an effective method for 
eradicating MRSA [107], although a recent meta-analysis of only randomised 
controlled trials in ICU patients was unable to demonstrate any significant benefit 
[see chapter 4]. 
Another approach to control MRSA carriage and infection is the administration of 
enteral vancomycin, both oropharyngeal and/or intestinal. The concept behind this 
measure is the control of oropharyngeal and intestinal overgrowth of MRSA, and, 
subsequently, the reduction of secondary endogenous infection due to MRSA 
transmission. Some studies in ICU patients demonstrated the efficacy and safety of 
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enteral vancomycin in controlling MRSA overgrowth, transmission, infection, and 
subsequent outbreak or endemicity [219-221]. Two randomised trials of enteral 
vancomycin showed that the administration of 4% vancomycin in the oropharynx 
controlled MRSA carriage and infection [216, 218].  
Based on the results of these studies we undertook a retrospective analysis of 
prospectively collected data of the incidence of MRSA infection in a 
medical/surgical ICU in which oropharyngeal vancomycin was used to prevent 
MRSA carriage and infection. 
 
7.2 Patients and Methods 
 
7.2.1 Setting 
The study was conducted on an eight-bed, medical-surgical ICU at the hospital in 
Gorizia, Italy. The ICU has an average annual admission rate of 310 patients. The 
ethical committee waived the need for patient’s consent as the study is retrospective 
and observational. 
 
7.2.2 Study design 
From January 2000 to December 2015, in order to undertake the infection control 
program of the Friuli-Venezia-Giulia Regional Health Service, the policy of the 
Hospital Infection Control Committee was the acquisition of data on infection in ICU 
patients who required mechanical ventilation for ≥ 3 days. These data were obtained 
prospectively by two physicians who were responsible for the infection control 
project in the ICU. The observation period ended with the extubation, death or 
discharge of the patient. All data were captured on a record form which was sent to 
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the chief of the Hospital Infection Control Committee at the end of each year. All 
data needed for this study were extracted retrospectively from those record forms. 
Information used in the study existed in an electronic database in which patients’ 
names and other details regarding the subjects’ privacy were not available to the 
researcher. 
Therefore, the design is longitudinal cohort retrospective study of prospectively 
collected data. Information was extracted in accordance with the retrospective chart 
review methodology [115, 239]. 
 
7.2.3 Patient population and data extraction 
The study included data on MRSA infection from January 2000 through December 
2015 amongst a cohort of ICU patients who were mechanically ventilated for ≥ 3 
days. 
The following data were extracted from the Hospital Infection Control Committee 
record forms. General characteristic of the study population, such as age, gender, 
simplified acute physiology score (SAPS) II, ICU mortality, days of ICU stay, 
number of patients with infection, number of infection episodes, and the day of 
infection onset, were recorded. Additionally, details on the type of infection, the 
classification of infection, and the microorganism causing infection were registered. 
Finally, patients with MRSA infection, episodes of MRSA infection, classification of 
MRSA infection and type of MRSA infection were retrieved. 
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7.2.4 Endpoints 
The primary endpoint of the study was the incidence of infection due to MRSA. The 
secondary endpoints were the type of MRSA infection and its classification 
according to the carrier state method, and the emergence of VRE and VISA define. 
 
7.2.5 Antibiotic policy 
Infection prophylaxis using SDD was routinely employed in the study population as 
it is included in the antibiotic policy of the unit for all mechanically ventilated 
patients. The decontaminating protocol has been approved by the hospital committee 
for drug administration since 1998. The SDD protocol consisted of a combination of 
enteral and parenteral antimicrobials, hygiene and surveillance cultures as follows 
[44]: 
1. a parenteral antibiotic was given for the first 4 days after admission (e.g. 
cefotaxime 80 mg/kg/day, or ceftazidime if the patient was a suspected 
pseudomonal carrier); 
2.  0.5 g of a 2% gel of polymyxin E/tobramycin/amphotericin B was applied to the 
oropharyngeal mucosa four times a day, and 10 ml of suspension containing 100 
mg of polymyxin E, 80 mg of tobramycin and 500 mg of amphotericin B (or 
1.000.000 unit of nystatin) was administered in the digestive tract through the 
nasogastric tube four times a day; 
3. surveillance samples of throat and rectum were taken on ICU admission and two 
times a week (e.g. Monday and Thursday) to detect the level of carriage; 
4. high level of hygiene. 
The main targets of the SDD protocol are aerobic Gram-negative bacilli and yeasts. 
By design the SDD manoeuvre is not active against MRSA. Due to the MRSA 
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endemicity in the ICU (i.e. at least one new case of MRSA infection per month) all 
ventilated patients also received oropharyngeal vancomycin as follows: from January 
2002 to December 2015 all ventilated patients received 1 ml of a 4% vancomycin gel 
applied in the oropharynx 4 times a day. It is important to emphasize that from July 
2002 to December 2003 and from January 2004 to June 2005 a prospective 
observational study of the efficacy of enteral vancomycin has been performed in the 
ICU. During the first period all patients received the enteral vancomycin protocol 
only when they were MRSA carriers, while in the second period all patients received 
the vancomycin protocol immediately on ICU admission, regardless of their carrier 
state. After the completion of the study, all ventilated patients continued to receive 
the same vancomycin protocol. 
Systemic antibiotics were given in the case of infection based on clinical ground and 
laboratory results. In general, a five-day course of antibiotics was given, followed by 
clinical re-evaluation. 
Surveillance samples of throat and rectum were taken on admission and twice 
weekly, thereafter. Diagnostic samples, i.e. tracheal aspirate, urine and blood, were 
obtained on clinical indication only. 
Enteral feeding through a nasogastric or a naso-jejunum tube or a percutaneous 
gastrostomy was administered with progression to full nutritional support within 96 
hours. Monitoring of gastric residual volume was performed every six hours. Stress 
gastric ulcer prophylaxis with proton pump inhibitors was routinely employed. 
Sucralfate was not used. Subglottic suctioning was not used. Ventilator circuits in the 
same patient were changed when necessary, heat moisture exchange filters every 1 
week or when necessary. Patients requiring long-term ventilation for more than 10 
days received a percutaneous or a surgical tracheostomy. 
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On 12 December 2008 the ICU moved to the new St. John of God Hospital in 
Gorizia. 
 
7.2.6 Definitions 
Lower respiratory tract infections included pneumonia and tracheobronchitis. 
Pneumonia was diagnosed on the presence of a new and/or progressive pulmonary 
infiltrate on chest radiograph persistent for > 48 h in addition to two clinical criteria 
and one confirmation criterion. Clinical criteria were the following: (1) core 
temperature ≥38.3°C or <36°C, (2) leucocytosis >12 x 109/L or leucopenia <4 x 
109/L, (3) purulent tracheobronchial secretions. Confirmation criteria included (1) 
endotracheal aspirate with semiquantitative cultures at a concentration of ≥105, (2) 
positive blood culture in the absence of an extrapulmonary focus, (3) a response to 
antimicrobial therapy in the absence of alternative diagnosis. Tracheobronchitis was 
defined by the presence of all the above features without the radiographic findings 
[240]. Urinary tract infection (UTI) was defined as freshly voided catheter urine 
containing >105 CFU/ml and ≥5 leukocytes per high power light microscopic field. 
Bloodstream infection (BSI) was the presence of clinical signs of generalized 
inflammation combined with at least one positive blood culture for all potential 
pathogens apart from coagulase-negative staphylococci for which two consecutive 
blood cultures were required. Other infections were diagnosed according CDC 
criteria [241]. 
Infections were classified according to the criterion of the carrier state [44]. Primary 
endogenous infections are caused by both normal and abnormal PPMs carried by the 
patient in throat and/or gut on admission to the ICU. Secondary endogenous 
infections are caused by PPMs not carried in throat and/or gut at the time of 
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admission to the ICU, but acquired during ICU-treatment prior to the infection. 
Surveillance and diagnostic samples yield the same microorganism in infections of 
endogenous origin. Exogenous infections are caused by PPMs introduced into the 
patients from the environment, either animate or inanimate; bacteria are transferred 
directly into an internal organ, without previous carriage. In exogenous infections 
surveillance samples are negative for PPMs that readily appear in diagnostic 
samples. According to the criterion of carriage, only secondary endogenous and 
exogenous infections were labelled ICU-acquired infections, whilst primary 
endogenous infections were considered to be imported infections. 
 
7.2.7 Sampling and microbiology 
Diagnostic and surveillance samples were processed in a semiquantitative and 
qualitative way. Standard methods for identification, typing, and sensitivity patterns 
were used for all microorganisms. In particular, until 2006, to differentiate S. aureus 
from other species of staphylococci, production of deoxyribonuclease (by a DNA 
agar-plate method), a slide-agglutination test to detect clumping factor and protein A 
(Prolex™ Staph Latex Kit, Prolab Diagnostics, Neston, Wirral, UK), and a slide 
agglutination kit for the rapid detection of penicillin binding protein 2a for MRSA 
(MRSA Screen, Biogenetics, Padova, Italy) were used. If the results were 
inconclusive, staphylococcal species were identified by a biochemical method (ID 32 
Staph, BioMerieux, Marcy l’Etoile, France). Sensitivity patterns were determined by 
the ATB and Vitek system (GPS-517 for staphylococci, GPS-516 for enterococci, 
GNS-502 for Gram-negative rods, BioMerieux, Marcy l’Etoile, France). In the 
following years a different method has been implemented using a Gram-positive card 
with the Vitek2® system to automatically identify Gram-positive microorganisms 
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(AST-P592). The breakpoint of vancomycin for VISA was 8 µg/mL and for VRE 
was 8 µg/mL until 2006. Afterwards the breakpoint of vancomycin for VISA and 
VRE were 2µg/mL and 4µg/mL, respectively [237, 242]. 
Standard methods for identification, typing and extended sensitivity patterns were 
used to confirm or refute the relatedness of microorganisms. 
 
7.2.8 Statistical analysis 
Data were presented as median with interquartile range, or as percentage, unless 
indicated otherwise. Exploratory data analyses were performed using the chi-square 
test with Yates correction for continuity, except when a small sample size required 
the Fischer’s exact test. If necessary, comparisons between continuous variables 
amongst two groups were done with Student’s t test for variables with normal 
distribution, and Mann-Whitney U test for non-normally distributed variables. The 
level of significance was set at 0.05. We decided a priori to compare the following 
sets of data: patients with MRSA infection and episodes of MRSA infection in the 
time periods from January 2000 - December 2001 (no oropharyngeal vancomycin) 
vs. January 2002 to December 2003 (use of oropharyngeal vancomycin only in 
MRSA carriers), and vs. January 2002 to December 2015 (use of oropharyngeal 
vancomycin in all ventilated patients). Odds ratio with 95% confidence interval (CI) 
was estimated. Computations were performed using MedCalc® Statistical software 
[243] and WinStat® for Excel. 
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7.3 Results 
 
7.3.1 General characteristics 
During the 16-year study period a total of 4,681 patients were admitted to the ICU. 
Among them, 1,113 patients (697 male, 62.6%) were ventilated for ≥ 72 hours, and 
were the basis of this retrospective cohort study. Patients had an ICU mortality of 
33.4%, a median SAPS II of 43, and a median ICU stay of 15.75 days. General 
characteristics of the study population are reported in Table 7.1. 
 
Table 7.1 General characteristics of the study population 
Year N° 
patients 
Age 
(IQR) 
Male 
(%) 
SAPS II 
(IQR) 
ICU stay 
(IQR) 
Mortality 
(%) 
2000 88 74.5 (67, 78) 56 (63) 44.5 (36, 45) 13 (9, 27) 31 (34.8) 
2001 69 73 (65, 79) 43 (62.3) 44 (35, 53.7) 18 (10, 32.25) 36 (52.2) 
2002 69 70 (57, 78) 48 (69.7) 43 (31.5, 59) 22 (11, 38.5) 26 (37.7) 
2003 76 68.5 (61-68) 45 (59.2) 43 (33, 53.75) 14.5 (9.25, 29.5) 24 (31.6) 
2004 74 74 (62, 79) 41 (55.4%) 39 (32, 47.5) 15.5 (9.75, 31,25) 26 (35) 
2005 83 73 (64-79) 55 (66.5) 42 (35, 49) 15 (8, 23) 25 (30.1) 
2006 38 73.5 (56.7, 78) 26 (68.4) 45 (38, 53) 14 (7-37.25) 15 (39.5) 
2007 51 71 (64-79) 29 (56.9) 44 (37, 54) 20 (12, 37) 16 (35.3) 
2008 74 73 (65, 78) 42 (65.6) 41 (36, 51.5) 16 (10, 25.5) 21 (32.8) 
2009 62 76 (21, 81) 39 (66.1) 44 (34, 53.5) 17 (7.25, 34.5) 16 (25.8) 
2010 74 76.5 (66.7, 82) 40 (54) 46 (39, 59) 11 (7, 23.5) 30 (41) 
2011 74 74 (63, 79.7) 50 (67.5)  48.5 (40, 54.7) 18 (10, 25) 22 (29.7) 
2012 72 74.5 /64, 81) 51 (70.8) 42.5 (37, 50) 14.5 (9, 25) 24 (33.3) 
2013 68 75 (68, 80) 39 (57) 41 (32, 52.2) 16.5 (7.7, 25) 21 (31) 
2014 68 76 (69, 81) 49 (72) 37.5 (33, 49) 15 (9, 24.75) 22 (32.3) 
2015 83 75 (65.5, 81) 44 (53) 39 (34, 48) 17 (10, 31,5) 17 (20.5) 
Total 1113 73.75 (71.5, 75) 697 (62.6) 43 (41, 44.37) 15.75 (14.5, 17.75) 372 (33.4) 
SAPS, Simplified Acute Physiology Score; ICU, intensive care unit; IQR, interquartile range. 
 
7.3.2 Overall infection and microorganisms 
Table 7.2 describes the distribution of the number of patients with infection, the 
infection episodes and the day of infection onset. There were 701 patients with 
infection (63%) suffering from 983 infection episodes. In the majority of years, the 
median day of infection onset was the first day of ICU stay.
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Table 7.2 Patients with infection and infection episodes over the study period 
Year Patients Infection 
episodes 
TB PN UTI BSI Other PE SE Exo 
2000 51 68 12 37 7 7 5 44 14 10 
2001 49 68 11 40 2 3 12 55 10 3 
2002 46 63 4 40 10 6 3 44 8 11 
2003 41 56 1 30 9 6 10 42 0 14 
2004 41 46 3 31 3 1 9 38 5 3 
2005 52 62 6 39 4 4 9 55 3 4 
2006 16 23 1 14 2 3 3 21 2 0 
2007 41 54 15 21 3 2 13 48 1 5 
2008 40 54 9 24 4 7 10 48 5 1 
2009 42 59 8 26 7 12 6 47 8 4 
2010 44 55 9 23 8 2 13 49 3 3 
2011 42 59 8 18 5 13 15 47 7 5 
2012 43 60 12 25 5 5 13 55 4 1 
2013 49 78 14 34 9 12 9 68 6 4 
2014 44 68 7 31 4 12 13 61 2 4 
2015 60 110 16 38 14 24 18 90 10 10 
Total  701 983 136 471 96 119 161 812 88 83 
TB, tracheobronchitis; PN, pneumonia; UTI, urinary tract infection; BSI, bloodstream infection; PE, 
primary endogenous infection; SE, secondary endogenous infection; Exo, exogenous infection. 
 
 
There were 136 episodes of tracheobronchitis, 471 pneumonias, 96 UTIs, 119 BSIs, 
and 161 episodes of other infections, such as peritonitis, meningitis or wound 
infection. 
Microorganisms causing infection are reported in Table 7.3. In 389 episodes (39.6%) 
the causative microorganism was not isolated. Gram-positive microorganisms 
accounted for 251 infection episodes (25.5%), Gram-negative microorganisms 
caused 303 infection episodes (38.8%), yeasts were involved in 32 episodes (3.3%), 
and the remaining 8 episodes were divided among viruses, Rickettsiae, and 
Chlamydiae. Pseudomonas aeruginosa was the most frequently encountered 
microorganism (12.1%), followed by MRSA (10%) and Escherichia coli (5%). 
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Table 7.3 Microorganisms causing 983 episodes of infection 
Microorganisms Episodes % 
NA 389 39.6 
Gram positive microorganisms 
    MRSA 
    Enterococcus spp 
    MSSA 
    CNS 
    Streptococcus pneumoniae 
    Streptococcus pyogenes 
    Clostridium spp 
    Listeria monocytogenes 
    Bacillus spp 
    Propionibacterium spp 
    Actinomyces spp 
    Corynebacterium spp 
251 
98 
48 
46 
27 
19 
3 
3 
2 
2 
1 
1 
1 
25.5 
10 
4.9 
4.7 
2.7 
1.9 
0.3 
0.3 
0.2 
0.2 
0.1 
0.1 
0.1 
Gram-negative microorganisms 
    Pseudomonas aeruginosa 
    Escherichia coli 
    Klebsiella spp 
    Serratia spp. 
    Proteus spp 
    Enterobacter spp 
    Stenotrophomonas maltophilia 
    Haemophilus influenzae 
    Citrobacter spp 
    Acinetobacter spp 
    Bacteroides spp 
    Morganella spp 
    Burkolderia cepacia 
    Providencia spp 
    Salmonella spp 
    Legionella pneumoniae 
    Moraxella catarrhalis 
    Bordetella spp 
    Prevotella spp 
303 
119 
49 
22 
19 
18 
17 
14 
10 
7 
6 
6 
4 
2 
2 
2 
2 
2 
1 
1 
30.8 
12.1 
5 
2.2 
1.9 
1.8 
1.7 
1.4 
1.0 
0.7 
0.6 
0.6 
0.4 
0.2 
0.2 
0.2 
0.2 
0.2 
0.1 
0.1 
Fungi 
    Candida spp 
    Aspergillus spp 
32 
30 
2 
3.3 
3.1 
0.2 
Other 
    H1N1 
    Cytomegalovirus 
    Chlamydia pneumoniae 
    Coxiella burnetii 
8 
3 
2 
2 
1 
0.8 
0.3 
0.2 
0.2 
0.1 
NA, not available; MRSA, methicillin-resistant Staphylococcus aureus; 
spp, species; MSSA, methicillin-sensitive Staphylococcus aureus; CNS, 
coagulase-negative staphylococci 
 
7.3.3 MRSA infection 
During the study period 145 (14%) infection episodes were due to S. aureus. MRSA 
was responsible for 98 episodes of infection (68.3% of S. aureus infections, 10% of 
all episodes) in 91 patients. Table 7.4 shows the infection episodes due to MRSA and 
the classification of infections. There were 27 (27.6%) episodes of tracheobronchitis, 
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44 (44.9%) pneumonias, 10 (10.2%) UTIs, 13 (13.3%) BSIs, and 4 (4%) episodes of 
other infections. Forty-eight (49%) episodes were primary endogenous, 29 (29.6%) 
were secondary endogenous, and 21 (21.4%) were exogenous. 
 
Table 7.4 Patients with MRSA infection, infection episodes and classification of 
infections over the study period 
Year Patients Infection 
episodes 
TB PN UTI BSI Other PE SE Exo 
2000 27 29 8 14 1 4 2 13 13 3 
2001 22 24 8 10 0 3 2 14 9 1 
2002 9 9 3 4 1 1 0 4 2 3 
2003 7 8 0 4 1 3 0 1 0 7 
2004 4 4 0 3 1 0 0 3 1 0 
2005 4 4 0 0 4 0 0 3 1 0 
2006 0 0 0 0 0 0 0 0 0 0 
2007 0 0 0 0 0 0 0 0 0 0 
2008 3 3 2 1 0 0 0 3 0 0 
2009 4 4 2 1 1 1 0 0 1 3 
2010 1 1 0 1 0 0 0 1 0 0 
2011 1 1 0 1 0 0 0 0 1 0 
2012 1 1 1 0 0 0 0 1 0 0 
2013 3 4 2 2 0 0 0 3 1 1 
2014 2 2 0 1 1 0 0 0 0 2 
2015 3 4 1 2 0 1 0 3 0 1 
Total 91 98 27 44 10 13 4 48 29 21 
TB, tracheobronchitis; PN, pneumonia; UTI, urinary tract infection; BSI, bloodstream infection; PE, 
primary endogenous infection; SE, secondary endogenous infection; Exo, exogenous infection. 
 
MRSA infections were in decline over the study period (Table 7.4, Figure 7.1). In 
particular, there was a reduction of MRSA secondary endogenous infection during 
the use of oropharyngeal vancomycin from 2002 until 2015. Table 7.5 shows the 
comparison between the period in which oropharyngeal vancomycin was not used 
(2000-2001) and periods in which oropharyngeal vancomycin was included. A 
significant reduction in MRSA infected patients and secondary endogenous MRSA 
infection was found in periods using vancomycin. Exogenous MRSA infections 
increased in patients treated with vancomycin, and primary endogenous infections 
were reduced but not significantly. 
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Figure 7.1 Incidence of MRSA endogenous and exogenous infections during the 
study period 
 
 
Table 7.5 Comparison of data sets in patients treated with and without oropharyngeal 
vancomycin 
Enteral vancomycin 2002-2003* Enteral vancomycin 2002-2015*  No enteral 
vancomycin 
(2000-2001) 
N (%) 
N (%) OR (95% CI) p N (%) OR (95% CI) p 
Infected patients 100 87 601 
Patients with 
MRSA infection 
49 (49) 16 (18.4) 0.23 (0.12-0.46) < 0.001 42 (7%) 0.08 (0.05-0.13) <0.001 
MRSA infection 
episodes 
53 17 45 
PE 
SE 
Exo 
27 (51) 
22 (41.5) 
4 (7.5) 
5 (29.4) 
2 (11.8) 
10 (58.8) 
0.4 (0.12-1.3) 
0.19 (0.04-0.91) 
17.5 (4.3-71.26) 
= 0.127 
= 0.037 
< 0.001 
21 (46.7%) 
7 (15.5%) 
17 (37.8%) 
0.84 (0.38-1.87) 
0.26 (0.1-0.69) 
7.44 (2.28-24.3) 
= 0.67 
= 0.007 
< 0.001 
Each group was compared with the group without enteral vancomycin; N, number; OR, odds ratio; CI, 
confidence interval; MRSA, methicillin-resistant Staphylococcus aureus; PE, primary endogenous infection; 
SE, secondary endogenous infection; Exo, exogenous infection. 
 
 
0
5
10
15
20
25
30
35
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
Year
M
R
SA
 in
fe
ct
io
n 
ep
is
od
es
Exogenous
Secondary endogenous
Primary endogenous
VANCOMYCIN 
  
135 
 
 
No VISA was isolated during the study period. MRSA MICs for vancomycin were 
always <1 mg/L. Four infection episodes of urinary tract infection were due VRE; all 
four episodes were primary endogenous (i.e. imported in the ICU). 
 
7.4 Discussion 
 
Four important issues emerged from this long-term, observational, retrospective 
study in 1,113 patients requiring mechanical ventilation for ≥72 hours: 
1. MRSA accounted for 98 (68.3%) of 145 S. aureus infectious episodes and 
most MRSA infections were lower respiratory tract infections; 
2. the majority of MRSA infections were primary endogenous, although an 
exogenous infectious problem was found in the ICU; 
3. there was a reduction of MRSA secondary endogenous infection after the 
implementation of oropharyngeal vancomycin; 
4. The manoeuvre was safe in terms of emergence of VISA and VRE. 
This study showed the emblematic picture of MRSA epidemiology in an Italian ICU. 
MRSA infection accounted for 10% of all infectious episodes in ICU, and for 68% of 
S. aureus infection. MRSA was the second most common microorganism causing 
infection after Pseudomonas aeruginosa, and was mainly isolated from the lower 
respiratory tract (72.5%), including 27 episodes of tracheobronchitis (27.6%) and 44 
episodes of pneumonia (44.9%). 
A survey in Italian ICUs showed that 22.7% of infectious episodes were due to S. 
aureus, and MRSA caused 53% of them [238]. Our findings are also in line with 
those of the Extended Prevalence of Infection in Intensive Care (EPIC) II study 
conducted in 75 countries in which MRSA was isolated in 8.7% of ICU infections in 
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Western Europe and 10.4% of ICU infections in Eastern Europe [28] Overall, 63.5% 
of ICU infections were located in the respiratory tract, with a significantly higher 
proportion of respiratory infections observed in Eastern Europe than Western Europe 
(71.6% versus 63.3%, p 0.05). Koulenti et al. [244] reported that MRSA was isolated 
in 16% of patients with nosocomial pneumonia. The majority of infections of the 
lower respiratory tract were usually due to MRSA, Klebsiella pneumoniae, 
Acinetobacter baumannii, P. aeruginosa and Enterobacter species [245]. In the 
survey of European ICUs, the most common causes of ventilator-associated 
pneumonia were Enterobacteriaceae (43.0%), followed by S. aureus (32.6%), of 
which 18% of episodes were due to MSSA and 14.6% to MRSA [244]. 
Approximately 20% of VAP episodes were due to P. aeruginosa [244, 246] 
However, significant variability has been shown in the distribution of pathogens 
causing VAP across Europe. In a multicenter study of VAP, the prevalence of MRSA 
was shown to be significantly lower in patients from a Spanish hospital than from a 
French hospital [247]. 
In this study, about half of MRSA infections were primary endogenous, i.e. they 
were caused by MRSA imported in the ICU by the patients’ own flora or the patient 
was admitted to the ICU with an MRSA infection. This is in line with previous 
studies showing that the majority of ICU infections are not due to bacteria acquired 
in the ICU, but to microorganisms imported in the ICU by the patient’s admission 
flora [41, 42]. These infections can not be classified as ICU-acquired. Only 
secondary endogenous and exogenous MRSA infections can be considered infections 
acquired during the treatment in the ICU. An important finding of this study is that 
21 MRSA infection episodes (21.4%) were exogenous. Interestingly, the majority of 
them (17 of 21 episodes) developed after the implementation of vancomycin. In 
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particular, MRSA exogenous infections were more common in 2002 (3 episodes), 
2003 (7 episodes), 2009 (3 episodes), and 2014 (2 episodes). These results indicate a 
serious breach of hygiene measures, and are not related to the vancomycin use. 
Exogenous infections are caused by PPMs introduced into the patient’s internal 
organs, such as the lower airways or the urinary tract, from the environment, either 
animate or inanimate, bypassing the carrier state. 
This study showed that, after the introduction of topical oropharyngeal vancomycin, 
MRSA secondary endogenous infections were significantly reduced, and outbreak 
and endemicity of MRSA, typically present in 2000 and 2001, were under control. 
The administration of oropharyngeal topical vancomycin gel is expected to reduce 
MRSA oropharyngeal carriage in overgrowth concentrations, and, subsequently, to 
control secondary endogenous MRSA infection of the lower respiratory tract. From 
an epidemiological point of view the import of MRSA into the unit is an important 
factor contributing to its endemicity. However, a second important factor, 
maintaining the endemicity, is based on the prevention and control of MRSA 
acquisition due to transmission from patients with oropharyngeal and gut overgrowth 
of MRSA. The concept that overgrowth may promote the spread of MRSA via hands 
of carers, and may be an independent risk factor for secondary endogenous 
colonisation and infection is in line with recent observations showing that the 
implementation of enteral antimicrobials controls outbreaks and endemicity of 
MRSA following eradication and reduction of overgrowth [103, 208, 209, 216, 218-
221, 223]. Two prospective randomised studies of enteral vancomycin have been 
published. An Italian study in mechanically ventilated patients showed that the 
administration of a 4% vancomycin gel in the oropharynx reduced lower respiratory 
tract infections due to MRSA acquired on the ICU and MRSA carriage (OR 0.26, CI 
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0.08-0.88, p<0.001; OR 0.25, CI 0.09-0.69, p<0.01, respectively) [218] A double-
blind randomised placebo controlled Spanish study using enteral vancomycin applied 
in oropharynx and gut in mechanically ventilated patients prevented acquisition, 
carriage and infection due to MRSA [216]. Three prospective, before-after, studies 
were undertaken to evaluate the efficacy of enteral vancomycin for the prevention of 
MRSA infections. An Italian research team demonstrated that the administration of 
only intestinal vancomycin eradicated MRSA gut carriage and was effective in the 
control of an MRSA outbreak (OR 0.37, 95% CI 0.24-0.58) [221]. In a 9-year 
prospective study on a burn ICU in Getafe, Spain, oropharyngeal and intestinal 
vancomycin was added to the classical SDD protocol to control MRSA transmission 
[219]. There was a significant reduction of MRSA acquisition and infection in 
patients receiving vancomycin. Similarly, the same Spanish group in a prospective 
49-month study found the same results in an ICU population of medical/surgical 
patients [220]. Finally, three observational studies were performed in ICU patients 
treated with enteral vancomycin. An Italian study [209] was based on the hypothesis 
that the prevention of MRSA carriage using 4% vancomycin gel applied in the 
oropharynx was more effective in reducing carriage and lower respiratory tract 
infection than the treatment of established MRSA carriage. In period one 98 patients 
received oropharyngeal vancomycin when they were MRSA carriers, i.e. two 
consecutive surveillance samples positive for MRSA. In period two 93 patients 
received vancomycin immediately on admission to the ICU. Patients with MRSA 
carriage were less in period two (p<0.001), as well as patients with MRSA lower 
respiratory tract infection, due to the reduction of secondary endogenous MRSA 
infections (p = 0.01). Another Italian research team [208] compared MRSA carriage 
and infection in two groups of mechanically ventilated patients receiving different 
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concentrations of oropharyngeal vancomycin gel. One group received a 2% gel and 
the other received a 4% gel. The 4% vancomycin protocol significantly reduced 
MRSA carriage, compared to the 2% vancomycin protocol. MRSA secondary 
endogenous infections were reduced by 4% vancomycin compared to 2% 
vancomycin. A 4-year observational study [223] from the paediatric ICU of the 
Alder Hey Children Hospital, Liverpool, UK, assessed the effect of throat and gut 
surveillance combined with enteral vancomycin on gut overgrowth, transmission of 
MRSA, infection and mortality. Children identified as MRSA carriers received 
enteral vancomycin (0.5 gr of 2% oropharyngeal paste four times a day in the 
oropharynx, and 40 mg/Kg/day oral vancomycin suspension in the gut). Enteral 
vancomycin reduced MRSA overgrowth, preventing secondary endogenous MRSA 
infections. 
This study demonstrates that the use of vancomycin is safe in terms of emergence of 
VISA and VRE. These results are in line with previous findings showing no 
emergence of VISA and VRE during the use of enteral vancomycin [208, 209, 214, 
219, 221, 223]. Other European studies, in which enteral vancomycin was combined 
with SDD, did not report any increased infection rate with VISA or VRE [210, 212, 
218]. All these studies were conducted in ICUs without a history of VISA or VRE. A 
5-year prospective study conducted in a Spanish ICU, in which enteral vancomycin 
was used, did not show any increase in the incidence of resistant microorganisms 
including MRSA [248]. The reason why enteral vancomycin does not select for 
VISA or VRE may be related to the high intestinal vancomycin levels between 3,000 
and 24,000 μg/gram of faeces obtainable after 2 grams/day of enteral vancomycin. In 
contrast, after 2 grams/day of parenteral vancomycin faecal vancomycin levels are 
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between 6 and 11 μg/gram of faeces [98]. These non-lethal, low concentrations of 
vancomycin in the gut may promote the selection of VRE and VISA. 
Although the strength of the study is the collection of data from a large number of 
patients during a 16-year period, this study has several limitations. Firstly, the design 
of the study is retrospective and most sources of error due to confounding factors and 
biases are common in retrospective studies. A weakness of retrospective studies is 
that they generate a great deal of missed data. A better design would be a cluster-
randomised trial or a stepped-wedge trial. However, although this study is 
retrospective, it includes prospectively collected data, and, in designing the study, we 
followed the recommendations for chart review methodology, such as the a priori 
description of clear and well defined research outcomes, the development of a 
standardized data abstraction forms, the description of explicit inclusion and 
exclusion criteria. Secondly, the retrospective comparison of two consecutive periods 
may provide a low level of evidence in order to establish a causal relationship 
between the outcome and the intervention assessed. Thirdly, changes in patient 
population and patients’ demographics, healthcare procedures, compliance with 
barrier precautions, different dynamics of endemic/epidemic strain transmission, and 
epidemiological changes in frequencies of MRSA may occur in a 16-year period. 
However, this study showed a small and not significant reduction in primary 
endogenous MRSA infections. Although data about MRSA carriage on admission 
and during ICU treatment were not available due to the study design, we could infer 
that the immediate use of oropharyngeal vancomycin may have brought under 
control MRSA carriage on admission, and, thus may have reduced primary 
endogenous MRSA infection. Fourthly, after 2006 the MIC breakpoint for MRSA 
susceptible to vancomycin was lowered from 4 mg/L to ≤ 2 mg/L, and VISA from 8-
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16 mg/L to 4-8 mg/L [236]. Therefore, the findings of the absence of VISA should 
be interpreted with caution. However, MRSA MICs for vancomycin were always <1 
mg/L. 
 
7.5 Conclusion 
 
This observational, retrospective study showed that MRSA infections were 10% of 
all ICU infections and that half of MRSA infections were primary endogenous due to 
MRSA present in the oropharyngeal and gut flora of the patients on ICU admission. 
The use of vancomycin significantly reduced MRSA secondary endogenous 
infections, avoiding MRSA endemicity. No emergence of VISA or VRE was 
demonstrated. 
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8 CONCLUDING REMARKS AND IMPLICATIONS FOR CLINICAL 
PRACTICE AND RESEARCH 
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8.1 Mupirocin and chlorhexidine failed to control MRSA infection and to reduce 
mortality 
 
8.1.1 Mupirocin 
The efficacy of oropharyngeal/nasal mupirocin on ICU overall infection and 
infection due to MRSA has been evaluated in a systematic review and meta-analysis 
of only randomised trials in critically ill patients (chapter 4). Although the analysis 
demonstrated a reduction of lower respiratory tract infection in patients receiving 
mupirocin, there was no effect of mupirocin on MRSA lower respiratory tract 
infection (OR 0.28, 95% CI 0.03-2.16, p=0.22). Mortality was not impacted. 
 
8.1.2 Chlorhexidine 
The efficacy of oropharyngeal chlorhexidine to control ICU infection, MRSA 
infection, and mortality, has been assessed in a systematic review of randomised 
controlled trials (chapter 5). Although the systematic review and meta-analysis 
demonstrated that oral care with chlorhexidine reduced overall lower respiratory tract 
infection, and lower respiratory tract infection due to Gram-positive and Gram-
negative “normal” flora, such as methicillin-sensitive S. aureus, S. pneumoniae, H. 
influenzae, and E. coli, there were insufficient data to assess the efficacy of oral 
chlorhexidine on lower respiratory tract infection due to MRSA. Bloodstream 
infections were not reduced by oral chlorhexidine, and the reduction in BSI due to 
Gram-positive and Gram-negative microorganisms, and “normal” flora was not 
significant, as was the increase in bloodstream infection due to “abnormal flora”. 
Bloodstream infections due to MRSA were not found in this review. Only in the 
subset of surgical, mainly cardiac, patients, chlorhexidine was effective in reducing 
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bloodstream infection. Mortality was not affected. Additionally, half the population 
of this review was surgical, and, therefore, the results can not be applied to the entire 
ICU population. This should warrant further large RCTs to test the effectiveness of 
oral chlorhexidine in preventing lower airway infection, in reducing mortality in 
medical and mixed critically ill patient, and in controlling MRSA infection. 
 
8.1.3 Why did they fail? 
 
8.1.3.1 Chlorhexidine concentration 
Chlorhexidine is an antiseptic effective against Gram-positive bacteria, Gram-
negative bacteria and fungi [147]. It has both bacteriostatic and bactericidal 
mechanisms of action, depending on its concentration. A recent systematic review 
assessed the efficacy of different concentrations of chlorhexidine mouthwash (i.e. 
0.12%, 0.2% and 0.3%) on the microbial load and the effect on dental plaque [249]. 
The authors concluded that the effectiveness of this agent is dose dependent. The 
meta-analysis of chapter 5 explored this issue, and did not find any difference 
between 0.12%-0.2% and 1%-2% chlorhexidine concentrations (OR 0.70, 95% CI 
0.52-0.94, and OR 0.59, 95% CI 0.35-0.97, respectively). However, these results 
should be taken with caution as clinical heterogeneity was present (e.g. most studies 
were surgical with a low period of ventilation, the number of daily applications 
varied from one to four, and the duration of treatment was different). 
 
8.1.3.2 RCTs are underpowered 
Price et al. [83], in a meta-analysis of the effect of chlorhexidine on mortality, found 
that it increased mortality (OR 1.25, 95% CI 1.05-1.50). Although the authors 
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acknowledged this issue, they were unable to explain this discrepancy of reduced 
pneumonia and higher mortality in patients treated with chlorhexidine. Similarly, the 
meta-analysis of chapter 5 showed a non significant increased mortality (OR 1.11; 
95% CI 0.92-1.33). RCTs included in the systematic review were not powered to 
detect mortality differences, and, despite combining the RCTs, the final sample size 
with a baseline mortality rate of 16% could be not enough to detect a survival 
benefit. This hypothesis is consistent with the very low baseline 2.6% mortality rate 
in surgical patients which are 52% of subjects included in the mortality analysis. In 
the remaining sample sizes of 678 medical and 1260 medical/surgical/trauma 
patients with a mortality rate of 33% and 29%, respectively, may be too small to 
detect a survival benefit. 
Similarly, the lack of any effect of mupirocin on mortality is due to the small sample 
size of the systematic review. 
 
8.1.3.3 Chlorhexidine may reduce immunity 
Several in-vitro studies have shown that chlorhexidine affects leucocytes and 
macrophages, and, thus, reduces immunity [250-254]. Although it is yet unclear how 
the reduced immunity may result in increased mortality in the critically ill, this 
hypothesis should be taken into account. 
 
8.1.3.4 Biofilm-producing MRSA 
A biofilm is a strong and complex microbiological structure with different 
distribution of cells, cell aggregates, bacterial toxins, polysaccharides and water. This 
structure protects microorganisms against host defence mechanisms and entry of 
antimicrobial agents and can be present on surfaces. Mupirocin, at standard 
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concentration, does not show sufficient bactericidal effect on MRSA in biofilm 
[255]. Similarly, chlorhexidine is less effective against biofilms of A. baumannii, E. 
coli, P. aeruginosa, and MRSA [256]. 
 
8.1.3.5 Mupirocin and chlorhexidine do not impact gut carriage 
An important issue of the effectiveness of mupirocin and chlorhexidine is that they 
only impact lower respiratory tract infections following control of throat overgrowth 
of PPMs. Additionally, chlorhexidine mainly controls lower respiratory tract 
infection due to oropharyngeal “normal” flora, not MRSA; bloodstream infection 
was not affected. Similarly, the effect of mupirocin on MRSA infection was not 
demonstrated. It is highly unlikely that oropharyngeal chlorhexidine or mupirocin 
may control gut overgrowth of abnormal flora, and the subsequent bloodstream 
infection following bacterial translocation. 
 
8.1.3.6 Damage of the lung and allergic reactions 
Chlorhexidine can be aspirated into the lower airways developing an acute 
respiratory distress syndrome [257]. In addition, some patients may suffer from 
allergic reactions, including anaphylaxis [258]. 
 
8.2 Enteral vancomycin: a possible approach to control MRSA 
 
8.2.1 Enteral vancomycin controls MRSA carriage and infection. 
Control of MRSA infection usually relies on five pillars in order to reduce 
transmission and subsequent infection: 
1. hand hygiene; 
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2. use of gloves, gowns and aprons (personnel protective equipment); 
3. isolation; 
4. care of patient equipment; 
5. care of the environment 
However, RCTs on gloves and gowns indicated that personal protective equipment 
had no effect on ICU infection and mortality [259, 260]. Handwashing alone can not 
control primary endogenous infections which are caused by MRSA already present 
in the patient’s oropharynx and gut on admission to the ICU [70]. 
Therefore, the new approach of enteral vancomycin in ICU patients challenges the 
traditional recommendations, including isolation, barrier precautions, and the use of 
chlorhexidine and mupirocin [103]. 
The prophylactic use of antimicrobials to control oropharyngeal and/or digestive 
tract carriage of PPMs in ICU patients, i.e. SDD, has been introduced four decades 
ago, and has been a subject of debate. Advocates of the use of SDD have shown 
consistent benefits [44, 84, 186], but they have frequently encountered a strong 
opposition from detractors who initially refused the clear effect of SDD on mortality 
reduction, and, afterwards, emphasised the overwhelming risk of antimicrobial 
resistance [261, 262]. The addition of vancomycin to the SDD antimicrobials might 
raise even more concerns as vancomycin is a first line parenteral agent against 
MRSA infection. 
Several studies have evaluated the efficacy of enteral vancomycin in decreasing 
MRSA carriage and infection rates. The core of this thesis is the systematic review 
and meta-analysis of randomised and non-randomised studies in ICU patients 
receiving enteral vancomycin (chapter 6). The endpoint was to assess the efficacy of 
enteral vancomycin to control MRSA carriage and infection in intensive care unit 
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patients. The review showed that in patients treated with enteral vancomycin overall 
infection rates, S. aureus carriage and infection, and MRSA carriage and infection 
were significantly reduced. 
Additionally, another central section of this thesis is the retrospective study on the 
incidence of MRSA infection in a medical/surgical ICU using oropharyngeal 
vancomycin to prevent MRSA carriage and infection (chapter 7). The study is 
unique in its design as it embraces a period of 16 years, from 2000 to 2015. The 
study showed that, in patients receiving enteral vancomycin, MRSA secondary 
endogenous infections were significantly reduced compared with patients who did 
not receive vancomycin. 
Enteral vancomycin aims to eradicate or reduce oropharyngeal and/or intestinal 
carriage of MRSA with two main endpoints: 1) a clinical endpoint of the control of 
endogenous MRSA infection in the individual patient; 2) an epidemiological 
endpoint of the control of MRSA dissemination to protect other patients in the ICU 
from acquiring MRSA following transmission via hands of carers. MRSA 
overgrowth is a risk factor for transmission via hands of carers, promoting secondary 
endogenous carriage, colonisation and infection, and maintaining MRSA endemicity 
in the ICU. Overgrowth of MRSA in the oropharynx may cause migration of the 
same microorganism into the lower respiratory tract causing colonisation and 
subsequent infection of the lower respiratory tract (i.e. secondary endogenous 
infection). Similarly, MRSA overgrowth in the gut may cause translocation and 
subsequent invasion of the bloodstream causing bloodstream infection. 
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8.2.2 Does enteral vancomycin impact mortality? 
The systematic review (chapter 6) demonstrated a significant 41% mortality 
reduction in 2,177 patients. However, in the majority of studies (i.e. 7 out of 9 
studies) enteral vancomycin was part of the SDD regimen, covering also AGNB and 
yeasts, and the reduction in mortality was still significant. In studies assessing the 
effect of only vancomycin the mortality reduction was not significant. Data on 
mortality are difficult to interpret due to the small sample size and the presence of 
confounding factors such as the concomitant use of SDD antimicrobials. 
 
8.2.3 Safety of enteral vancomycin 
 
8.2.3.1 Emergence of VRE and VISA 
The secondary endpoint of the systematic review (chapter 6) was to evaluate the 
safety of the manoeuvre, i.e. the emergence of resistance to vancomycin, in particular 
the emergence of VRE and VISA. The systematic review showed that VRE and 
VISA were not a clinical problem. Additionally, the observational study (chapter 7) 
supports the safety of enteral vancomycin as the emergence of VISA and VRE was 
not demonstrated. 
Enteral vancomycin has been successfully used in the treatment of MRSA post-
operative enteritis [263], and for treating Clostridium difficile-associated infection 
[264]. In this context it has been reported that oral vancomycin was safe and well-
tolerated. 
Antimicrobial resistance often develops when antibiotics do not exert a full 
bactericidal activity, due to low concentrations. While non-lethal, low 
concentrations of vancomycin in the gut may promote the selection of resistant 
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clones, high levels of faecal vancomycin concentrations during enteral 
administration may explain the absence of VRE and VISA. However, early stages 
of vancomycin resistance are often not documented with the standard identification 
methods which do not identify h-VISA. Tests to identify h-VISA were not 
performed in the retrospective study of chapter 7. Similarly, studies included in the 
systematic review of chapter 6 did not mention the use of specific identification of 
heteroresistance. However, the retrospective study observed that vancomycin MIC 
for MRSA was always lower than 1 mg/L. Likewise, several studies included in the 
systematic review clearly reported that MIC for vancomycin was always lower than 
1 mg/L. Owing to these finding it is unlikely that heteroresistant clones would have 
been identified if more sensitive test had been performed. 
 
8.2.3.2 Impact on gut microbiota 
The majority of antimicrobials may alter the microbiota composition. Data from 
critically ill patients receiving enteral vancomycin are limited to VRE and VISA. In 
the last years, research has focused on the effect of SDD on microbiota. Few studies 
have shown that SDD may affect the microbiota of the critically ill patient. However, 
the clinical impact has not yet been clarified. 
Benus et al. [91] showed that in faecal samples of patients enrolled in a multicentre 
trial, AGNB were significantly reduced by SDD compared to SOD and standard 
care. F. prausnitzii was reduced by SDD regimen compared to SOD and standard 
care. Enterococci increased in SDD group compared to SOD and standard care. The 
decrease of butyrate production due to the decrease of F. prausnitzii group of 
bacteria may have some consequences. Butyrate is a primary source of energy for 
colonocytes and promotes the growth of colonocytes preventing mucosal atrophy 
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[265]. However, also enteral feeding, a common manoeuvre in critically ill patients, 
has been reported to reduce faecal butyrate concentrations in healthy volunteers 
[266]. Buelow et al. [92] evaluated the impact of SDD on the gut microbiota in one 
ICU patient during and after ICU stay, and searched for two common 
aminoglycoside resistance genes in twelve ICU patients who received SDD. 
Hospitalization and administration of SDD has large, but highly individualized, 
effects on the gut resistome. Selection for transferable antibiotic resistance genes in 
anaerobic commensal bacteria could impact the risk of transfer of antibiotic 
resistance genes to opportunistic pathogens. The same Dutch researchers [93] 
compared the gut microbiota of 10 ICU patients receiving SDD and 10 healthy 
subjects. The microbiota of SDD patients was characterized by lower microbial 
diversity, lower levels of E. coli and anaerobic Gram-positive butyrate-producing 
bacteria, and increased abundance of Bacteroidetes and enterococci. Four genes 
providing resistance to aminoglycosides, macrolides, disinfectants and tetracyclines 
were more present in ICU patients than in healthy subjects, but genes providing 
resistance to chloramphenicol and tetracycline were more present in healthy subjects. 
The risk associated with SDD on selection of antibiotic resistance was very limited. 
The limitation of this study is that the microbiota and microbiome of SDD ICU 
patients was compared with the microbiota and microbiome of healthy subjects. 
Other factors, including underlying critical illness, parenteral or enteral feeding and 
antibiotic therapy may affect the composition of the microbiota during ICU stay. 
These studies have been undertaken in settings with low level of antibiotic resistance 
and can not be generalizable to other countries or hospitals where resistant bacteria 
are more prevalent. However, a recent, 4-year, cohort study in an ICU setting with 
high level of resistance found that SDD was effective in reducing infections due to 
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multi-drug resistant bacteria [267]. Colistin and tobramycin-resistant colonisation 
was not significantly increased. 
An important consideration with the use of both SDD and SOD is the increase of 
enterococci in the gut in overgrowth concentrations, as they are intrinsically resistant 
to the SDD antimicrobials, and the reduction of Gram-negative bacteria. Antibiotic-
resistant gene transfer has been shown in vivo between enterococci and other 
bacterial species [268]. In a study of 9 patients receiving SDD, although vancomycin 
resistance was not detected among E. faecalis and E. faecium isolates, multiple 
Enterococcus species carrying some antibiotic resistance and virulence genes were 
demonstrated [269]. However, it is unclear whether the clonal replacement observed 
in enterococci was due to nosocomial strains or populations that were previously 
present in lower abundances. Future studies are needed to test this hypothesis. 
Knowledge of the impact of enteral vancomycin on the intestinal microbiota is scarce 
and is mainly associated with its use in C. difficile infection. Importantly, the 
majority of patients with C. difficile infection received antibiotics before vancomycin 
administration, limiting a true understanding of the vancomycin effects on intestinal 
microbiota. In a study by Isaac et al [100], nine patients, who were antibiotic free in 
the previous three months, received a two-week course of oral vancomycin. The 
control group did not receive the drug. Vancomycin treatment diminished the 
richness and diversity of human microbiota, reduced the level of Bacteroidetes 
phylum, whilst Proteobacteria and Fusobacteria phyla increased. Additionally, 
among Proteobacteria, abnormal AGNB increased. However, patients included in 
this study were not critically ill patients, and, therefore, these results can not be 
generalizable to the ICU population. In a recent report [270] the use of enteral 
vancomycin combined with SDD antimicrobials was associated with two cases of 
  
153 
 
 
vancomycin-dependent enterococci (VDE) carriage. VDE are enterococci which 
demonstrate specific requirements for glycopeptides antimicrobial agents. Although 
these microorganisms can cause nosocomial infection, the clinical significance of 
these isolates is not entirely clear. 
 
8.3 Implications for clinical practice 
Carriage and overgrowth of PPMs, including MRSA, in the oropharynx and gut are 
risk factors for transmission via hands of carers, promoting secondary endogenous 
MRSA carriage, colonisation of sterile organs and infection, and maintaining MRSA 
endemicity in the ICU [103]. 
The use of oral care with mupirocin or chlorhexidine to control lower respiratory 
tract infection and MRSA infection in ICU patients is not supported by the results of 
this thesis. Two systematic reviews (chapters 4 and 5) did not demonstrate any effect 
on MRSA infection, while the effect on overall lower respiratory tract infection was 
not robust. 
The new concept of enteral vancomycin and surveillance cultures of throat and 
rectum in critically ill patients has been applied to only MRSA carriers by Spanish 
[220], Italian [221] and English [223] researchers. MRSA ICU endemicity has been 
limited using oropharyngeal and intestinal vancomycin both in adults [220] and in 
children [223], and MRSA outbreak has been controlled using intestinal vancomycin 
[221]. 
Subsequently, due to MRSA endemicity in their ICUs, the Spanish and Italian 
research groups employed this manoeuvre prophylactically in all ICU patients to 
prevent acquisition and carriage of MRSA [208, 209, 219]. These experiences were 
based on the hypothesis that the prevention of MRSA carriage using enteral 
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vancomycin was more effective in reducing MRSA carriage and lower respiratory 
tract infection than the treatment of established MRSA carriage. They rendered the 
unit virtually free of MRSA. 
Interestingly, the study of chapter 7 confirmed these results and showed that in an 
ICU with MRSA endemicity the use of oropharyngeal vancomycin prophylactically 
in all ventilated patients was able to reduce overall MRSA infection, and MRSA 
secondary endogenous infection. 
Additionally, patients with severe underlying diseases may be MRSA carriers prior 
to ICU admission [271], and contribute to maintain the MRSA endemicity in the ICU 
(i.e. primary endogenous carriage). The use of enteral vancomycin in all ICU patients 
is an attempt to reduce transmission of MRSA from MRSA index cases to the other 
patients of the ICU, i.e. secondary endogenous carriage. 
Therefore, in case of an intensive care unit with MRSA endemicity or outbreak, the 
use of oropharyngeal and/or intestinal administration of vancomycin in all ventilated 
patients (combined with hygiene measures) may be considered a strategy to control 
MRSA carriage and subsequent infection. Surveillance cultures of throat and rectum, 
to evaluate the efficacy of the manoeuvre and to detect resistance at early stages, are 
mandatory. 
There are no data about infection and re-colonisation of the digestive tract of ICU 
patients after the cessation of enteral vancomycin or the discharge from the ICU. The 
SDD experience demonstrated that once SDD was stopped, incidence of hospital 
acquired infection was higher than in patients not treated with SDD [97]. Similarly, it 
could be hypothesised that after the discontinuation of enteral vancomycin, patients 
may be re-colonised by MRSA and/or enterococci and MRSA or enterococcal 
infections may increase. Therefore, in patients who received enteral vancomycin (as 
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well as SDD/SOD) and are discharged from the ICU, a careful monitoring of the 
carrier state is mandatory to detect the possible emergence of resistant bacteria or 
enterococcal carriage. 
 
8.4 Implications for research 
The results of this thesis suggest some interesting fields of research. 
Additional RCTs are needed to assess the effectiveness of mupirocin and oral 
chlorhexidine to prevent lower respiratory tract infection and to reduce mortality in 
critically ill patients. These RCTs should be adequately powered to detect the effect 
of these manoeuvres on lower respiratory tract infection, including MRSA infection, 
and mortality. 
This thesis demonstrated that enteral vancomycin may control MRSA carriage and 
infection. However, the low quality of studies included in the systematic review and 
the presence of confounding factors may affect the robustness of the results. 
Therefore, large, high quality, randomised trials are warranted to confirm these 
findings. 
There are no studies in ICU about the re-colonisation of the patient’s digestive tract 
and the incidence of infection after the discontinuation of enteral vancomycin or after 
ICU discharge. A randomised trial should focus on this issue. 
There are limited data on the impact of enteral vancomycin on the intestinal 
microbiota in ICU patients. Although the results of this thesis reject the hypothesis of 
a possible emergence of VISA and VRE during enteral vancomycin, changes in gut 
microbiota and the emergence of resistant microorganisms should be acknowledged. 
The potential consequences of enteral antimicrobials on the whole gut microbiota 
and microbiome need careful appraisal in RCTs or cluster-randomised trials in which 
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ICU patients receiving enteral vancomycin, with or without SDD, are compared to 
controls not receiving those antimicrobials. 
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